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" ... There'sjasmine! Alcohol there! Bergamont there! Storax there! Grenouille went on 
crowing, and at each name he pointed to a different spot in the room, although it was so 
dark that at best you could only surmise the shadows of the cupboards filled with bottles." 
(Patrick Susskind, Perfume) 
~ 3 FEB 2005 
The only lifelong, reliable motivations are those that come from within, 
and one ofthe strongest of those is the joy and pride that grow from 
knowing that you've just done something as well as you can do it. 
(Lloyd Dobens and Clare Crawford-Mason, Thinking About Quality) 
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ABSTRACT 
The targeted delivery of drugs is one of the most actively pursued goals in anti-HlV and 
anti-cancer chemotherapy. This project takes a proof-of-concept approach to the 
devclopment of protein-based drug delivery systems - delivery systems that would 
package, target, and deliver cytotoxins to diseased cells. 
Primarily, this project explores the use of the potent anti-HN protein, cyanovirin-N 
(CV-N), to actively targct and deliver cytotoxic natural products to HN-infected cells. 
This project also investigates the use of human serum albumin (HSA), a 66 kDa protein, 
as a macromolecular carrier to passively target and deliver cytotoxic natural products to 
cancerous cells. 
To facilitate release of the toxin within infected cells, an enzymatically-cleavable 
tetrapeptide was incorporated in the conjugates. Maleimido-activated tetrapeptide toxin 
constructs were prepared in readiness for selective reaction with proteins carrying thiol 
functionalities. Release ofthe toxin, norhomohalichondrin B, was demonstrated in vitro. 
Native CV -N conjugates were prepared by thiolation of the lysine 8-amino groups, and 
the subsequent reaction with maleimido-activated compounds. Reaction across all lysine 
residues was demonstrated. A singly-substituted tyrosinamide conjugate of 
CV-N was prepared. Two recombinantly produced mutant CV-N proteins allowed for the 
production of selectively modified, double- and single-norhomohalichondrin B 
conjugates of CV-N. The conjugates retained the anti-HN activity of the parent protein. 
Homohalichondrin B, doxorubicin, and tyrosinamide conjugates of HSA were prepared. 
The syntheses exploited the availability of a free thiolmoiety at cysteine-34 ofHSA, and 
the specific and selective reaction of this thiol with the maleimido-activated tetrapeptide 
derivatives. 
All toxin conjugates demonstrate excellent cell toxicity. Further research to investigate 
whether this is targeted toxicity is currcntly underway. 
v 
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INTRODUCTION 
1.1 Human Immunodeficiency Virus 
1.1.1 The Global HIV / AIDS Epidemic 
AIDS acquired immunodeficiency syndrome was first reported in the United States in 
1981 and has since become a worldwide epidemic. AIDS is caused by the human 
immunodeficiency virus (HIV). By destroying or damaging the cells of the body's 
immune system, HIV progressively destroys its ability to fight infections and certain 
cancers. I 
In 2003, New Zealand had a record 188 newly identified HIV cases.2 An estimated 1,400 
people are living with HIV/AIDS in New Zealand in 2004.2 
As of the end of 2003, an estimated 40 million people worldwide - 37 million adults and 
2.5 million children younger than 15 years - were living with HIV/AIDS. Approximately 
two-thirds of these people live in Sub-Saharan Africa; another 18 percent live in Asia and 
the Pacific. An estimated five million new HN infections oeeurred worldwide during 
2003; that is, approximately 14,000 infections each day. More than 95 percent of these 
new infections occurred in developing countries, and nearly 50 percent were among 
females. In 2003 alone, HIV I AIDS-associated illnesses caused the deaths of 
approximately three million people worldwide.3 
HIV is primarily a bloodbome and sexually transmitted disease. The chief routes of HIV 
transmission are by exposure to contaminated blood or blood products, insertive or 
receptive sexual intercourse, and vertieal transmission from mother-to-child.2,3 
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1.1.2 Overview 
HN disease is characterised by gradual deterioration of immune function. Most notably, 
crucial immune cells called CD4+ cells are disabled and killed during the typical course 
of infection. These cells, sometimes called "T -helper cells", play a central role in the 
immune response, signaling other cells in the immune system to perfonn their 
functions. 4-7 
A healthy, uninfected person usually has 800 to 1,200 CD4+ T -cells per cubic millimeter 
(mm3) of blood. During HIV infection, the number of these cells in a person's blood 
progressively declines. When a CD4+ T-cell count falls below 200 mm-3, he or she 
becomes particularly vulnerable to the opportunistic infections and cancers that typify 
AIDS, the end stage of HIV disease.6 People with AIDS often suffer infections of the 
lungs, intestinal tract, brain, eyes and other organs, as well as debilitating weight loss, 
diarrhoea, neurological conditions and cancers such as Kaposi's sarcoma and certain 
types oflymphomas.6,8 
1.1.3 Classification of HIV 
The human immunodeficiency virus (HN) is a member of the Retroviridae family. 
Retroviruses such as HlV are RNA-containing viruses that replicate through a DNA 
intennediate by virtue of a viral-coded RNA-directed DNA polymerase, also called 
reverse trans criptas e. Within the retrovirus family, HIV is classified as a lentivirus, 
having genetic and morphologic similarities to animallentiviruses such as those infecting 
cats, sheep, goats, and non-human primates.9 Electron microscopy reveals the most 
prominent morphological characteristic, a cylindrical or cone shaped capsid (as illustrated 
in Figure 1.1) in the mature virion. Like HIV in humans, the animallentiviruses primarily 
infect cells ofthe immune system, including T-Iymphocytes and macrophages.6-8 
HIV is subdivided into two distantly related types, HIV-l and HlV-2. HN-l is the 
predominant worldwide isolate from individuals with AIDS, or at high risk for the 
development of AIDS. HIV-2 is endemic among people in West Africa.6 
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1.1.4 Origins of HIV 
Debate around the origin of HN has sparked considerable interest and controversy since 
the beginning of the epidemic. There is now clear evidence that the origins of HlV -1 and 
HN-2 represent cross-species (zoonotic) infections. All HN-l strains are closely related 
phylogenetic ally to a strain of SIV (simian immunodeficiency virus) that naturally infects 
a subspecies of chimpanzee (Pan troglodytes), whose habitat corresponds to regions in 
West Africa, in which human HlV -1 infection is endemic.lO,ll A primate reservoir of 
HlV -2 has also been identifiedY 
In human populations there are three major groups ofHN-l, named M, N and O. Group 
M has given rise to the worldwide pandemic, diverging into various subtypes, A-K. 
HlV-l groups 0 and N, are largely confined to Gabon, Cameroon and neighbouring 
countries close to the natural habitat of Pan troglodytes. 12 
1.1.5 The HIV Virion 
The mature HN virion (Figure 1.1) is a roughly spherical (actually icosahedral) particle 
with a diameter of ~ 11 0 nanometers.7 The central core contains four viral proteins (p24 -
the major capsid protein, p17- a matrix protein, p9, and p6), two copies of the HN RNA 
genome, and three viral enzymes (reverse transcriptase, integrase, and protease) essential 
for viral replication.6,7 
The outer envelope is aequired during virion budding and is studded with approximately 
72 knobs formed by the two major viral-envelope glycoproteins (gp120 and gp41). The 
envelope structures are derived from a 160 lcDa precursor, gp160, which is cleaved into a 
gp120 external surface protein and a gp41 transmembrane protein.6,13 Electron 
microscopy and X-ray crystal structures suggest that these proteins are organised into 
trimcrs. 14 Both proteins are extensively glycosylated.13,15 
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Increasing knowledge about HIV -I (hereafter referred to as HIV) has permitted the 
characterisation of this virus in considerable detail , induding the mechanisms whereby it 
infects cells and becomes cytopathic to them. A key to the development of drug 
intervention strategies is a knowledge of the viral life cycle (Figure 1.2). 
1.l.6 The Life Cycle of HIV 
CD4 is a membrane glycoprotein and plays a central role in orchestrating immune 
responses. 6 The chief target cells for HIV infection are human CD4+ T -lymphocytes and 
macrophages. The CD4 moiety is also found at the surface of monocytes, endothelial 
cells, and microglial cells.6. 16.17 An infection is initiated by binding of the virion envelope 
gp 120 to the CD4 receptor on the host cell. The CD4--gp 120 interaction occurs with high 
affinity and is an obligate step of the virus life cycle. 14 15,18-20 Upon binding to CD4, 
gp 120 undergoes a conformational change that enables it to bind to a co-receptor 
molecule, such as the chemokine receptors CCR5 and CXCR4,21 which act as fusion co-
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receptors. 14 15 ,2 1-23 The structure of the ternary complex, containing a portion of HI V-I 
gp120 bound to CD4 and a neutralising monoclonal antibody, was determined by X-ray 
crystallography. IS This structural analysis was fundamental in advancing the 
understanding of the HIV infection process. 
Figure 1.2: The HIV Replica/ion Cycle. (Reproduced with permission from Professor Robin Weiss, 
Department of Immunology and Molecular Pathology, University College London, London. Copyright 
permission from Nature Publishing Group) 
The interaction of gp 120 with CD4 and co-receptor initiates conformational changes in 
the transmembrane protein gp4l, which mediates fusion of the viral and cellular 
membranes. The essential parts of this protein are an N-tenninal fusion peptide, and N-
terminal heptad repeat and a C-terminal heptad repeat. Current models show gp41 
adopting a 'pre-hairpin' conformation that places the fusion peptide near to or in the 
target cell membrane. Intramolecu~ar interactions between the C- and N-heptad repeats 
results in a hairpin conformation that leads to a juxtaposition of the host cell and viral 
membranes, followed by fusion. 19,20,24 
Conceptually, the use of agents to block viral entry is an attractive target in the treatment 
of HIV infection. Unfortunately, this area of drug development has had limited success. A 
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number of inhibitors are showing promising results and several of these will be reviewed 
below. The focus of this thesis has been the development of a proof-of-concept approach 
to an anti-HIV therapeutic. The research has taken advantage of the specific delivery 
opportunities offered by cyanovirin-N (CV-N), an 11kDa protein that binds specifically to 
the HIV envelope protein gp 120.25 
The proteins that surround the viral nucleic acid are digested away, leaving the genome 
exposed to the cytoplasm of the celL The viral genome is composed of two identical 
segments of single-stranded RNA, which are complexed with the enzyme known as 
RNA-dependent DNA polymerase or reverse transcriptase. The viral reverse transcriptase 
converts viral RNA into first single- and then double-stranded DNA.7,2o,26 The viral 
reverse transcriptase is, in some sense, the most logical target for antiviral chemotherapy, 
since human cells do not possess this enzyme. This enzyme is the target of many anti-
retroviral drugs that are now in clinical use. Importantly, the HIV reverse transcriptase is 
very error-prone, and the resulting nucleotide mismatcbes introduce a high mutation rate 
in the viral genome,z6 As will be noted later, the genotypic and phenotypic diversity of 
HIV is a major factor in pathogenicity, in circumventing host defence, and in developing 
resistance to antiretroviral drugs. 
The proviral DNA duplex is transported to' the cell nucleus where it is inserted 
(integrated) by the virally encoded enzyme integrase, into the host cell genome. Proviral 
DNA, once integrated, is the equivalent of cellular DNA. No method has yet been devised 
to excise proviral DNA from cells.7,2o,26 The integrase enzyme provides yet another target 
for drug activity, and development ofintegrase inhibitors is ongoing. 
Once integrated into the host cell genome, HIV can establish a virus-producing infection 
or a latent infection depending upon critical host factors, particularly whether the infected 
cell is in an activated or resting state.27 In a permissive cellular environment, cellular 
replication will now include the duplication of the proviral DNA segments. These 
segments can be transcribed by host cell RNA polymerases to yield viral messenger RNA 
(mRNA), which in tum, can be translated into viral proteins. Final maturation of the 
virion proteins, mediated by protease, takes place, and these newly made viral proteins 
ultimately assemble with viral RNA molecules at the plasma membrane to yield 
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infectious viral progeny that bud out from the ceI1. 6,7,2o,26 Inhibitors of the protease 
enzyme make up a large number of the anti-HIV treatments currently in clinical use. 
An analogous mechanism to the one discussed above mediates cell-cell fusion between 
HIV envelope-expressing (productively infected cells) and CD4-expressing cells.6 
By contrast, with a latently infected cell, the HIV provirus DNA is not expressed as viral 
RNA, viral proteins or virions, but is replicated as DNA by the host cell DNA 
polymerase, as are other cellular genes, and is transmitted to progeny cells by cell 
division. Without expression or surface adherence of HIV proteins, such latently infected 
cells are not affected by anti-HIV immune mechanisms. Further, a latently infected cell, 
such as a CD4+ T -lymphocyte, can be activated by antigens, mitogens, certain cytokines, 
and other viral gene products, to initiate transcription and translation of the HIV provirus 
DNA and the production and spread of infectious virus. 7,27,28 Complete viral eradication is 
dependent on elimination ofthe latent reservoir. 
1.1.7 The Course of HI V Infection 
Although the course of HIV infection may vary somewhat among individual patients, a 
common pattern of development has been recognised (Figure 1.3).29-32 The pattern is 
characterised by three phases: the acute or primary infection (first viremia), the 
asymptomatic, and the symptomatic (AIDS) phase. 
The overall effect of HI V on the immune system is to gradually lower its ability to mount 
an immune response. From the original infection, there is usually a period of 8-10 years 
before the clinical manifestations of AIDS occur; however this may be two years or less.5 
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Figure 1.3: The Typical Course of HIV infection. (Reproduced with permission from Dr Robert Wallace,29 
Department of Biology, City College of New York, New York and Dr Anthony Fauci/2 Laboratory of 
Immunoregulation, NIH, USA) 
Primary infection, which generally lasts for two to eight weeks, is typically associated 
with high levels of virus. 30,32 The patient often experiences fever, rash, and swollen lymph 
glands.3o The result is an initial fall in CD4+ cells.30,32 
With the emergence of anti-retroviral immune responses, and in particular of specific 
cytotoxic T lymphocyte response, levels of plasma HN-RNA decline precipitously. After 
about three months of infection, plasma HIV -RNA levels stabilise and remain relatively 
constant during the asymptomatic phase.3o,32 Studies show that during this clinically latent 
phase of disease, there is a very dynamic process of viral production and clearance.28 
The asymptomatic phase is characterised by a slow, gradual depletion of CD4+ T 
lymphocytes. Eventually the immune system collapses, mirrored by a return to high-level 
virus production. The inevitable outcome of the progressive deterioration of the immune 
system is clinically apparent disease or an acquired immunodeficiency syndrome (AIDS) 
defining illness. Even with treatment, death usually occurs within two years?0,32 
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1.1.8 Treatment Strategies 
The development of potent anti-retroviral drugs is central to the control of HIV infection 
and the prevention of disease. In recent years significant progress has been made towards 
the chemotherapy of HIV. The current armamentarium for the treatment of HIV 
infections consists of nineteen formally approved drugs. 33 A representative sample of 
these compounds can be seen in Figure 1.4. 
The drugs licensed for clinical use fall into one of the following five categories: a) 
nucleoside reverse transcriptase inhibitors; and b) nucleotide reverse transcriptase 
inhibitors, that, following phosphorylation steps, act as chain terminators at the substrate 
binding site of the reverse transcriptase33 ,34 (for example zidovudine (1), abacavir (2) and 
tenofovir disoproxil (3)); c) non-nucleoside reverse transcriptase inhibitors, that interact 
with the reverse transcriptase at an allosteric, non-substrate binding site33,34 (for example 
nevirapine (4) and delavirdine (5)); d) protease inhibitors, that specifically inhibit, as 
peptidomimetics, the virus associated protease33 ,34 (for example ritonavir (6)); and e) the 
viral entry inhibitor, enfuvirtide (7), that inhibits virus-cell fusion through an interaction 
with its homologous region in gp41. 33 ,35 
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Figure 1.4: A Selection of Licensed Anti-HIV Drugs, 
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In addition to the anti-HIV compounds that are currently available, there are a large 
number that are presently under preclinical or clinical development. Some examples 
include the virus adsorption inhibitors (for example, cosalane derivatives, cyanovirin-N); 
CXCR4 and CCR5 antagonists (AMD3100 (8), TAK-779 (9)); nucleoside/nucleotide 
reverse transcriptase inhibitors (for example, amdoxovir (10)); integrase inhibitors (for 
example, S-1360 (11)); and peptidomimetic (for example, TMC-126 (12)) and non-
peptidomimetic (for example, tipranavir (13)) protease inhibitors.33 ,35,36 
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Figure 1.5: Anti-HIV drugs under development. 
Highly active anti-retroviral therapy (HAARTi7-40 refers to a broad category of treatment 
regimes usually comprised of three or more anti-retroviral drugs used concurrently. The 
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goal of this approach is to reduce the viral load to below detection levels, to limit disease 
progression, and to delay the occurrence of resistant mutants that would compromise its 
therapeutic efficacy. Most HAART regimes include drugs from at least two of the 
categories mentioned above. 
HIV reverse transcriptase lacks proof reading capability, so the mutation rate is high (1 in 
104 to 1 in 105 nucleotide mutations per replication cycle ).41 An important benefit of the 
multi-drug therapy is that drug resistance develops more slowly with HAART than with 
older monotherapy regimens. This is a result of fewer absolute viral replication cycles, 
resulting in a decreased probability of resistance mutations emerging?8,42 
The use of HAART has reduced HIV viremia in many patients to undetectable levels38,43 
and substantially delays the onset of AIDS by halting the progressive loss of CD4+ 
T _lymphocytes.43,44 HIV infection has changed (at least in the western countries4o), from a 
progressive disease that ultimately results in death from opportunistic infection or 
malignancy, to a chronic condition with slow disease progression that requires life-long 
therapy. 
However, these clinical benefits of HAART still hold limitations. First, the high cost and 
limited availability of drugs used in HAART make the clinical benefits largely available 
only to persons in developed countries.34,40 Second, HAART regimens require patients to 
take many tablets per day.45 Third, the potential side effects45 and the risk of developing 
HIV resistant to any of the anti-retroviral compounds makes long-term maintenance on 
HAART unrealistic.40,44,45 Lastly, the initial hope that prolonged suppression of HIV by 
current HAART regimens could result in the clearance and eradication of virus from an 
individual has been shown to be improbable.45 
Given that the latent reservoir for HIV appears to represent a major barrier to virus 
eradication, 6,27 ,28,46,47 a good deal of research is exploring approaches for eliminating this 
reservoir. One strategy involves activating latently infected cells and "flushing out" the 
reservoir.27,46 The goal is to promote viral transcription and replication in cells that 
harbour latent virus. Virus produced from these cells should be unable to infect other cells 
due to the presence of anti-retroviral agents.27 
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Viral gene expression in latently infected cells can be reactivated by a wide variety of 
signals including cytokines, such as interleukin-2, tumour necrosis factor, antigens, 
bacterial infections and lipopolysaccharides,z7,28,45,47 A number of studies of combination 
regimes ofHAART and interleukin-2 have been undertaken and show positive results but 
have not been successful in eradicating infection.45 
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Also, compounds like the plant-derived prostratin (14)/7 a number of other non-tumour 
promoting phorbol esters,46 and the deacetylase inhibitor trichostatin A (15)48 have been 
found to potently induce latent virus from quiescent T -cells in vitro. The preliminary 
results with prostratin are encouraging, but its clinical potential is hampered by low 
potency,z7,46 
1.1.9 Vaccine Development 
A safe, effective and readily available vaccme remains the ultimate goal for the 
containment of HIV. The appeal of a vaccine encompasses both preventative and 
therapeutic considerations.49 In addition to their ability to inhibit infection, vaccines 
against HIV may also boost immune responses that control viral replication. To date, no 
vaccine has been accepted for standard treatment of infected individuals, but the eoncept 
of vaccination remains a goal for future treatment of the disease.49-53 
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Three main types of therapeutic vaccines have been clinically tested to date. 
1) Subunit vaccines containing HIV-1 proteins: 
Recombinant envelope glycoproteins (rgp160/rgp120) have advanced in clinical 
trials.49,52 These reflect the preventative vaccine effort, based on the fact that neutralising 
antibodies are directed primarily against these proteins.49 Vaccines of HIV immunogen 
(whole inactivated HN, depleted of gpI60 and gpI20 proteins) and other viral proteins 
and pep tides have also been developed. 52 
2) Recombinant viral vectors encoding viral proteins: 
Live viral vectors, primarily recombinant poxviruses (for example, canarypox) are able to 
carry large sequences of foreign DNA and, by mimicking microbial infection, induce 
. h t' .. 4952 Immune responses to t ese an Igens m VlVO. ' 
3) DNA vaccines: 
Use of plasmid DNA enables vaccination with select sequences of genetic material that 
express immunogenic HIV proteins with the goal of eliciting long-lived humoral and 
cellular responses.49,50,52 
Candidate HIV vaccines have been evaluated in over 70 phase I trials, in more than 3,500 
patients, with only one progressing on to phase III trials. 54 
The most extensively studied vaccine candidate, AIDSV AX BIB, contains recombinant 
fonns of HIV gpI20 from two subtype B strains.51 ,52,55 In late 2002 this vaccine became 
the first to finish phase III clinical trials. However, results were disappointing with 
AIDSV AX BIB not inducing broad neutralising antibodies or T-cell responses, and 
failing to protect against infection with a vaccine efficacy of3.8%.51,55 
Phase I and II trials are in progress for a further 20 vaccines.51 
Clinical trials of the anti-retroviral drugs have employed viral load as a marker to detect 
clinical efficacy. No immunological endpoint has been identified which correlates to 
survival in a similar manner for the testing of vaccines. 52 All of the therapeutic vaccines 
investigated have been safe and well tolerated.49 Many have demonstrated 
immunogenicity, as measured with a variety of immunological parameters (for example, 
cytotoxic T -lymphocytes and antibodies).49 
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No vaccines have yet demonstrated clinical benefit.49 
Despite these factors, there is hope for a vaccine against HIV. Two cohorts of people who 
possess natural immunity to infection by HIV have been described. 54 Firstly, individuals 
who are homozygous for a 32-base pair deletion in the CCR5 receptor remain uninfected, 
despite multiple exposures to HIV. It is not clear whether this genetically-based resistance 
to infection can be utilised in a vaccine strategy. The second group of individuals who 
appear to possess immunity from infection are a number of African prostitutes who 
remain HIV negative despite multiple exposures. The immune correlate or protection is 
unknown, although it has been noted that they show a detectable CD8+ cytotoxic T-
lymphocyte response. 54 
Jon Cohen aptly describes the quest for a vaccine in his 2001 book, "Shots in the Dark: 
The Wayward Search for an HIV Vaccine.,,56 It is likely that the eventual HIV vaccine 
will involve a combination of multiple vaccine ideas and technologies and it will take a 
concerted effort from the scientific, commercial and political communities to develop, 
test, licence and deliver. 
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1.2 Natural Products 
For thousands of years manldnd has lmown about the benefit of drugs from nature. The 
curative powers of certain compounds have been discovered by various means: from folic 
remedies to targeted research, and from serendipitous accidents to systematic 
investigations. Throughout recorded history and in all societies, the identification of 
substances effective against illness and disease has been an important activity.57 In the 
fourth century B.C., Hippocrates described a 'tea' made by boiling willow bark in water. 
The concoction was used as a treatment for fevers. Over the centuries that folic remedy 
ultimately led to the synthesis of aspirin, a true "wonder drug" that has aided millions, 
arguably billions, of people. 58 
Williams et al.59 define a natural product, or a secondary metabolite, as "a substance that 
has no lmown role in the internal economy of the producing organism". There are many 
hypotheses as to why natural products are produced. Williams et al. argue that the ability 
to synthesise secondary metabolites, which may repel or attract other organisms, has 
evolved as one aspect of an organism's strategy for survival. 
1.2.1 Marine Natural Products 
Among the least explored of the planet's organisms are the invertebrates, algae, fungi, 
and bacteria of the marine environment. The majority of phyla and more than 90% of all 
classes of organisms are represented in the marine environment.60 With oceans covering 
more than 70% of our planet's surface, the marine environment is composed of a 
tremendous variety of habitats. These habitats differ markedly in salinity, temperature, 
pressure and light. 
For more than two decades, there has been an ongoing quest to discover new drugs from 
the sea. There is little doubt that marine biodiversity is a source of chemical diversity. It 
has proved to be a rich reservoir of biologically active natural products. Over 14,000 
compounds have now been described.61 
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Considering the diversity of chemical structures found in nature with the narrow spectrum 
of structural variation of even the largest combinatorial library, natural products will 
continue to play an important role in drug discovery. Despite achievements in synthetic 
chemistry and advances towards rational drug design, natural products will continue to be 
essential in providing medicinal compounds and as starting points for the development of 
synthetic analogues. 
Below is a brief overview of two species of marine organisms that have been responsible 
for producing the natural products central to this thesis. 
1.2.2 Blue-green Algae (Cyanobacteria) 
Blue-green algae or cyanobacteria are a remarkable group of simple photosynthetic 
microorganisms. In evolutionary terms they represent a link between bacteria and green 
plants. Their cellular organisation (prokaryotic), is characterised by the lack of 
membrane-bound organelles such as a nucleus, mitochondria or chloroplasts, and 
resembles that found in bacteria. Their principal mode of nutrition, oxygen-evolving 
photosynthesis, however, is similar to that which operates in all other eukaryotic algae 
and in green plants. 62 
Cyanobacteria are, perhaps, the most primitive things living on earth. Their fossilised 
remains have been found in sediments from the Early Precambrian period.63 It seems 
likely that some 3 billion years ago, they were responsible for ehanging the earth's 
atmosphere to one rich in oxygen that could support plants and animals. 62 
Blue-green algae are found widely in various environments, from the intertidal zone of 
marine shores, to damp rocks and salt marshes, freshwater lakes and the glass wans of 
aquariums. Cyanobacteria are found not only in aquatic samples, but also in soils, 
animals, and higher plants. 62 
Cyanobacteria have proven to be a source of biologically active and structurally unique 
natural products. The structures of two representative compounds are shown below. 
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Anatoxin-a (16) is an alkaloid neurotoxin,64 and the cyclic depsipeptide, cryptophycin-1 
(17), acts as a microtubule depolymerising agent.65 
anatoxin-a (16) cryptophycin-l (17) 
Figure 1. 7: Two representative natural products isolated/rom cyanobacteria. 
The focus of this thesis is an 11 kDa protein, cyanovirin-N, isolated from cultures of the 
blue-green alga Nostoc ellipsosporum. This protein will be reviewed in depth in the 
following chapters. 
Little experimental evidence exists to establish the full ecological significance of 
cyanobacterial metabolites. Secondary metabolite production is often sensitive to 
environmental factors and current research shows that some compounds produced by 
marine cyanobacteria kill off or discourage fish and invertebrate grazers and denude the 
local populations of algae and other cyanobacteria that might compete for the same 
nutrients.64 
1.2.3 Sponges 
Sponges arc a common and diverse group of about 10,000 multi-cellular animals 
belonging to the phylum Porifera. They lack true tissue and organs and therefore have a 
level of structural organisation that is intermediate between other invertebrate groups and 
the protozoans. 66 
Sponges are specially adapted for a stationary filter-feeding life. Water containing food 
particles is drawn into the internal cavity of the sponge through numerous pores. The 
water is strained of food and expelled.66 
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These invertebrates are benthic organisms and are widely distributed in both fresh and 
salt water, and at all depths and latitudes.66 
Sponges have provided a diverse array of bioactive metabolites. Four interesting 
compounds are discussed here. In 1955, Bergman isolated unusual nucleosides named 
spongouridine (18) and spongothyrnidine (19) from a Caribbean sponge. Further 
biological and synthetic studies led to the development of compounds such as acyclovir 
(20) with potent antiviral activity.67,68 Calyculin A (21), a cytotoxic polyketide is a 
selective inhibitor of protein phosphatase 1 and 2A and is widely used as a research tool 
in life science fields. 68 Homohalichondrin B (22) is a polyether macrolide which is an 
exceedingly potent tubulin-binding antimitotic agent with in vivo activity against a 
number of pre-clinical models.67 This project has investigated harnessing the potency of 
homohalichondrin B. 
Marine invertebrates are sessile organisms that lack a developed immune system. They 
are prone to predation, fouling or the overgrowth by other organisms. The production of 
biologically active natural products is proposed to act as a chemical defence against these 
types of invasive and life threatening events. In some cases, microorganisms are known 
or suspected to be the biosynthetic source of marine invertebrate natural products.69 
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Figure 1.8: A selection of natural products isolated from marine sponges, and the synthetically developed 
anti-viral compound, acyclovir. 
1.2.4 The Marine Chemistry Group 
The Marine Chemistry Group at the University of Canterbury was formed in 1975. The 
prime objective of the Group is the isolation and identification of biologically active 
marine natural products. Historically, work has concentrated on natural products from 
marine invertebrates. In 1983 a large-scale collection programme was initiated with 
marine invertebrates collected from around New Zealand waters, and from McMurdo 
Sound in Antartica. From these specimens a large number of novel natural products have 
been isolated and their structures determined. 
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More recently, the Marine Chemistry Group has turned to the investigation of marine 
fungi as a new source of novel and exciting bioactive natural products. 
The Marine Chemistry Group is also exploring new drug delivery approaches, polymer 
therapeutics, and protein conjugates, as a means of enhancing the value of marine toxins. 
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1.3 The Halichondrins 
1.3.1 Discovery and Isolation 
The attention of Hirata and Demura was caught by the remarkable in vivo anti-tumour 
activity exhibited by an extract of the marine sponge Halichondria okadai Kadota.70,71 
Bioassay against B-16 melanoma cells guided the isolation of a class of complex 
polyether macrolides. This extremely bioactive group of compounds were named the 
halichondrins.70,71 Subsequently, the halichondrins have been isolated from a variety of 
marine sponges including Axinella Sp.,72,73 Phakellia carteri,74,75 and Lissodendryx Sp.76,77 
To date the structures of 14 halichondrin and three closely related halistatin congeners 
have been reported. The structures of three representative halichondrins are shown in 
Figure 1.9. 
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Figure 1.9: Norhalichondrin B, halichonddn Band homohalichondrin B. 
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The structures are characterised by a novel 2,6,9-trioxatricyclo[3.3.2.03,7]-decane system 
(rings C-E), a 22-membered lactone ring (Cl-C30), two exocyc1ic olefinic groups and 
several pyranose and furanose rings.70,78 The halichondrins are divided into three families, 
A, Band C, distinguished by the degree of oxygenation at C12 and C13 (Figure 1.10). 
Within each family variation occurs beyond the C45 position as seen in Figure 1.9. 
(halichondrin, homohalichondrin or norhomohalichondrin). 70,78 
A B C 
Figure 1.10: The three families of halichondrins. 
The structure of norhalichondrin A was unambiguously established by X-ray analysis.71 
The absolute configurations of halichondrin B (24), norhalichondrin B (23), and 
homohalichondrin B (22) were proven by total synthesis.79,80 
Comparison of the cytotoxicity of the halichondrins isolated against the in vitro B-16 
melanoma cell-line (Table 1.1) showed that halicholldrill B (24) was the most cytotoxic. 
Halichondrins with B-type C-E rings and homQ- or hali-type terminal moieties gave the 
most potent results. 
Compound 
Homohalichondrin A 
Norhalichondrin A 
Halichondrin B (24) 
Homohalichondrin B (22) 
Norhalichondrin B (23) 
Halichondrin C 
0.26 
5.2 
0.093 
0.1 
NRb 
0.35 
a Inhibition Concentration. (Concentration at which the growth of cells is 50% of the 
control value for untreated cells.) 
b Data not reported (NR) but result inferior to that for halichondrin B (24). 
Table 1.1: Cytotoxicity against B-16 Melanoma cells (ng/mL).70 
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A number of hemi-synthetic derivatives of the halichondrins have been investigated to 
establish the structural and conformational features essential for the high levels of 
biological activity.77,s1 The halichondrins are sensitive to exposure to acid conditions81 
and the products of this degradation (C38 epimer, and cleavage of the ether links between 
8,14 and 9,12) showed significant decreases in cytotoxicity. Opening of the lactone Cl-
C30 ring, and modification of the olefinic groups at C9 and C26, demonstrated similar 
results.77 Modification beyond C47 did not result in significant changes in the biological 
activity ofthe resulting halichondrins.77 
Hirata et al. investigated the anti-tumour activities of halichondrin B (24) and 
homohalichondrin B (22) by in vivo testing on mice with B-16 melanoma, P388 
leukaemia and L-121O leukaemia tumours.70 A 300% increase in life expectancy of the 
afflicted mice was reported, relative to the control, for both compounds. By 1992 the NCI 
had also demonstrated that halichondrin B (24) and homohalichondrin B (22) were active 
in vivo against a variety of tumour types. 82 
1.3.2 Mechanism of Action 
An evaluation of the differential activity (mean-graph profile) of halichondrin B (24) 
against the NCI 60 human tumour cell line panel using the COMP ARE83 algorithm 
demonstrated that the halichondrin pattern closely resembled those of tubulin-binding 
compounds like vincristine.84 Bai et al.84 confirmed that halichondrin B was an extremely 
potent anti-mitotic agent Halichondrin B (24) inhibits in vitro polymerisation of purified 
tubulin and microtubule assembly dependent on microtubule associated proteins. It was 
shown to be a non-competitive inhibitor of the binding of vinblastine to tubulin and to 
inhibit nucleotide exchange on tubulin. 
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1.3.3 Further Development 
In 1992, the NCI Decision Network Committee selected halichondrin B (24) for pre-
clinical anti-cancer drug development (DNIIA status). Two factors, in particular, have 
mitigated against any further development ofhalichondrin B (24) at the NCr. 
The most important problem is that of supply of the halichondrins. It has been estimated 
that 1-5 kg/annum of halichondrin B (24) would be required for the compound to be 
marketed as a commercial drug.78 A variety of supply options are being investigated. 
The natural supply of the highest yielding of the halichondrin containing sponges, 
Lissodendoryx sp., is limited to an exclusive site off the Kaikoura Peninsula of New 
Zealand. It has been established unambiguously that the halichondrins could never be 
supplied on a commercial scale by collection from the wild.78,85 
Aquaculture feasibility trials have shown some initial encouraging results.78 
There is some thought that a symbiont could be responsible for the production of the 
halichondrins. Preliminary cell separation studies are currently being undertaken by 
National Institute of Water and Atmospheric Research (NIWA) and the University of 
Canterbury Marine Chemistry Group. Identification of the producing organism raises the 
possibility of fermentation of the microorganism, or transfer of relevant portion( s) of the 
genome to a vector appropriate for fermentation. 78 
The scarcity of the halichondrins, their potent cytotoxicity, and their academically 
challenging structures, has encouraged considerable synthetic effort in this area. The total 
synthesis of halichondrin B (24) and norhalichondrin B (23) was achieved by Kishi and 
coworkers in 1992.79 Significant improvements have been made to the syntheses but they 
still entail over 100 synthetic steps.86 With such an extensive synthetic route, a 
commercially cost effective supply of the halichondrins is unlikely by total synthesis. The 
groups of Salomon, Rorita and Y onemitsu, and Burke have also made noteworthy 
contributions to the synthesis ofhalichondrin B (24).87 The synthesis of the right-half diol 
(25) was reported by Stamos et at. 86 This diol (25) exhibits the same activity pattern 
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pattern as the parent halichondrin B (24), with a reported cytotoxicity within one order of 
magnitude of the parent compound.86 This discovery has concentrated synthetic efforts on 
the right-half segment of halichondrin B. 
HO 
right-half diol (25) 
Figure 1.11: The right-half diol from halichondrin B. 
The existence of a synthetic route for halichondrin B (24) and the knowledge that its 
activity resides in the macro cyclic lactone CI-C38 moiety has permitted development of 
structurally simplified synthetic analogues that retain the exceptional activity of the 
parent.88 The macro cyclic ketone analogues, ER-076349 (26) and ER-086S26 (27), 
(Figure 1.12) have been synthesised by Towle et al.,88 and have highly potent activities in 
vitro and in vivo. 
ER-076349 (26) 
H3CQ 
OH ~ 
H H2N~"", 
o 
ER-086S26 (27) 
Figure 1.12: Structures of the mac/'ocyclic ketone analogues ER-076349 and ER-086526. 
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Retention of the extraordinary in vitro and in vivo activity of halichondrin B (24) in 
structurally simplified, fully synthetic analogues establishes the feasibility of developing 
commercially viable halichondrin-based agents as highly effective, novel cytotoxic drugs. 
The second factor preventing further drug development relates to the potent cytotoxicity 
of the halichondrin series of compounds and their non-selectivity for diseased cells. This 
problem can be addressed by focusing on delivery methods (see below). The Marine 
Chemistry Group at the University of Canterbury have worked in collaboration with the 
NCI, the London School of Pharmacy and the Welsh School of Pharmacy on the 
development of polymer therapeutics89 and conjugates of CV_N9o based on the 
homohalichondrin B (22) skeleton. 
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1.4 Cyanovirin-N 
1.4.1 Discovery and Isolation 
The phannaceutical industry has, as already alluded to, depended heavily on the process 
of empirically screening large numbers of pure organic compounds or crude natural 
product extracts to provide new leads. 
In 1988, the United States National Cancer Institute (NCI) began a comprehensive pre-
clinical drug development program. As part of this agenda, a broad screening program 
was conducted to evaluate synthetic and natural products for anti-HN activity. In part, 
this screening program focused on extracts from unusual microorganisms, including 
cyanobacteria.91 
The Laboratory of Drug Discovery Research and Development (LDDRD) selected an 
aqueous cellular extract of a cultured cyanobacterium Nostoc ellipsosporum for detailed 
investigation. This decision was based on the extract's strong inhibition of HN in an 
empirical screen, and because there were preliminary indications that the active 
constituent was a protein, and not due to the presence of sulfolipids, sulfated 
polysaccharides or any other lmown anti-HN chemical class.25,91 
In 1997, anti-HIV bioassay guided fractionation of the extract led to the isolation and 
purification of a unique protein, Cyanovirin-N (CV-N, 28).25,91 A 101 amino acid 
sequence (Figure 1.13) was deduced by N-tenninal Edman degradation of the intact 
protein and peptide fragments produced by endoproteinase digestions. Amino acid 
analysis confinned the sequence. CV -N (28) contains four cysteines that fonn two 
intrachain disulfide bonds. The positions of these disulfide linkages were established by 
fast atom bombardment mass spectral studies of peptide fragments generated by 
enzymatic digestion of CV-N (28). No amino acid residues undergo post-translational 
modification. Electrospray ionisation mass spectrometry (ESI MS) showed molecular 
ions for the native protein with mass-to-charge ratios consistent with the calculated 
molecular weight of 11,009 Da,z5,91 
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CV-N (28) is a highly potent virucidal protein that irreversibly inactivates diverse primary 
clinical isolates and laboratory adapted strains of HIV-l, HIV-2, and simian 
immunodeficiency virus. EC50 values are generally in the 1-10 nM range. CV-N (28) 
prevents in vitro fusion and transmission of HIV -1 between infected and uninfected 
cells.25,91 This protein is not toxic to host cells or peripheral blood lymphocytes, even at 
concentrations as high as 9 IlM.25 
The physiological role of CV -N within the cyanobacterium is presently unknown. 92 
CV-N (28) is extremely resistant to physico-chemical denaturation and can withstand 
multiple freeze-thaw cycles, dissolution in organic solvents such as acetonitrile and 
methanol, treatment with denaturants, detergents, and heat (up to 100°C) with no 
significant loss of anti-viral activity.25,91 
1.4.2 Recombinant Production 
The use of genetically engineered organisms for the large-scale production of proteins can 
provide a ready source of material for further development and investigation. There must 
be an abundant supply of CV -N (28) for it to make any progress as an anti.;.HIV 
prophylactic and/or therapeutic. 
A DNA coding sequence corresponding to the chemically deduced protein sequence was 
synthesised by Mori et a1. 25 A recombinant protein indistinguishable from natural CV-N 
(28) can be successfully expressed in Escherichia coli using a variety of expression 
vectors.25,93 
A number of CV -N mutant proteins have also been produced by recombinant methods to 
explore functional domains, sequence requirements for activity,93,94 and to facilitate the 
development of CV -N conjugates that may be useful therapeutics in the future. 95 
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1.4.3 Primary Structure of Cyanovirin-N 
Domain A I- LIK 
51- I> N 
T S T E R T N G GIN.S 
A AE KTRAQ Q Y K 
-50 
-101 
= similar aminu acids • = identical amino acids * = gap to facilitate alignment Domain B 
cyanovirin-N (CV -N, 28) 
Figure 1.13: Amino acid seqllence ofCV-N. 
Searches of available databases did not reveal any homologies of greater than eight 
contiguous amino acids or >20% total sequence homology between CV-N (28) and any 
amino acid sequences of known proteins.25,9l Internally, however, the sequence shows a 
high degree of homology. Figure 1.13 shows the amino acid sequence of CV-N (28). To 
faciliate visuaEsation of the internal sequence homology, the sequence has been separated 
into two portions. The upper portion of the sequence represents amino acids 1-50 
(Domain A) and the lower portion of the sequence represents amino acids 51-101 
(Domain B). Two intramolecular disultide bonds are indicated by linking cysteine 
residues, and are essential for the structural stability and anti-HIV activity of the native 
protein. Sequence comparison between Domain A and Domain B show high sequence 
similarity (32% identity and 26% conservative changes, thus 58% overall homology) 
suggesting that the cyanobacterial gene coding for CV -N (28) might have arisen through 
d d I· . 2591 tan em gene up 1catlOn. . 
1.4.4 Three-Dimensional Structure ofCyanovirin-N 
Bewley et al. reported the solution structure of CV -N (28) in 1998.96 (Figure 1.14) The 
structure was determined using double and triple resonance multidimensional 
heteronuclear nuclear magnetic resonance O\IMR) spectroscopy, making use of uniformly 
15N _ and 15N/ l3C labelled protein. The elucidation involved extensive use of dipolar 
couplings that provided long-range structural information. 
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Domain A 
Residues I-50 
Doma,in B 
Res,idues 51-10 I 
Domain A 
Residues 1-39, 90-10 I 
Domain B 
Residues 40-89 
32 
Figure 1.14: Solution structure of CV-N as determined by NlvlR spectmscopy96 a) sequential domains 
highlighted. b) structural domains highlighted. The diagrams were produced with Protein Explorer from 
the RCSB PDB, entry 2ezn. 
CV -N (28) is an elongated protein with a length of ~55 A in length with a maximum 
width of ~25 A. The secondary structure elements comprise ten ~-strands and four short 
helical turns. The protein displays internal two-fold pseudosymmetry due to the two 
sequence domains mentioned above. The two repeats, however, do not form separate 
domains since the overall fold is dependent on numerous contacts between them. Rather, 
two symmetrically related structural domains are formed by strand exchange between the 
two repeats.96 (Figure 1.14) 
The crystal structure of CV -N (28) (Figure 1.15) was solved by Yang et al. in 1998,97 and 
was found to consist of a dimer of two molecules of CV -N (28). This dimer represents an 
unusual and unexpected case of an almost symmetric domain swapping and consists of 
two quasi-monomers, with one made up of residues 1-50 (Domain A) and 51'-101' 
(Domain B') and the other of 51-101 (Domain B) and 1-50 (Domain A'). The domain-
swapped crystal structure shows a flexible linker, or hinge, extending between residues 49 
and 54. The two sequence-based domains are therefore moving around the hinge, forming 
either a monomer by intramolecular interactions or a dimer by intermolecular 
interactions.97 The domain swapping occurs under non-physiological conditions, 
demonstrated structurally by NMR spectroscopy98 and X-ray crystallography.97 
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Specifically, the dimer occurs following purification by reversed phase HPLC at low pH, 
and also under crystallisation conditions. The dimer can be convelted through to the 
thermodynamically more stable monomer by incubation at pH>5 at 38°C.92 
II 
II 
• 
Domain A 
Residues 1-50 
Domain B 
Residues 51-101 
Domain A' 
Residues 1 '-50' 
Domain B' 
Residues 51'-101' 
Figure 1.15: Crystal structure of the domain-swapped CV_N9 7 The diagram was produced with Protein 
Explorerji'om the RCSB PDB. entry fl5b. 
1.4.5 Mechanism of Action 
Early studies revealed that CV -N (28) bound with high affinity to the HIV surface 
glycoprotein gp 120?5 Biochemical studies addressing the mechanism behind the potent 
anti-viral activity of CV -N (28) have included binding,99,100 hybridisation, IOl 
mutagenesis94 studies, and investigations into the activity of CV -N (28) at discrete steps 
along the HIV -1 envelope-mediated fusion pathway. 102 All of these studies confirm the 
initial findings that CV -N (28) interacts with gp 120 (and not with CD4 or chemokine 
receptors) with high affinity and that these interactions are responsible for its potent anti-
viral activity at least by preventing the requisite interactions between gp 120 and cellular 
+: . 99 'O! 102 ( ' V N b' d . . f 120 ( receptors lrom occurnng. . , . - appears to 10 to umque regIOns 0 gp as 
yet to be determined) which are involved in essential fusion event(s), independent of 
and/or subsequent to the initial interactions with CD4, preceding viral entry.99 
Gp120 is one of the most highly glycosylated viral proteins known, with a carbohydrate 
component constituting approximately 50% of the total molecular weight. '03 CV -N (28) 
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was found to bind to non-glycosylated gp 120 with considerably less affinity than to 
gIycosylated gp 120.25 It was subsequently reported that the anti-viral activity of CV-N 
(28) is mediated through specific interactions with the HIV envelope glycoproteins, 
gp 120, and possibly gp4I. I()() Further investigations have indicated that CV -N (28) binds 
to these proteins through unique interactions with the high mannose oligosaccharides 
oligomannose-8 and -9 (Man-8 and Man-9 respectively) present In both 
glycoproteins.100-103_104 NMR titration experiments with the disaccharide Manal-2Mana 
demonstrated the presence on CV -N (28) of two binding sites of differing affinities, 
which mapped to opposite ends of the molecule (Figure 1.16).105 Manal-2Mana 
represents the terminal accessible disaccharide present in Man-8 and Man-9. The NMR 
solution structure of CV -N complexed with Mana 1-2Mana has also been reported (Figure 
1.16).105106 This revealed that the high-affinity site (S2) consists of a deep pocket where 
the disaccharide is almost completely buried and involved in an extensive hydrogen-
bonding network. The low-aftini ty site (S 1) consists of a cleft that only partially 
surrounds the Manal-2Mana structure. 106 
SI S2 
Domain A Domain B 
Figure 1.16: Solution NMR structure of the CVN-Manal-2Mana complexllJ5.1U6 The protein is depicted as 
a ribhon with the N- and C-termini labelled. The bound ligands, Manal-2Mana, are shown in ball and stick 
representation. The high-affinity binding site is labelled as S2 and the low-affinity binding site as SI, The 
two structural domains, A and B, are indicated. The diagram was produced with Protein Explorer from the 
RCSB PDB, entry IllY. 
Recently, Chang Leng et al. published results that showed that only a single high affinity 
carbohydrate-binding site, that is, a monovalent CV -N carbohydrate interaction, is 
required for inhibition of HIV fusion. ,07 
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In addition to the interactions with specific oligosaccharides, the data from a 
thermodynamic analysis indicates that discrete protein-protein interactions may play an 
important ancillary role in the tight binding of CV-N (28).104 The data from a crystal 
structure of a domain swapped CV-N dimer with Man_9,108 and the recent identification 
and characterisation of peptides that bind to CV -N (28),109 further supports the possibility 
ofprotein-protein interactions in the binding of gp120 and CV-N (28). 
1.4.6 Applications ofCyanovirin-N 
CV-N (28) has also demonstrated inhibition of fusion andlor infection of human 
herpesvirus 6 and measles viruS. 102 Very recently CV-N (28) has been shown to have 
highly potent anti-viral activity against the influenza virus110 and the Ebola virus. lll The 
activity against Ebola is particularly exciting as there are currently no effective therapies 
for this virus. These studies broaden the range of viruses known to be inhibited by CV-N 
(28), and highlights potential clinical utility. The broad-spectrum anti-viral activity 
against diverse enveloped viruses further implicates carbohydrate moieties on viral 
surface proteins as common viral molecular targets for CV -N (28). 
A high throughput screen has been developed based on the interaction of the HIVgp41 
ectodomain with CV-N (28). This has resulted in the isolation of new compounds that can 
bind competitively to gp41 in a manner similar to CV-N (28), therefore providing new 
anti-viral leads. 1 12 
Boyd et al. propose the use of CV-N (28) as method of inducing an immune response in 
animals.1l3,114 The generation of anti-CV -N antibodies with an internal image of gp 120 
has been demonstrated by administering CV -N (28) to rabbits. 113,1l4 This raises the 
possibility of using either CV-N (28) or anti-CV-N antibodies to prevent or treat a viral 
infection in an animal. 
Another approach to the application of CV-N (28) is to immobilise the protein on a solid 
matrix in order to screen for and exclude HIV from blood or plasma. Biotinylated CV-N 
was coupled to streptavidin coated magnetic beads to provide sessile CV_N. 115 When 
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reacted with a primary isolate of HIV the sessile CV-N removed a fraction of the 
infectious virions but left behind a larger fraction of replication-incompetent virions. The 
latter fraction could be used as a vaccine for HIV. 1l3,115 
HIV can be transmitted by vaginal and rectal sexual intercourse. An effective microbicide 
is one strategy that could significantly reduce the spread of HIV infection. The in vitro 
and in vivo efficacy of CV -N (28) has been studied in vaginal transmission models. CV-N 
(28) was found to have no adverse effects and was a highly active infection-blocking 
agent in the model systems.1l6 Similar results have been demonstrated with a CV-N gel as 
a topical microbicide for the prevention of rectal transmission of a pathogenic chimeric 
simian/HIV -1 virus.117 In vitro studies indicate that CV -N (28) is fully active against 
representative strains of all known HIV subgroups and no CV-N-resistant virus has 
emerged after numerous tests. 116 Together these results suggest that CV -N (28) is a 
promising agent for development as a topical microbicide for the prevention of sexual 
transmission of HIV infection. 
An effective microbicide may require a system that delivers and maintains an effective 
concentration ofthe drug at the mucosal sites of entry ofHIV. Giomarelli et al. have been 
exploring the feasibility of endogenous production of CV -N (28) at mucosal surfaces by a 
colonizing commensal bacterium such as Streptococcus gordonii. The initial results are 
positive with S. gordonii expressing CV-N (28) in a biologically active form. ll8 
In addition to direct virucidal applications, CV-N (28) has been used in creating a 
recombinant chimeric toxin molecule in which the translocation and cytotoxic domains of 
Pseudomonas exotoxin A are linked to CV-N (28).95 In the resulting molecule, CV-N 
(28) serves as the targeting moiety that binds to HIV-infected cells expressing gp120. The 
chimeric molecule demonstrates enhanced cytotoxicity for HIV infected H9 cells 
compared with uninfected H9 cells, although with the diminution of the overall gp120 
binding activity.95 These results highlight the potential for a similar application of CV-N 
(28) - one that attached low molecular weight, non-proteinaceous cytotoxic agents to CV-
N (28) - that would not diminish its gp 120 binding activity. This concept provides the 
foundation for the work presented in this thesis. 
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1.5 Drug Delivery 
The development of drugs is often hampered by a poor therapeutic index. 119,120 The 
therapeutic index is the relationship between the concentration of a drug that results in 
treatment efficacy, and the concentration that causes toxicity. Ideally, medications should 
have a high therapeutic index so that they can exert their beneficial effects without 
causing harm to the patient. A major disadvantage of many clinically established drugs, 
and of newly isolated compounds showing promising cytotoxicity, is their lack of 
selectivity for infected tissue, causing systemic toxicity and severe side effects. They are 
often of low molecular wcight and readily gain access to the cells by rapid passage across 
the plasma membrane. 121,1 22 The high potency of many compounds, like the halichondrins 
for example, only serves to exacerbate the problem. Thus, in order to increase the 
therapeutic index of these agents, drug delivery systems are required which target the 
drug, through both passive and active mechanisms, to the site of infection. To achieve site 
specific targeting, it is necessary to identify unique features of affected cell biology that 
will concentrate the drug within a particular region. Tn addition, delivery systems can 
address and correct problems related to the physical characteristic of a drug, including 
solubility and stability.123 
One approach that has been found to alter the pharmacokinetic behaviour and overcome 
the toxicity of cytotoxic compounds to healthy tissue thereby increasing the therapeutic 
index of these agents - is to attach the cytotoxic compounds to soluble 
macromolecules. 121 ,124 In recent years, such conjugates have been extensively studied as 
drug carriers facilitating site-specific delivery of immunosuppressants and anti-cancer 
drugs. Numerous pre-clinical studies have shown that macromolecules such as antibodies, 
serum proteins, polysaccharides, poly(arnino acids), or synthetic polymers are taken up by 
tumour tissue. 125 These polymers accumulate in solid tumours due to the passive 
mechanism of the enhanced permeability and retention (EPR) effect. 121,122,126 The entry of 
macromolecules into tumours is mediated by a 'leaky' blood supply to the tumour. This is 
in contrast to normal tissue where a continuous layer of endothelial cells allows diffusion 
of small compounds but not macromolecules. In general, solid tumour tissue does not 
have a lymphatic drainage system, resulting in retention and accumulation of 
macromolecules. 
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Polymer therapeutics is a rapidly growing field in the development of drugs. The basic 
design of a polymer therapeutic l21,127 (Figure 1.17) attaches the toxin to a water-soluble 
polymer (synthetic or biological) so that it can be transported through the blood stream. 
This attachment is via a small biodegradable biolinker. This biolinker acts as a spacer 
between the drug and the polymer, and, more importantly, can be specifically designed to 
resist cleavage during circulation in the body but be amenable to enzymatic or hydrolytic 
cleavage after entry into a diseased celL 128,129 Drug conjugation to a macromolecule limits 
cellular uptake to the mechanism of endocytosis. This provides an ideal opportunity to 
control the rate of drug liberation by careful tailoring of the drug-polymer linker. A 
targeting residue attached independently to the polymer is the key to targeting receptors 
found predominantly on cells of interest. 
Polymer Backbone 
Figure 1.17: Schematic diagram of the basic features of a'soluble polymer therapeutic121,m 
Blood proteins, serum albumin, transferrin, and low-density lipoprotein (LDL), have 
attracted attention regarding their potential as drug delivery systems for improved 
chemotherapy. These endogenous proteins are suitable as drug carriers for a number of 
reasons: 
• They are readily available in a pure fonn and exhibit good biological stability. 
III They are biodegradable, non-toxic, and non-immunogenic. 1l9 
«I They exhibit a preferential uptake in tumour tissue by the EPR effect. 130,131 
• Tumour cells express high amounts of specific transferrin or LDL receptors on 
their cell surface.132,133 Numerous examples of cytotoxic agents have been 
developed as conjugates with the proteins above in an effort to improve selectivity 
and toxicity profiles. Promising results have been obtained. 119,134-136 
Chapter One - Introduction 39 
Drugs that actively target affected cells are sought after for treatments of cancer and HIV. 
As mentioned briefly above, transferrin and LDL are potential carrier proteins for the 
targeted delivery oftoxic drugs to tumour cells due to receptors on the cell surface. CV-N 
(28) linked to the cytotoxic domains of Pseudomonas exotoxin A showed targeted 
delivery to HIV -infected cells because of its affinity to gp 120.95 Monoclonal antibodies 
have attracted enormous interest as targeted therapeutics. A variety of antibody-toxin 
conjugates are showing therapeutic potential as tumour-specific 137 or HIV -specific 
targeted agents. 138,139 In particular, an anti-HIV molecular conjugate containing the 
effector domains of the Pseudomonas exotoxin A linked to a single chain antibody, with 
specificity for the highly conserved CD4 binding site of gp120, has been produced. This 
conjugate is able to kill cells productively infected with diverse strains of HIV while 
sparing uninfected cells in vivo.27 
The research of the last few decades has resulted in a number of polymer-based products 
that are now on the market or have entered clinical trial. One approach of particular note 
involving soluble macromolecular drug carriers is SMANCS. In the clinical formulation, 
neocarcinostatin (NCS) is conjugated to two chains of a styrene-maleic anhydride 
copolymer (SMA). SMANCS is marketed in Japan for the treatment of hepatocellular 
carcinoma. 140 
Polyethylene glycol (PEG)-modified adenosine deaminase (ADAGEN®) and PEG-L-
asparaginase (ONCASP AR®) were the first PEG modified enzymes on the market in the 
early 1990s. PEG-ADA is used for the treatment of ADA-deficient Severe Combine 
Immunodeficiency Syndrome, and PEG-L-asparaginase is used to treat lymphocytic 
leukemia and malignant lymphosarcoma. PEG-modification resulted in a prolonged 
plasma clearance of the enzymes. Both products are in clinical use today. 140 
An anti-HIV hybrid protein toxin, CD4-PE40 (soluble CD4 linked to the translocation 
and toxic domains of Pseudomonas exotoxin A), has been developed to selectively target 
and kill cells expressing the HIV -envelope glycoproteins.39,13S,139 The genetically 
engineered protein displays high potency and specificity for killing HIV-l infected cells 
in vitro and in vivo animal models. Disappointingly, the conjugate has demonstrated little 
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evidence of anti-HN efficacy in initial Phase I clinical trials. It is believed however, that 
this drug should be reconsidered in combination with HAART.39 
PKI and PK2 are both derivatives of HPMA copolymer with the anti-tumour agent 
doxorubicin linked onto it via the peptidyl spacer Gly-Phe-Leu-Gly. PK2 also contains 
galactose as a targeting group to facilitate liver targeting. 141 PKI is currently undergoing 
Phase II evaluation for treatment of breast, colon and non-small-celliung cancer. Phase I 
results revealed that PKI displayed greatly reduced toxicity with maintained anti-tumour 
efficacy compared with free doxorubicin. 142 The maximum tolerated dose ofPKl is about 
four times higher than the usual clinical dose of free doxorubicin. 142 PK2 has entered 
Phase I clinical testing.143 
These positive results demonstrate that the coupling of cytotoxic agents to suitable 
macromolecules is a promising approach of circumventing the toxic side effects of these 
agents to normal cells, and of improving their efficacy towards infected cells. Primarily, 
this thesis explores the use of the 11 kDa protein, CV -N, to actively target and deliver 
cytotoxic natural products to HIV-infected cells. This project also investigates the use of 
human serum albumin, a 66 kDa protein, as a macromolecular carrier to passively target 
and deliver cytotoxic natural products to cancerous cells. 
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1.6 Project Aims 
1.6.1 Anti-HIV Therapeutics 
Mori et at. created a chimeric molecule in which the cytotoxic domain of Pseudomonas 
exotoxin A is linked to CV-N (28) (Section 1.4.6).95 The conjugate demonstrates 
enhanced cytotoxicity for HIV infected H9 cells compared with uninfected H9 cells. As a 
result of the large proteinaceous toxin, however, it shows a diminution of the overall 
gp120 binding activity.95 
The primary aim of this project was to design and follow a synthetic strategy that attached 
low molecular weight, cytotoxic agents to CV-N (28) that would not diminish its gp120 
binding activity. The resultant conjugates would be fully chemically characterised. Their 
selective cytotoxicity to HIV-infected cells and gp120 binding activity would also be 
assessed. Previous work by Scott Bringans90 established the viability of this approach by 
synthesising fluorescently-Iabeled conjugates of native CV-N (28). Biological testing of 
these derivatives showed no interference with the anti-HIV activity of the protein. 
A number of factors needed to be taken into consideration in the development of a CV-N-
toxin conjugate: 
• Firstly, the modifications made to CV-N (28) must not interfere with the binding 
capabilities of the protein to gp 120. 
• Secondly, ideally the toxin would behave under a prodrug strategy until the 
conjugate was internalised and the "active" drug was released within the infected 
cell. However, any synthetic modifications to the toxins must still allow the toxin 
to retain its inherent biological activity. 
• Thirdly, with limited toxin and protein supply, synthetic steps must be carefully 
planned and as high yielding as possible. 
• Finally, a protein-conjugate must be internalised before it can function to kill a 
cell. Most virologists believe that retroviral envelope proteins found on the cell 
surface are in the process of leaving the cell via viral budding. However, Pincus et 
al. 138 showed that, at least a portion of the cell-surface envelope protein is 
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reintemalised. Their studies demonstrated that there is a recirculating pool of 
envelope protein, and that the rates of intemalisation were subject to regulatory 
influences. These results demonstrate the feasibility of creating a CV -N-toxin 
conjugate as an anti-HIV therapeutic. 
The focus of this project has been on the development of a proof-of-concept approach to 
an anti-HIV therapeutic. The aim was to take advantage of the specific, targeted, delivery 
opportunity offered by CV-N, and the bioactivity of several natural products, to develop 
novel anti-HIV therapeutics with high specificity and high toxicity towards HIV infected 
cells. 
1.6.2 Anti-Cancer Therapeutics 
Section 1.5 introduced the phenomenon of macromolecules accumulating in solid tumors. 
The plasma protein, human serum albumin (lISA), exhibits a significant uptake in tumour 
tissue as demonstrated by Matsumura et al. I31 and Sinn et al. 130 A number of conjugates 
in which anti-cancer drugs, for example chlorambucil134 or doxorubicin,I44 have been 
bound to albumin through acid-sensitive linkages have been developed. The positive in 
vitro and in vivo anticancer activity demonstrated by these conjugates encouraged a 
second aim of this project. This would investigate the use of human serum albumin as a 
macromolecular carrier, to passively target and deliver selected cytotoxic natural products 
to cancerous cells. The chemistry developed in Section 1.6.1 would be utilised to attach 
low-molecular-weight, cytotoxic agents to HSA. 
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STRATEGY DEVELOPMENT 
2.1 Introduction 
As outlined in the previous chapter, the primary aim of this project was to develop an 
anti-HlV therapeutic agent, by attaching low-molecular-weight cytotoxic compounds to 
CV-N (28). The target structure is shown schematically in Figure 2.1. The rationale was 
that CV-N (28) would target and deliver the drug to infected cells. Selective cleavage of 
the biolinker, within diseased cells, would release the drug and the inherent cytoxicity. 
This strategy was adapted from the polymer therapeutic model proposed by Ringsdorf in 
1975. 127 
selective cleavage for 
controlled drug release 
~ 
" 
low-molecular-weight 
carrier/targeting agent cytotoxic componnd 
Figure 2.1: Schematic of a eVoN-drug conjugate. 
In the development of this strategy, attention needed to be focused on each of the 
individual components ofthe conjugate in Figure 2.1. This chapter describes: 
1) The selection of an appropriate biolinker that would allow controlled release of a 
drug within HN -infected cells. 
2) The selection of a synthetic method by which the biolinker unit could be 
covalently coupled to CV -N (28). 
3) The establishment of a synthetic route to prepare an activated biolinker that could 
participate in the coupling strategy planned in 2). 
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4) The selection of appropriate cytotoxic drugs, and hemi-synthetic modification of 
these compounds, so that they could be functionalised in such a way as to be 
covalently attached to the biolinker. 
5) Proof-of-principle of the conjugation strategy in 2) with a model protein and a 
model biolinker-toxin construct. This objective provided the opportunity to 
develop purification methods and establish approaches for evaluating the 
structures of the conjugates. 
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2.2 Biolinker Development 
Careful tailoring of the protein-drug biolinker is essential to the creation of a "prodrug" 
that is stable during transport but allows drug liberation at an appropriate rate 
intracellularly. Acid labile, pH-dependent hydrazone and acetal linkages145 have been 
fashionable for drug conjugation. The proton pump present in the endosomal and 
lysosomal membranes creates an acidic intravesicular environment (typically pH 6.5 -
5.5) so drug liberation is triggered following intemalisation of the conjugate. 141 ,145 
Peptidyl linkers were popularised by the successful design of anti-cancer HPMA 
copolymer-Gly-Phe-Leu-Gly-doxorubicin conjugates. 146,147 The tetrapeptide linker, Gly-
Phe-Leu-Gly, was shown to be stable in bloodstream circulation,148 but be cleaved by the 
cathepsin enzymes following endocytic uptake of the conjugate from the tumour 
interstitium. 149,150 
Macromolecules, particularly proteins, can be taken up by the cell via endocytosis, 
transported in the form of endosomes and finally directed to degradation by fusion of 
these vesicles with lysosomes. 141 ,145,151 Lysosomes are organelles which form by pinching 
off from the Golgi apparatus and which contain a multitude of hydrolytic enzymes, 
including proteases, esterases and glycosidases. 145 The term "cathepsin" is used to refer to 
intracellular proteases, mostly localised in the lysosomes, which are active at weakly 
acidic pH values (approximately pH 5.0).151 Most of the lysosomal proteases are cysteine, 
or thiol dependent proteases. Cathepsin B has been the most extensively investigated. 
Various physiological roles have been ascribed to this enzyme, including degradation of 
defective or damaged proteins within celllysosomes, endosomal processing of exogenous 
proteins and participation in bone remodelling.15l,152 Cathepsin B also shows enhanced 
expression in tumours. The enzyme is believed to be involved in degradation of the extra-
cellular matrix, enabling cancer growth and invasion. 152,153 
The tetrapeptide, Gly-Phe-Leu-Gly, shown in Figure 2.2, has been designed as a substrate 
for the cathepsin enzymes,149,150 and in particular, has been shown to be degraded in vitro 
by cathepsin B. 128,146,147 The success of the HPMA copolymer-Gly-Phe-Leu-Gly-
doxorubicin conjugates (PIG and PK2), both in vitro and within Phase IIII clinical 
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evaluation,141-143 made the tetrapeptide an attractive biolinker option for the protein 
therapeutic model being developed in this project. 
phenylalanine, Phe 
glycine, Gly 
I~ 
~ 0 glycine, Gly 
o 
~0N~ yo 
leucine, Leu 
Figure 2.2: Biolinker; tetrapeptide Gly-Phe-Leu-Gly, a substrate for the cathepsin enzymes. 
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2.3 Coupling Method 
Bioconjugation involves the linking of two or more molecules to fonn a novel complex 
having the combined properties of its individual components. Natural or synthetic 
compounds with their individual activities can be combined to create unique substances 
possessing carefully engineered characteristics. Modification and conjugation techniques 
are dependent on two interrelated chemical functionalities: the reactive functional groups 
that are present on the derivatising reagents and the functional groups that are present on 
the target macromolecules to be modified. Without both types of functional groups being 
available and chemically congruent, the process of conjugation would be impossible. 
The technology ofbioconjugation has affected nearly every discipline in the life sciences, 
serving research, diagnostics and therapeutic markets. The development of this field has 
resulted in an arsenal of reagent systems and conjugation strategies154 to select from in the 
design of unique applications. 
Several factors needed to be taken into consideration in the development ofa CV-N-toxin 
conjugate. Firstly, the bond between biolinker and protein must be sufficiently stable so 
as to resist cleavage in circulation of the body. And secondly, there is the requirement to 
attach toxin molecules to CV -N (28), without affecting the tenuous relationship between 
amino acid functionality and the three-dimensional folding of the polypeptide chain. CV-
N (28) must retain its ability to bind to gp120, and hence retain the unique anti-HIV 
activity. Scott Bringans90 synthesised fluorescently-labeled conjugates of native CV-N 
(28). These conjugates had been prepared by activating a fluorescent compound with an 
N-hydroxysuccinimide (NHS) ester. NHS ester-containing compounds react with 
nucleophiles, with a marked preference for N-based nucleophiles, with release ofthe NHS 
leaving group to fonn an acylated product. The alternative reaction of such esters with a 
sulfhydryl or hydroxyl group does not yield stable conjugates, fonning thioesters or ester 
linkages, respectively. Both of these bonds hydrolyse in aqueous environments. [54 Thus, 
in protein molecules, NHS ester reagents couple principally with the 8- and N-tenninal 
amines. 154 Biological testing of the CV -N derivatives prepared in this manner, 
demonstrated that modification of the amine functionalities of CV -N (28) created 
conjugates with good retention of the native anti-HN activity.90 The NHS ester reagent 
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hydrolysed rapidly in the aqueous environment. An alternative 'modifier' of the amines 
was sought that would eliminate this hydrolysis problem at the start of the bioconjugation 
process. 
Traut's reagent, 2-iminothiolane (2-IT, 29), has been used previously as a protein cross-
linking agent,155,156 and is also being developed by Kratz and Beyer135,157 as a strategy for 
conjugating the transferrin protein to natural products, such as chlorambucil. The cyclic 
imidothioester reacts with primary amines in a ring-opening reaction that generates a free 
thiol (Figure 2.3). 2-IT (29) has been shown to react preferentially with exposed lysine 8-
amino groups and at the N-terminal a-amino groUp.158 Traut's reagent (29) is fully water-
soluble and reacts with primary amines in the pH range 7 - 10. The cyclic imidothioester 
is stable to hydrolysis at acid pH values, but its half-life in solution decreases as the pH 
increases beyond neutrality. At high pH (10), 2-IT (29) is also reactive with aliphatic and 
aromatic hydroxyl groups, although the rate ofreaction is only about 0.01 that of primary 
amines. 154 
Maleimide derivatives can then be selectively bound to the introduced sulfhydryl groups 
on the carrier protein. The sulfhydryl functionality adds to the double bond of a 
maleimide group in a fast and selective Michael reaction forming a stable thioether bond. 
Maleimide reactions are specific for sulfhydryl groups in the pH range 6.5 - 7.5. 154 At pH 
7, the reaction of the maleimide with sulfhydryls proceeds at a rate of 1000 times greater 
than its reaction with amines while at higher pH values some cross-reactivity of amino 
groups can take place. 154 Figure 2.3 depicts the use of this methodology to produce a CV-
N-drug conjugate. CV-N has six primary amino groups that can be thiolated, and hence 
up to six equivalents of a maleimido-activated drug construct could be conjugated to the 
protein. The thioether linkage is stable in blood circulation. 157 
Owing to the highly selective nature of the thiolation reaction, followed by the 
preferential and rapid binding of the sulfhydryl to a maleimido derivative, the synthetic 
strategy in Figure 2.3 was selected to produce CV -N drug conjugates. 
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Figure 2.3: Synthesis of a CV-N-drug conjugate using thioether bond formation. 
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2.4 Synthetic Route to an Activated Biolinker 
Based on the considerations outlined in Sections 2.2 and 2.3, y-maleimidobutyric-Gly-
Phe-Leu-Gly-OH (30) was selected as the target maleimido-activated biolinker. This 
compound could then be subsequently coupled to chosen toxin derivatives. 
et
0 4(jH~2 
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#' 0 
~~~AyOH 
o 2y28 0 
27 
y-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30) 
Figure 2.4: The target maleimido-activated biolinker: y-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30) 
2.4.1 Solid Phase Peptide Synthesis 
The importance of peptides in biological processes is beyond doubt. Their wide spectrum 
of activity marks them out as a class of compounds of significant interest in areas from 
medicinal chemistry through to molecular biology. It is therefore not surprising that there 
has been a constant drive to develop new and improved strategies for peptide synthesis. 
Solid Phase Peptide Synthesis (SPPS) was first introduced by Merrifield in 1963,159 and 
has dominated synthetic peptide research since. The concept of SPPS is illustrated in 
Figure 2.5. SPPS is based on sequential addition of a-amino and side chain protected 
ammo acid residues to an insoluble solid support. The base-labile 
fluorenylmethoxycarbonyl (Fmoc)-group is often used for N-a-protection. After removal 
of this group, the next protected amino acid is added using either a coupling reagent or a 
pre-activated protected amino acid derivative. The resulting peptide is attached to the 
resin, via a linker, through its C-terrninus and may be cleaved to yield a peptide acid or 
amide depending on the linking agent used. The revolutionary principle behind SPPS is 
that if the peptide is bound to an insoluble support then any unreacted reagents left at the 
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end of any synthetic step can be removed by a simple wash procedure, greatly decreasing 
the time required for synthesis.159-161 
H 0 x/N00~ 
f: 1 depro'ootion of a-mUno group 
o 
H2N0o~ 
R1 
~1 H 0 
x/N0 0H 
R2 
I 
Y2 Y2 
I 
R2 H 0 X'N~N00~ 0 
H 0 R 
I 1 
Y1 
Coupling 
Repeat above cycles 
Deprotection of a-amino groups 
Cleavage from resin 
Figure 2.5: Schematic of Solid Phase Peptide Synthesis. R: side chains. X: tempormy a-amino protecting 
group. Y: side chain protecting groups. 
The maleimido-tetrapeptide derivative, 30, was synthesised on solid phase, with the 
maleimide introduced in the final step, at the N-terminal position of the tetrapeptide. 
Although several types of polystyrene-based resins have been used for synthesis of 
peptides using the Fmoc strategy, the most successful and widely used resin is that of 
Wang. 162 The resin consists of a polystyrene bead onto which an acid-labile linker has 
been attached. Attachment of the first amino acid to Wang resin has often been 
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accomplished usmg dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine 
(DMAP). This method is fraught with the problem of racemisation of the amino acids 
(though not a problem in this case, with the first amino acid being glycine) and formation 
of dipeptides (through premature loss of Fmoc) due to the basic nature of DMAP .163 For 
this reason, the esterification of glycine to the hydroxyl group on the resin followed the 
method described by Sieber. 163 This esterification method is a good alternative, requiring 
longer loading times, but virtually eliminating racemisation and dipeptide formation. 
Wang resin (2 g, 3 mmol hydroxymethyl groups) and 1.1 equivalents Fmoc-Gly-OH were 
shaken in DMF at RT for 15 minutes. Pyridine (6.9 equivalents) and 2,6-dichlorobenzoyl 
chloride (3.5 equivalents) were added successively and the suspension was shaken for 15 
hours. After washing, any remaining hydroxyl groups of the resin were benzoylated with 
four equivalents benzoyl chloride and six equivalents of pyridine in dichloroethane. 
The extent of functionalisation of the resin was measured by UV determination of the 9-
fluorenylmethylpiperidine after cleavage of the Fmoc-group with piperidine. A small 
amount of resin (0.5 - 1 mg) was weighed into two quartz cuvettes. A piperidine/DMF 
solution was dispensed into each cuvette along with a third that was used as a solvent 
blank. A UV spectrum of each sample taken after five minutes. The loading of the resin 
was determined on the basis of a linear relationship between absorbance at 290 nm and 
quantity ofFmoc amino acid present. One mmol'ofFmoc-amino acid gives an absorbance 
of 1.650. An average loading of 0.873 mmol Fmoc/g resin, and hence 0.873 mmol 
glycinel g resin, was determined. 
The glycine-loaded reSIn was subsequently used in a batch-wise synthesis of the 
tetrapeptide. The peptide resin was contained in a filter reaction vessel, to allow bubbling 
of the resin with nitrogen gas from below, and removal of solvent and excess reagents by 
vacuum after each step. The glycine-resin (2 g, 0.873 meq/g) was bubbled in DMF for 30 
minutes to preswell the resin. Thus, the reactions occur not on the surface of a rigid 
particle, but within the support of a solvated gel which permits easy access to the growing 
peptide chain. The glycine residue was then deprotected by subjecting it to mild base 
treatment using piperidine (20% piperidinelDMF, 20 mL) for ten minutes. The reaction 
mixture was filtered by suction and washed with DMF and IP A. The completion of the 
deprotection was monitored to ensure the success of the SPPS. The qualitative ninhydrin-
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based Kaiser test164 (Section 8.1.6) was used to detennine the presence or absence of free 
amino groups. A positive result was recorded with the expected dark blue colour typical 
of free amines, so the synthesis continued. Two equivalents of Fmoc-Leu-OH were 
combined with two equivalents of the in situ coupling reagent, HBTU, two equivalents of 
HOBt, to prevent racemisation, and four equivalents of the base, DIPEA, for two minutes. 
This solution was then bubbled with the glycine-resin for one hour. The beads were 
washed with DMF and IP A before being reanalysed with the Kaiser test. A negative 
result confinned that the coupling procedure was complete. The steps described to this 
point completed one cycle; the peptide chain was lengthened by one amino acid residue. 
Further cycles were carried out in the same way by alternating deprotecting and coupling 
with the remaining amino acids, Fmoc-Phe-OH and Fmoc-Gly-OH, and the maleimido-
acid, y-maleimidobutyric acid. The sample was left to dry overnight in the presence of 
P20 S under vacuum, before the completed maleimido-tetrapeptide was liberated from the 
resin by treatment with a TFA solution (95% TFA, 2.5% TES and 2.5% water) for 20 
minutes. The solution was drained and the resin was rinsed with further TF A. The acidic 
fractions were combined and alternately concentrated under vacuum and precipitated with 
water to remove TF A from the solution. 
The crude peptide product was purified by semipreparative reverse phase HPLC. A 
solvent gradient comprising the following steps was used: an isocratic hold on 15% 
CH3CNIH20 (0.05% TF A) for two minutes; a linear gradient to 50% CH3CNIH20 over 
20 minutes; a return to 15% CH3CNIH20 over one minute; and finally an isocratic hold 
on 15% CH3CNIH20 for two minutes. The system was monitored at 213 nm and a peak 
eluting at 15.6 minutes was collected manually and the solvent removed under nitrogen 
gas flow to give 30. 
2.4.2 Characterisation of y-maleimidobutyric-Gly-Phe-Leu -Gly-OH (30) 
The IH NMR (Figure 2.6) and l3C NMR spectra of 30 were readily assignable with 
reference to COSY, HSQC and CIGAR 2D NMR experiments. Detennination of 
connectivity between spin systems within the same amino acid allowed the identification 
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of individual amino acid residues, while heteronuclear couplings across the peptide bond 
were used for elucidation and confirmation of the sequence. 
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Figure 2.6: IH NMR spectrum ofy-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30)(500 MHz, CDJOD) 
The chemical shift assignments for the IH and 13C NMR spectra are shown in Table 2.1, 
with the structure and major CIGAR correlations shown in Figure 2.7. 
NMR analysis was carried out in CD30D. This resulted in a loss of the proton signals 
beyond 7.80 ppm over time. This was due to the exchange of the amide protons by the 
ionisable deuterium atom of the solvent. For this reason the amide protons were not 
assigned. All expected HSQC correlations were present in the spectra, therefore allowing 
immediate assignment of IH chemical shifts to their 13C counterparts. A useful starting 
point for the structural elucidation was the readily assigned lone proton of the maleimide, 
the singlet at 6.80 ppm. A CIGAR correlation comlected the ketone at position C2. A 
CIGAR correlation from the proton multiplet at 3.50 ppm back to C2 linked the alkyl 
chain to the maleimide functionality. With H4 now established, the assignment of H5 and 
H6 was also possible due to COSY correlations. H5 was correlated to both H4 and H6, 
and was placed in the centre of the alkyl chain. This order of assignment was confirmed 
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with a correlation from H6 into the carbonyl at position C7. The first glycine residue was 
connected to the maleimide entity, C7, due to CIGAR correlations through the amide 
bond from the two a-protons at 3.80 ppm and 3.72 ppm respectively. In turn, these a-
protons established the assignment of the carbonyl at CIO with further CIGAR 
correlations. The phenylalanine residue was subsequently linked into the peptide via a 
CIGAR correlation from the a-proton multiplet at 4.62 ppm to the carbonyl, CIO. Access 
into the aromatic ring of phenylalanine was gained through CIGAR correlations from 
HI2 to C20 and C2l. The phenylalanine carbonyl, C13, was confirmed with CIGAR 
correlations from both the a- and p-phenylalanine protons. A further CIGAR correlation 
from the leucine a-proton linked the leucine residue into the peptide chain. The leucine a-
proton also fed important CIGAR correlations into the branched leucine alkyl side-chain, 
allowing assignment of positions 25 to 28. Finally, the second glycine residue completed 
the tetrapeptide, with CIGAR correlations from the a-proton at position H18, across the 
amide bond into C16, and into the carboxylic acid at C19. An HSQC correlation 
confirmed the chemical shift ofCl8. 
Atom No .. I H 3(pphtt 13C 3(ppm)~ Atom No. in· 3 (ppm)a .. 13C~ (ppin)b 
1 6.80 (s) 134.3 15 4.41 (m) 51.9 
2 - 171.5 16 - 171.5 
---- --------
3 - - 17 - -
4 3.50 (m) 36.6 18 3.86 (s) 40.6 
5 1.84 (m) 24.1 19 - 173.6 
6 2.21 (t,7.5) 32.2 20a 3.15 (dd, 8.5, 13.5) 37.0 
7 - 174.4 20~ 2.96 (dd, 8.5,13.5) 37.0 
8 - - 21 - 137.2 
9a 3.80 (d, 16.5) 42.5 22 7.19 (m) 129.1 
9~ 3.72 (d, 16.5) 42.5 23 7.25 (m) 128.3 
10 - 171.0 24 7.22 (m) 126.7 
11 - - 25 1.62 (m) 40.4 
12 4.62 (m) 55.0 26 1.62 (m) 24.5 
13 - 172.4 27 0.93 (d, 6.5) 22.3 
14 - - 28 0.89 (d, 6.5) 20.5 
Table 2.1: IH and J3C NMR data for y-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30). Recorded at 500 MHz 
in CD30D. 
(/ IH chemical shift values (c5 ppm and referenced to CD2HOD, c5H 3.31) followed by multiplicity and 
coupling constant (J/Hz). The amides were only partially observed in the IH spectrum but had exchanged 
before characterisation by other experiments could take place. 
b J3C chemical shift values (c5 ppm) as determinedfrom HSQC experiments. 
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28 0 
Figure 2. 7: Important CIGAR correlations/or y-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30) 
y-Maleimidobutyric-Gly-Phe-Leu-Gly-OH (30) was subsequently reacted with the toxin 
derivatives. This is discussed below. 
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2.5 Cytotoxin Development 
There is already a plethora of natural compounds that have the potential to be effective as 
anti-HIV or anti-tumour agents (Chapter 1). Many of these compounds possess non-
specific toxicity restricting their efficacy in vivo. One of the main limitations can be 
viewed simply as an inability to deliver therapeutic agents properly to diseased cells. 
Early clinical studies with HPMA copolymer conjugates have shown, unequivocally, that 
drug conjugation can significantly decrease non-specific toxicity while maintaining anti-
tumour activity.142,143 It is clear that if designed correctly, protein- or polymer-drug 
conjugates could provide an ideal 'package' for compounds whose therapeutic potential 
has been overshadowed by unacceptable toxicity. Attaching hydrophobic compounds to 
hydrophilic proteins or polymers also provides the possibility of circumventing the 
problems associated with poor drug solubility. 165 
There needed to be a careful selection of an appropriate cytotoxin(s) to complete the 
model in Figure 2.1. The prospective compound needs to be amenable to derivatisation, 
and attachment to the biolinker, while still retaining an inherent cytotoxicity. This is, after 
all, the essential warhead of the conjugate. 
The tetrapeptide, Gly-Phe-Leu-Gly, was chosen as a biolinker based on its ability to act as 
a substrate for the cathepsin enzymes (Section 2.2). Because of the peptide nature of this 
linker, the strategy was to attach the cytotoxin to the peptide via a peptide bond. The 
amide linkage serves as the basic unit from which all proteins are made, and resists 
hydrolysis in circulation of the body. Following endocytosis of the conjugate, hydrolysis 
by the cathepsin enzymes would release the cytotoxin within diseased cells. Release of 
the cytotoxin would be in a specific and controlled manner. The biolinker carries a free 
carboxylic acid, so it follows that the toxin must be functionalised with an amine moiety, 
in order for amide conjugation to occur. 
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2.5.1 Homohalichondrin B (22) 
Homohalichondrin B (22) was selected from the library of potent cytotoxic compounds 
isolated by the Marine Chemistry Group at the University of Canterbury. There was no 
doubt that this compound showed potential as a pharmaceutical based on its potent in 
vitro and in vivo cytotoxicity (Section 1.3) As outlined in Section 1.3.3 further 
development of this compound has been hampered by supply issues. However, even with 
a ready supply of homohalichondrin B (22), the critical issue of this compound's high 
potency and lack of selectivity for infected tissue must be addressed. Homohalichondrin 
B (22) was an ideal candidate to attach to CV-N (28), or HSA, in the hope that the 
therapeutic profile of the cytotoxin could be improved. Homohalichondrin B (22) was 
also chosen because there was an extensive in-house lmowledge of the chemistry of the 
halichondrins. Synthetic methods have already been devised by Rachel Lill89 and Scott 
Bringans90 that have led to the successful production of norhomohalichondrin B amine 
(31). This amine derivative ofhomohalichondrin B could be subsequently attached to the 
biolinker via a peptide bond. 
2.5.1.1 Preparation of nor hom ohali chondrin B amine (31) 
Based on the previous discussions, the target maleimide-activated biolinker-halichondrin 
B construct was y-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32). 
Figure 2.8: The target maleimido-activated biolinker-homohalichondrin B. 
Homohalichondrin B (22) first needed to be functionalised with an amine moiety, and 
then further conjugated with the maleimido-biolinker prepared in Section 2.4. 
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Rachel Lill completed the series of reactions outlined in Figure 2.9, These steps present 
the synthetic route that she took to convert homohalichondrin B (22) to 
norhomohalichondrin B amine (31),89 
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Figure 1.9: A jive-step conversion ofhomohalichondrin B (11) to norhomohalichondrin B amine (31).89 
The scheme in Figure 2.9 shows initial oxidation ofthe diol (22) to an aldehyde (33) with 
subsequent reduction back to the primary alcohol. Tosylation with tosyl chloride was then 
followed by the formation of the azido norhomohalichondrin B derivative, The final step 
involved hydrogenation of the azide to the amino-derivative, with Lindlar's catalyst. 
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Although these reactions were ultimately successful in achieving the desired end amino 
product, the synthetic scheme was time consuming, purification difficulties were 
experienced at each stage, and the number of manipulations resulted in significant 
compound loss over the five steps, 
Scott Bringans pursued a different route90 adapted from a method developed for the 
conversion of 17-formyl-normycalamide A to 17-amino-normycalamide A by Sean 
Devenish,166 
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Figure 2.10: A simple two-step conversion of homohalichondrin B (22) to norhomohalichondl'in B amine 
(31),90 
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This strategy (Figure 2.10) bypassed the need for a five step synthetic scheme by forming 
norhomohalichondrin B amine (31) in two simple quantitative steps from 
homohalichondin B (22). It was therefore the method of choice for the generation of an 
amino derivative of homohalichondrin B that could be subsequently attached to the 
biolinker. 
Homohalichondrin B (22, 2 mg) was stirred with an aqueous solution of sodium periodate 
(30 mM) at room temperature for 24 hours. The aqueous reaction mixture was extracted 
with ethyl acetate, and the organic fractions were combined and taken to dryness. The lH 
NMR spectrum (Figure 2.11) matched a spectrum for norhomohalichondrin B aldehyde 
(33) produced by Rachel LilL 89 Of particular interest was the distinctive doublet peak for 
the aldehyde resonance (H54) at 9.71 ppm, and the readily visible proton peaks 
representing H53 and H50 ofthe '0' ring, at 4.52 ppm and 3.97 ppm, respectively. 
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1\ 
~~l .. ",wM'~ 
! IlIiill,j·jlliiilii illj,jliiliiIJJiliiJ,jilillljillqjl!lllijH))llii1l,nipiJlfT!lTfTmJT1' 
9.74 9.68 ppm 
~"I~' ~'~'~"I-'~~'·'I~'~~'I~'~~"I-'~"'~' 'I~'~~'~I"~' ~'~'-'I~'~'~"'~I~"'~' 
5.0 4.5 4.0 3.5 3.0 2.5 2.1l 1.5 ppm 
Figure 2.11: J H NMR spectrum of norhomohalichondrin B aldehyde (33)(500 MHz, CD30D). 
Final confirmation that 33 had been prepared was sought through MS analysis. Initially, 
in both EST and FAB analyses, no product was observed as only a peak isobaric with the 
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parent homohalichondrin B diol (22) was present. The sample had been prepared in 
methanol. Comparatively, when the sample was prepared in acetonitrile, the expected 
molecular ion of norhomohalichondrin B aldehyde (33) (MH+ 1091.5607, C6oH83018 
requires 1091.5579) was seen. Presumably methanol had been acting as a nuc1eophile and 
adding to the aldehyde (33), forming a hemiacetal that was isobaric with the diol (22). 
This reaction was reversible. 
The preparation of norhomohalichondrin B amine (31) involved the reductive amination 
of norhomohalichondrin B aldehyde (33) with ammonia. A solution of 31 (1.7 mg), 100 
equivalents of ammonium acetate, and crushed 3 A molecular sieves, in dry methanol 
(saturated with ammonium carbonate) was stirred for 30 minutes. The molecular sieves 
were employed to promote imine formation by absorbing water, thus driving the 
dehydration to completion. The methanol was saturated with ammonium carbonate to 
maintain the pH of the reaction, removing any acetic acid that was produced in the 
process. Sodium cyanoborohydride (five equivalents) was added in ammonium 
carbonate-saturated dry methanol. Sodium cyanoborohydride was utilised as it allows for 
selective reduction of carbon-nitrogen double bonds. 167,168 The reaction progress was 
monitored by TLC (Si02), with the disappearance of 31 and the appearance of a 
ninhydrin active spot near the baseline after 12 hours indicating that the reaction was 
complete. The reaction solution was diluted in water and passed through a C 18 cartridge, 
washed with further water, and then eluted with methanol. The IH NMR spectrum (Figure 
2.12) of the methanol fraction was shown to contain norhomohalichondrin B amine (31) 
by comparison to the spectrum of an amine previously produced by Rachel Lill. 89 
Notably, the aldehyde resonance at 89.71 ppm was no longer present, and the resonances 
ofH53 and H50 of the aldehyde (present in Figure 2.11) had moved. Rachel Lill had not 
been able to complete the assignment of the '0' ring of the amine due to severe overlap in 
the 2D NMR spectra.89 HRESIMS provided further confirmation that the amine, 31, had 
been prepared. Norhomohalichondrin B amine (31) was acylated with the maleimido-
tetrapeptide, 30, without further purification. 
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Figure 2.12: iH NMR spectrum ofnorhomohalichondrin B amine (31)(500 MHz, CDJOD). 
2.5.1.2 y-Maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32) 
The carboxyl functionality of the maleimido-tetrapeptide (30, 858 J.1g) was activated by 
conversion to a succinimidyl ester by stirring with N-hydroxysuccinimide (NHS, 1.8 
equivalents) and dicyclohexylcarbodiimide (DCC, 1.8 equivalents) in dry THF, for two 
minutes under nitrogen atmosphere. Norhomohalichondrin B amine (31, 0.9 equivalents) 
was added to the reaction system in dry THF, and the reaction was stirred under an inert 
atmosphere. An excess of 30 to the amine 31, ensured complete reaction of the toxin. The 
toxin is more precious than the readily synthesised peptide biolinker. The reaction was 
visualised by analytical reverse phase HPLC after 60 hours, showing the disappearance of 
the amine 31, and the appearance of a less polar peak. Collection of this peak, and 
subsequent ESI MS analysis, confirmed that it represented the coupled product 32. To 
achieve sufficient purity for conjugation to the protein, 32 was purified by analytical 
HPLC (CI8). A 50-minute method was developed (Section 8.2.7) without an acid 
additive in the solvent system. This avoided acid-catalysed degradation of 
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norhomohalichondrin B as discussed in Section 1.3.1. The peak eluting at 33.7 minutes 
was collected. Insufficient sample (0.4 mg) was obtained for NMR analysis, but 
HRESIMS analysis confirmed the preparation of y-maleimidobutyric-Gly-Phe-Leu-Gly-
norhomohalichondrin B (32). 
2.5.2 Doxorubicin (34) 
o OH 0 
doxorubicin (34) 
Figure 2.13: The anthracycline antibiotic, doxorubicin (34). 
Doxorubicin (34) is an anthracyc1ine antibiotic with potent cytotoxicity.169 It is currently 
used in cancer chemotherapy, but the therapeutic index of doxorubicin is compromised by 
its dose-related side effects, notably cumulative cardiotoxicity, myleosuppression and 
development of drug resistance.!69,170 One approach that has been taken to overcome the 
toxicity of this drug to normal tissue - thereby increasing the therapeutic index of this 
agent is the attachment of doxorubicin to a carrier polymer that exhibits significant 
uptake in tumour cells. PKI is a synthetic N-(2-hydroxypropyl)methylacrylamide 
copolymer-doxorubicin conjugate currently undergoing Phase II evaluation in the United 
Kingdom.l7l PKI has shown promising antitumour activity, and is essentially non-toxic 
in vitro until lysosomal proteases release free doxorubicin from the drug, within the cell. 
Doxorubicin is linked through its amine functionality to the polymer via a peptidyl 
spacer. PKI is essentially allowing doxorubicin to act as a pro-drug, designed to be 
inactive until it is released at a specific point.!7l 
Doxorubicin (34) was chosen as a complementary toxin to homohalichondrin B (22) for 
several reasons. Firstly, the strategy of attaching doxorubicin to CV-N could achieve site-
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specific delivery of doxorubicin to HN-infected cells, increasing the therapeutic effect 
and minimising the side-toxicity of the drug. Conjugation to HSA, would create a protein 
equivalent to PKI that could be targeted at tumour cells. Secondly, as an important design 
issue, doxorubicin (34) already contains a free amine on the glycoside moiety. This 
reduces synthetic steps to the maleimido activated-tetrapeptide-conjugate, and avoids 
extra manipulations and consequential losses of the precious toxin. Thirdly, as mentioned 
above, attachment of a peptide to the aminoglycoside abolishes doxorubicin's cytotoxic 
activity. 171 ,172 The administration of a prodrug of doxorubicin, through attachment of the 
maleimido-tetrapeptide (30), to the glycoside, would allow selective activation by HIV 
infected cells, or tumours, and would reduce general systemic exposure to the active drug. 
This would thereby increase the therapeutic index of doxorubicin (34). Invariably, drug-
delivery systems have been designed around the anthracycHne as the compound has been 
one of the most widely used chemotherapeutics. 144,172-174 Many of these systems are 
showing therapeutic promise. l71 The conjugates of doxorubicin (34) proposed in this 
thesis could be compared to those already prepared in the literature, and would provide a 
basis of comparison to the unique homohalichondrin derivatives prepared in this project 
of work. 
The commercial supply of doxorubicin (34) is as the hydrochloride salt. This results in 
the amine being unavailable for coupling to the tetrapeptide construct. Therefore the 
doxorubicin sample must first be converted to the free base. A reversed phase CI8 
cartridge was pre-equilibrated with 0.05% NH40H!H20. Doxorubicin hydrochoride (3 
mg) was dissolved in 0.05% NH40H/H20, resulting in a dark purple solution that was 
immediately loaded onto the cartridge. The cartridge was washed with five column 
volumes 0.05% NH40HfH20. Washing with acetone (five column volumes) eluted 34 in 
quantitative yield after drying under N2(g). The IH NMR spectrum in CD30D was 
identical to that previously reported. 175 
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2.5.2.1 y-Maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35) 
The target maleimide-activated biolinker-doxorubicin counterpart construct to 32 was y-
maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35). 
o OH 0 
y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35) 
Figure 2.14: The target maleimido-activated biolinker-doxorubicin. 
The maleimido-tetrapeptide (30, 2.26 mg) was coupled with 0.9 equivalents of 
doxorubicin (34) in the manner described for the norhomohalichondrin B amine (31) 
example described in Section 2.5.1.2. The reaction was left to stir under nitrogen 
atmosphere for 24 hours at which time analytical HPLC established the reaction had gone 
to completion, with consumption of the amine 34. A short 13-minute solvent gradient 
(Section 8.2.9), on an analytical reverse phase HPLC system, was utilised to purify 
compound 35 from the reaction mixture. A peak with an absorbance at 480 nm eluting at 
4.3 minutes was collected and the solvent removed under nitrogen gas flow to give 35 as 
a red solid. The IH NMR spectrum in CD30D (Figure 2.15) was assigned as far as 
possible through comparison with the spectra of 30 (Section 2.5.1.2) and 34.175 Figure 
2.15 displays the assigned peaks. Insufficient mass was obtained to carry out 2D NMR 
experiments. Notable was the obvious disappearance of the glycine a-proton resonance at 
3.86 ppm upon the coupling of the tetrapeptide and the aminoglycoside. Ultimately, 
however, HRESIMS was essential to confirming that y-maleimidobutyric-Gly-Phe-Leu-
Gly-doxorubicin (35) had been prepared. (MNa+ 1105.4034 (Cs4H62N601SNa requires 
1105.4018). 
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Both doxorubicin (34) and y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35) 
proved difficult to handle, adsorbing onto the glass surfaces of the vials and NMR tubes 
that they were contained in. This did result in loss of product, so transfer of 34 and 35 
from their respective containments was kept to a minimum. 
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Figure 2.15: lH NMR spectrum of I'-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35) (500 MHz, 
CD30D). 
2.5.3 Tyrosinamide (36) 
Tyrosinamide (36), was included in the complement of toxins to be conjugated to HSA 
and CV-N (28) because it is capable of incorporating a radio label tracer. This would 
allow cellular and body distribution studies to be carried out in the future. Tyrosinamide 
(36) can be radioiodinated utilising chloramine T and sodium [125I]iodide (Figure 2.16).176 
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Figure 2.16: Radioiodination of tyros in amide. 
OH 
2.5.3.1 y-Maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37) 
69 
Like doxorubicin, tyrosinamide (36) was partieularly attractive as it had a free amine 
available for incorporation into an amide bond. The target compound is illustrated in 
Figure 2.18. The primary amine is more nucleophilic than the primary amide, so coupling 
with the tetrapeptide will occur exclusively at the primary amine. 
The maleimido-tetrapeptide (30, 3 mg) was activated as a succinimidyl ester and eoupled 
with tyrosinamide (36, 0.9 equivalents) in the same. manner as for the halichondrin 
(Section 2.5.1.2) and doxorubicin (Section 2.5.2.1) examples. The reaction was left to stir 
under argon atmosphere for 24 hours. Compound 37 was purified from the reaction 
mixture using a semi-preparative reverse phase HPLC system and a 25-minute solvent 
gradient (Section 8.2.10) at a flow rate of 5 mL/min. The system was monitored at 213 
nm and a peak eluting at 13.8 minutes was collected to give 37. 
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Figure 2.17: NMR spectrum of y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37) (500 MHz, 
CD30D). 
The IH NMR (Figure 2.17) and l3C NMR spectra of 37 were readily assignable in 
conjunction with TOCSY and HSQC 2D NMR experiments. The assigned IH and l3C 
NMR spectral data are tabulated in Table 2.2. HRESIMS provided final confirmation that 
y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37) had been prepared. 
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y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37) 
Figure 2.18: The target maleimido-activated biolinker-tyrosinamide. 
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2 
3 
4 ].49 (m, 2.3, 6.7, 9.0) 36.6 
......... _-
5 1.83 (m) 25.0 
6 2.20 (t, 7.2) 32.1 
7 
8 
90.* 3.65 (d, 16.5) 42.5 
9~* 3.86 (d, 16.5) 42.5 
10 
11 
4.60 (dd, 5.6, 9.1) 55.2 
4.22 (dd, 4.8, 10.2) 52.8 
18* 3.76 (dd, 13.6, 16.5) 42.7 
19 
---f 4:?Q(dd, 5.0, 9.3) 
240. 
24~ 
25 
26 
35 7.07 (d, 8.8) 
36 6.68 Cd, 8.5) 
37 
55.2 
36.8 
36.8 
129.1 
128.4 
126.8 
29.4 
27.3 
22.3 
20.5 
130.2 
115.0 
71 
Table 2.2: IH and l3C NMR data for y-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30). Recorded at 500 MHz 
in CD.lOD. 
a IH chemical shift values (0 ppm and referenced to CD2IlOD, OH 3.31) followed by multiplicity and 
coupling constant (JIHz). The amides were only partially observed in the iH spectrum but had exchanged 
before characterisation fi'om other experiments could take place. 
h Be chemical shift values (b ppm) as determined from HSQC experiments. 
* interchangeable 
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2.6 Mass Spectronletry 
ESI MS has been essential to this PhD project so a summary of the technique will follow. 
So as not to lUlderplay the outstanding contribution of MALD1 to protein analysis (but 
which was not available as a technique in this project), a brief description of this 
technique has also been included. 
Since 1912 when Joseph Thomson first described the ability to separate atoms and 
molecules based on different size and charge,l77 mass spectrometry (MS) has been an 
indispensable tool in the analysis of small molecules. Few measurements are as 
fundamental as mass, but despite intense MS development, the goal of analysing large 
macromolecules, particularly proteins, remained elusive for over 70 years. 
During the 1990's, changes in MS instrumentation and techniques revolutionalised 
protein chemistry and fundamentally changed the way protein analysis impacts biological 
research. These changes were catalysed by two technical breakthroughs in the late 1980s 
- specifically, the development of the two ionisation methods, electro spray ionisation 
(ES1) by John Fenn178 and matrix-assisted laser desorption ionisation (MALDI) by Koichi 
Tanaka,179 and Franz Hillenkamp.180 The important application of these techniques to 
biological macromolecules was recognised with Fenn and Tanaka being awarded the 
2002 Nobel Prize in Chemistry. 
These methods solved the difficult problem of generating ions of large, non-volatile 
analytes, like proteins and peptides, for direct transfer into the gas phase and into the MS 
for mass analysis, and to achieve all that without analyte fragmentation. 178,181-186 The goal 
was to get the proteins to "fly", or as John Fenn said, to give "wings to molecular 
elephants" .184 Due to the lack or minimal extent of analyte fragmentation during the 
processes, ESI and MALD1 are also referred to as "soft" ionisation methods. 183,186 
These techniques have been successfully applied to a wide range of compolUlds and 
biological systems, including proteins and peptides, nucleic acids, drugs and metabolite 
systemsI80,181,183,185,187,188 as well as to some synthetic polymers. I85 ESI and MALD1 are 
becoming the methods of choice for the detection and characterisation of post-
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translational modifications of proteins,180,187,188 for example glycosylations and 
phosphorylations. These ionisation methods are even allowing studies of molecular 
complexes that only have weak non-covalent interactions, such as protein-protein, 180,181 
and enzyme-substrate complexes. 189 
2.6.1 Matrix Assisted Laser Desorption Ionisation 
The principle of MALDI is based on a low melting point substrate (matrix) doped with 
analyte compound. Under pulsed laser irradiation, usually in the ultraviolet spectra 
region, the matrix material (typically a small organic molecule with absorbance at the 
wavelength of the laser employed, for example sinapinic acid) evaporates easily and 
transports the analyte molecules to the analysis region of the mass spectrometer with 
minimal fragmentation of the analyte. A charging of analyte molecules occurs during 
pulsed laser-induced desorption. MALDI has been demonstrated to have the advantage of 
spectral simplicity owing to the production of mainly singly charged ions. 179-181 ,183,185-
187,190 
The MALDI technique is considered an off-line ionisation technique because the sample 
is purified, deposited, and dried on a sample plate before the analysis. 186 
2.6.2 Electrospray Ionisation 
ESI MS is based on an elegant idea proposed originally by Dole in the 1960s.191 Liquid 
containing the analyte is passed through a needle at high voltage to electrostatically 
disperse, or electro spray, a mist of small, highly charged droplets that rapidly evaporate 
and which impart their charge onto the analyte molecules. A countercurrent of hot 
nitrogcn gas assists this. This process takes place at atmospheric pressure and is therefore 
very gentle (without fragmentation of analyte ions in the gas phase). The ions are then 
transferred into the vacuum of a mass spectrometer, where they are separated and 
detected based on their mass-to-charge (mlz) ratio. 178,180-182,184,186,187 
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A wide range of compounds can be analysed by ESI MS; in principle the only 
requirement is that the molecule be sufficiently polar to allow attachment of a charge. 
Proteins and peptides are prominent examples of this category. They are thought to be 
protonated predominantly at the basically charged sites - the amino terminus, and at 
arginine, histidine and lysine residues. 181 ,182 
Fenn also discovered the process of multiple charging, which gives proteins, on average, 
one charge per kDa, and leads to the characteristic appearance of ESI spectra. 178,192 
(Figure 2.19) Multiple charging is the process by which molecules, particularly proteins 
and peptides, can pick up more than one charge and thereby generate a series of peaks at 
(Mr + n X mH)/n where Mr is the relative molecular mass of the protein, mH is the 
molecular mass of a proton and n is the number of charges. Since mass spectrometers 
normally measure mass-to-charge ratio, increasing the number of charges on the ion 
effectively multiplies the mass range of the instrument. It brings the ions into the range of 
mlz ratios measurable on typical mass spectrometers. 178,181,182,192 
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Figure 2.19: Electrospray mass spectrum of a protein (cyanovirin-N). The attachment of many protons 
(from less than five to more than ten in this case) leads to a series of mass-to-charge ratio peaks for a 
single protein species. The insert shows a computer deconvolution of the series of peaks into a single peak 
at the correct protein mass. 
These spectra can be simplified by deconvolution, an algorithm that sums up the signal 
intensity into a single peak at the molecular weight of the analyte. l92 The maximum 
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entropy (MaxEnt) algorithm 193 has been used to process the spectra presented in this 
thesis (see Figure 2.19, inset). 
The ESI technique is an online ionisation technique because of the ease with which it can 
be interfaced with popular chromatographic and electrophoretic liquid phase separation 
techniques. 186 For example, when liquid chromatography and mass spectrometry are 
coupled (LC MS), MS analysis of the components of a sample takes place on-line as they 
elute from the chromatography column. In this scenario, sample cleanup, separation, and 
concentration are an achieved in a single step. 
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2.7 Conjugation Strategy: Model Systems 
Due to the limited availability of CV-N (28) and the toxin derivatives, model systems 
were used to optimise the thiolation conjugation strategy. 
It is well documented that 2-IT (29) is fully water-soluble and reacts with primary amine 
residues in the pH range 7 - 10 (Section 2.3). The literature cites a number of different 
buffer systems that have been used successfully with 2-IT (29).154 Obviously, they must 
be non-amine-containing. A sodium borate-based buffer (0.1 M sodium borate, 0.15 M 
NaCl, 0.001 M EDTA) was chosen to maintain the pH of the reaction system at 8.0. This 
buffer became referred to as the 'reaction buffer'. Sulfhydryl groups are susceptible to 
oxidation and formation of disulfide cross-links. To prevent disulfide formation, oxygen 
was removed from all buffers by bubbling argon through all the solutions. In addition, 
ethylenediaminetetraacetic acid (EDTA) was added to the buffers to chelate metal ions, 
preventing metal-catalysed oxidation of sulfhydryl groups. 
2.7.1 A Small-Molecule Model- p-alanine 
NccFmoc-lysine initially appeared as a good mimic of the lysine side chains in the 
protein, but difficulties were experienced due to insolubility in the reaction buffer. 
~-alanine (39) was an easier amine model to work with as it was more water-soluble. 
~-alanine (1 mg) was stirred with 1.3 equivalents of 2-IT (29) in reaction buffer. After 
one hour 1.3 equivalents of y-maleimidobutyric acid (40) were added and stirred for a 
further ten minutes. ESI MS showed that the desired conjugate product 41 had been 
formed. Hydrolysed 2-IT (29), with subsequent reaction with the maleimide, was also a 
significant product present. This reaction side-product indicated that the intermediary 
thiolated protein product would have to be purified so as not to waste any of the precious 
maleimide-natural product combinations. The observations also implied that the 2-IT (29) 
reagent would need to be prepared freshly for each reaction, and used immediately. 
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Figure 2.20: A small-molecule model for the thiol-maleimide strategy. 
2.7.2 A Protein Model Lysozyme 
Chicken egg white lysozyme was selected as a model protein. With 129 amino acid 
residues, lysozyme has a molecular weight of approximately 14.3 kDa,194 an ideal model 
molecular weight for the 11lcDa cyanovirin (28). Lysozyme is also readily commercially 
available. The protein has six lysine residues, and therefore seven possible sites for 
thiolation. 
A method for purification of any protein derivatives needed to be established. It was 
important that thiolated protein was separated from the thiolation reagent so that an 
excess of the toxin component did not have to be added. As the protein molecular weight 
is significantly different from the thiolating reagent, initial separation/purification could 
be achieved by size exclusion gel filtration chromatography. Using a G-25 support, with 
an exclusion limit of a molecular weight of 5,000 Da, the conjugate/protein components 
elute before the thiolation reagent, 2-IT (29). 
Lysozyme (200 ).!g) was loaded onto a 0-25 column and eluted with a standard borate 
buffer (PH 7.2, 0.0025M sodium borate, 0.15 M NaCI). Mild elution conditions were 
required to minimise denaturation of the protein and to preserve the activity of the 
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conjugates. The column was monitored by a UV detector reading at A 206 run, and a peak 
eluting at the void volume (as determined by previous elution of the polysaccharide blue 
dextran) was collected. 
The sample was initially analysed by direct infusion into the ESI MS. Although a protein 
component was obviously present, signal intensity was very low, and difficult to interpret. 
It is well reported that buffer-related cations, for example Na+, produce additional 
features in an ESI-mass spectrum and usually manifest themselves as peaks near singly 
and multiply charged analyte ion signals.187 These modifications inherently cause a 
reduction in analyte signal, because the signal is spread over multiple m/z peaks. For this 
reason, the proteins, and the resultant conjugates, would need to be visualised by reverse 
phase LC MS. A long gentle solvent gradient system was employed (Chapter 8). The 
online coupling of the LC to the ESI MS served to eliminate these buffer-related issues, 
and separate the protein components. Traditionally, protein and peptide reverse phase 
HPLC separations are performed at low pH with a tri:tluoroacetic aeid (TF A)-containing 
mobile phase where the TF A functions as an ion-pair reagent and complexes with the 
basic residues in proteins and peptides. 195 However, the formation of these complexes 
suppresses the ionisation of the protein, reducing sensitivity.180 TF A was replaced in this 
project by either 0.5% formic acid (v/v) or 5% acetic acid (v/v) producing excellent 
chromatography and MS signal intensity. 
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Figure 2.21: The ESI-mass spectrum of chicken egg white lysozyme. The inset shows the deconvoluted. 
neutral-scale mass spectnlm. 
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The lysozyme sample was analysed, this time by LC MS. A broad peak eluted from the 
LC, visible in both the diode array (Iv 254 nm) and total ion current spectra, at ~41-43 
minutes. Figure 2.21 illustrates the ESI-mass spectrum that was represented by this peak. 
MaxEnt deconvolution of the mass spectrum collapses the charge state envelope to a 
single, principal peak (inset, Figure 2.21) at 14,305 Da. 
2.7.2.1 Thiolating Lysozyme 
Section 2.3 discussed the use of 2-IT (29) to thiolate proteins, and the subsequent 
utilisation of the thiol(s) in a coupling strategy with a maleimide. This section outlines the 
development of this strategy with a model protein, lysozyme, in preparation for work with 
CV-N (28). Figure 2.22 illustrates this methodology. 
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Figure 2.22: Thiollmaleimide strategy for the modification oflysozyme. 
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Lysozyme (200 Ilg) was dissolved in reaction buffer (200 ilL). Five equivalents of 2-IT 
(29) in reaction buffer (10 ilL) were added and the mixture was flushed with argon and 
capped for five hours at room temperature. The mixture was separated on a G-25 column 
as described previously and the protein fraction analysed by LC MS. Deconvolution of 
the ESI data produced the spectrum in Figure 2.23. This spectrum illustrates that two 
main protein components were present, unreacted lysozyme (14,306 Da) and a singly-
thiolated lysozyme (14,407 Da). 2-IT has an exact mass of 101.03 Da. 
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Figure 2.23: The deconvoluted ESI-mass spectrum of the reaction between lysozyme and 2-IT (29). 
Importantly, the thiolated protein had survived chromatography on the G-25 column 
without cross-linking through the fonnation of disulfide bonds. The protein could 
therefore be purified from the thiolation reagent before reaction with the maleimide. 
2.7.2.2 Thiolated Lysozyme and y-Maleimidobutyric acid. 
Immediately after the analysis above, the thiolated lysozyme solution was reacted with a 
model maleimide, y-maleimidobutyric acid (40, MW 183.2, five equivalents, in minimal 
DMF). The reaction mixture was analysed by LC MS after two hours. Again, a single 
broad peak eluted at ~41 minutes, and analysis of this peak (Figure 2.24) revealed that it 
encompassed unreacted lysozyme and the expected singly-modified conjugate product 
(14,589 Da). 
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Figure 2.24: The deconvoluted ESI-mass spectrum of the reaction between thiolated lysozyme and 
y-maleimidobutyric acid (40). 
2.7.2.3 Thiolation Optimisation Time and Temperature Dependence 
To test the time dependence of the thiolation reaction, lysozyme was reacted with five 
equivalents of 2-1T (29) for 1, 5, 12, 24 and 48 hours at room temperature. At the 
conclusion of each of these time periods any free thiols were capped with the addition of 
five equivalents of y-maleimidobutyric acid (40) in situ. Each of these samples were 
analysed by LC MS. A single broad peak eluted after ~42 minutes in each case. Analysis 
of the ESI MS data of these peaks (Figure 2.25) revealed an interesting situation. After 
one hour of reaction a single addition of 2-1T/maleimide (14,590 Da) was visible. 
Substantial unreacted protein (14,305 Da) remained. Five hours of reaction afforded a 
second addition of the thiollmaleimide (14,873 Da). However, a peak 84 mass units 
higher than lysozyme (or 17 mass units lower than the thiolated protein, 14,390 Da) was 
also visible. Further, a peak with one addition of the thiol/maleimide and one 'plus 84' 
(14,673 Da) was also seen. After 12 hours, no maleimide addition was seen, but two 
(14,474 Da), three (14,557 Da) and four (14,641 Da) additions of 84 mass units were 
visible. This derivative appeared to be 'dead end' derivative, and did not react with the 
maleimide. No significant change was seen after 24 and 48 hours of reaction. 
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Figure 2.25: Deconvoluted mass spectra of the addition 2-IT (29) to lysozyme, and then capped with the 
maleimide, 40, at room temperature, after (a) one hour; (b) five hours; and (c) 12 hours 
The set of time dependent reactions was repeated at O°C in an ice bath. The deconvoluted 
ESI MS data are represented in Figure 2.26. This time, the addition process appeared to 
be considerably slower, but the presence of the by-product was significantly less. No 
addition was seen after one hour of reaction. After five hours of reaction however, a 
single addition ofthiol/maleimide was present (14,590 Da). Twelve hours of reaction saw 
the appearance of two additions of the thiollmaleimide (14,874 Da). No by-product was 
present. Two (14,874 Da) and three (15,157 Da) additions ofthiol/maleimide were seen 
after 24 hours. A small proportion of varying combinations of thiol/maleimide and the 
'plus 84' product was now visible. A mass of 14,673 Da, for example, represents one 
thiollmaleimide and one 'plus 84'. No significant change was seen after 48 hours. The 
optimum reaction time was established to be 12 hours, with no non-thlol by-product 
produced at this time. Section 2.8.1.4 describes the characterisation of this thiolation by-
product. 
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Figure 2.26: Deconvoluted mass spectra of the addition 2-IT (29) to lysozyme, and then capped with the 
maleimide, 40, at 0 after (a) one hour; (b) five hours; (c) 12 hours; and (d) 24 hours. 
2.7.2.4 Characterisation of Thiolation By-product 
Reaction products of protein and 2-IT (29) were shown to contain the expected 
derivatives together with a second product with mass 17 units lower. The characterisation 
of the thiolation by-product proved too difficult to achieve on the protein scale. 
Benzy1amine (42) was chosen as a model amine with the advantages that it was soluble in 
the aqueous reaction conditions but was also soluble in organic solvents to aid in the 
purification procedures. Any products could also be characterised by NMR spectroscopy. 
Benzy1amine (42, 10 mg) was dissolved in degassed thiolation buffer and one equivalent 
of 2-IT (29) was added. The reaction was left for 24 hours at room temperature. At this 
time oily droplets were present in the mixture and these were extracted into ethyl acetate. 
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ESI MS revealed that this fraction contained only the 'plus 84' product (MH+ 192) and 
not the thiolated product (43) (MH+ 209). 
As alluded to previously it was assumed that this by-product was not a thiol as it did not 
react with the maleimido compounds introduced. A IH NMR spectrum (500 MHz, 
CDCh) was obtained but it was not until HSQC and CIGAR 2D NMR experiments were 
recorded that this product, 44, (Figure 2.27) could be characterised. The arrows indicate 
the important correlations revealed in the 2D experiments. These correlations established 
that 44 contained a five-membered heterocycle. All protons of the heterocycle correlate to 
the imine carbon. This assignment would not be possible if it were an open chain 
structure. 
benzylamine (42) (29) 
thiolation buffer 
pHS 
.. 
Figure 2.27: Reaction o/henzylamine (42) and 2-IT (29). . 
NH 
() ~SH I ~ ~ 
(43) 
~ V' 
(44) 
The initially formed thiol product, 43, decays to the non-thiol product, 44. In this process 
the thiol adds to the imine carbon resulting ultimately in the formation of the cyclised 
product, 44, by the loss of ammonia. Several publications have also recently cautioned in 
the use of2-IT (29) due to the formation of this particular side product. 196,197 
2.7.2.1 Thiolation Optimisation - Ratio of2-IT 
To determine the optimum ratio of 2-IT (29) to lysozyme, a series of reactions were 
carried out using varying amounts of2-IT (29). 
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Lysozyme (200 /lg) was reacted with 5, 10, 25, 50 and 100 equivalents of 2-1T (29) in 
reaction buffer at OCC. After 12 hours of reaction the available thiols were capped with 
equal equivalents of y-maleimidobutyric acid in situ. 
(a) 101 ~ O~'~'I~.~'.;~i~li~;~'~i~~I~¥in,~i~~~~~~;~'~I~'~~i~'~'~'I~~.rI '~'~'~'rli~' 
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Figure 2.28: Total Ion Current ESl+ chromatograms for the addition of vmying concentrations of 2-IT 
(29) to lysozyme, and then capped with the maleimide, 40. (a) 5 equivalents 2-IT; (b) 10 eqUivalents 2-IT; 
(c) 25 equivalents 2-IT; (cO 50 equivalents 2-IT; and (e) 100 equivalents 2-IT. 
Each sample was analysed by LC MS, and the resultant total IOn current (TIC) 
chromatograms are shown in Figure 2.28. With increasing concentration of 2-IT, the 
protein peak, eluting after ~42 minutes, broadens and shifts slightly to a longer retention 
time. A selection of the MaxEnt deconvoluted mass spectra, presented in Figure 2.29, 
reveals that the shift in retention time is due to the addition of up to five of the 
thiollmaleimide combinations (in the case of the 100 equivalents of 2-IT (29)). An 
increase in the ratio of 2-1T (29) to lysozyme resulted in an increased number of 
thiolations, and subsequent reactions with the maleimide. A single addition (14,590 Da) 
of the 2-1T/maleimide was visible with five equivalents of 2-IT (29). Ten equivalents of 
2-1T (29) resulted in a second addition (14,874 Da). Further additions were produced with 
25, 50 and 100 equivalents of 2-IT (29). Six and seven thiolations were never seen. This 
may be due to the folding pattern of lysozyme, with some of the lysine residues being less 
accessible within the protein. Despite the cold reaction conditions, the thiolation by-
product was still present, though somewhat reduced, and will need to be monitored in the 
reactions with CV-N (28). 
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Figure 2.29: Deconvoluted mass spectra of the addition ofva/ying concentrations of 2-IT (29) to lysozyme, 
and then capped with the maleimide, 40. (a) 5 equivalents 2-IT; (b) 10 equivalents 2-IT; (c) 25 equivalents 
2-IT; and (d) 100 equivalents 2-IT. 
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2.8 Conclusions 
This chapter has outlined the development of a strategy to create CV-N (28)-toxin 
conjugates of the general design in Figure 2.1. 
A tetrapeptide, Gly-Phe-Leu-Gly, was selected as a biolinker, and as a substrate for the 
lysosomal cathepsin enzymes. This peptide has been designed to allow controlled release 
of the toxin - not too fast, not too slowly within cells. 149 
A thioether bond was chosen to link the protein with the biolinker. This bond is stable in 
systemic circulation. The linkage could be achieved by thiolating the protein with an 
amine-specific reagent, 2-iminothiolane (29), and subsequent reaction with a maleimido-
activated biolinker. Lysozyme was used as a model system to investigate the 
thiollmaleimide methodology. A number of thiollmaleimide additions were seen, and 
some degree of control could be achieved by varying reaction time, and the ratio of 2-IT 
(29) to the protein. Some caution needs to be taken in the use of 2-IT (29), due to the 
production of a non-thiol by-product that cannot be conjugated. 
A maleimido-activated biolinker was synthesised on solid-phase and subsequently 
coupled to three toxins (homohalichondrin B (22), doxorubicin (34), and tyrosinamide 
(36)) via an amide bond. Homohalichondrin B (22) was hemi-synthetically modified so 
that it was functionalised with an amine (31) and could be coupled to the construct. 
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NATIVE CV-N CONJUGATES 
3.1 Introduction 
In Chapter Two a strategic approach to developing CY -N-toxin conjugates, like that 
illustrated in Figure 2.1, was introduced. This involved the selective conversion of 
exposed protein amino groups to sulfhydryl functionalities using 2-IT (29), and then the 
subsequent Michael addition of the sulfhydryl to a maleimido-activated biolinker-toxin 
construct The viability of the thiollmaleimido approach was tested on a model system 
with the protein lysozyme, and a simple maleimide derivative. The conjugation 
methodology was ultimately successful with varying degrees of thiol/maleimide loading 
on the protein. 
1 N-terminal 
Lys99 
/' 
.. 
Lys48 
Lys84 
Figure 3.1: SO/Iltion structure of CV-N (28) as determined by NMR spectroscopy. The protein is depicted 
as a ribhon with the Lysine (Lys) residues shown in ball and stick representation. The N-termina/, Leu I, is 
a/so highlighted The diagrum W(JS produced with Protein £xp/orerji'om the RCSB PDB. entry 2ezm. 
This chapter describes the equivalent approach to the preparation of conjugates of native 
CY -N (28). With lysine residues at amino acid positions, 3, 48, 74, 84 and 99, CY -N (28) 
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has six possible sites for thiolation. The lysine residues, and the leucine N-tenninal, are 
highlighted in the representation of the solution structure ofCV-N (28) in Figure 3.1. The 
amino groups all appear to be exposed on the surface of the protein, and therefore 
available for reaction with 2-IT (29). 
Initially, CV-N was thiolated and derivatised with model maleimides in an effort to assess 
reactivity of the amino groups within CV-N (28), and the selectivity of the thiolation 
process. 
Finally, the synthesis of a CV-N-tyrosinamide conjugate was undertaken. 
The Molecular Targets Development Program, NCI-Frederick, Frederick, MD, USA, 
kindly supplied the CV-N (28) used in this project. The protein was recombinantly 
produced and is stored at 1 mg/mL in 0.9% saline solution. 
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3.2 LC MS ofCV-N (28) 
The analytical LC MS methodology, developed with lysozyme in Chapter 2, was applied 
to a pure sample of CV -N (28). A single peak eluted from the reverse phase system with a 
retention time of approximately 46.5 minutes (Figure 3.2). This peak was clearly visible 
in both the diode array and TIC chromatograms. 
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Figure 3.2: Chromatogram of purified CV-N (28); Diode Array trace at A 254 nm, and Total Ion Current 
(TIC) ES+ trace. 
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Figure 3.3: The ESI-mass spectrum of CV-N (28). The inset shows the deconvoluted, neutral-scale mass 
spectrum. 
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The ESI-mass spectrum of this peak is presented in Figure 3.3. The spectrum of CV-N 
(28) consists of a simple and well-resolved series of charge state ions. This spectrum is 
easily deconvoluted to a single peak with the expected molecular weight of CV -N (28), 
11,009 Da (inset, Figure 3.3). 
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3.3 Modification of CV-N (28) 
3.3.1 A Model System ~ 2-IT (29) and y-maleimidobutyric acid (40) 
The CV-N conjugate (45) illustrated in Figure 3.4 was chosen as a model target to test the 
viability of the thiolation approach with CV-N (28). The small molecule, model 
maleimide, y-maleimidobutyric acid (40) had been ideal for the preliminary lysozyme 
investigations and was expected to provide a good starting point for modifying CV-N 
(28). 
NH 0 )~s~ ~ 
H ~N~OH 
(45) 0 
Figure 3.4: CV-N-maleimidobutyric acid conjugate. 
CV-N (28, 100 /-lg) was reacted with 5, 10, 25, 50 and 100 equivalents of 2-IT (29) in 
reaction buffer at O°c. After 12 hours of reaction the thiolated protein was capped with 
equal equivalents of y-maleimidobutyric acid (in minimal DMF to aid with aqueous 
dissolution) in situ. Each sample was analysed by LCMS and the resultant diode array 
chromatograms (A. 254 nm) are presented in Figure 3.5. 
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Figure 3.5: Diode Array chromatograms (A. 254 nm) for the addition ofvwying concentrations of 2-IT 
(29) to CV-N (28), and then capped with the maleimide, 40. (a) 5 equivalents 2-IT; (b) 10 equivalents 2-IT; 
(c) 25 equivalents 2-IT; (d) 50 equivalents 2-IT; and (e) 100 equivalents 2-IT. 
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With increasing concentration of 2-IT (29), an increasing number of products were 
produced. Analysis of the ESI-data (Figure 3.6) demonstrated that these peaks 
represented sequential addition of the thioVmaleimide combination. A maximum of five 
modifications was seen. Although base-line separation was not achieved between product 
peaks, each peak was quite clearly different from each other and ESI MS analysis was 
able to identify the primary product represented by each peak. 
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Figure 3.6: CV-N-maleimidobutyric acid conjugate (45): (a) one addition of thiollmaleimide; (b) two 
additions; (c) three additions; (d) four additions; and (e) five additions. 
CV-N (28, 100 Ilg) was thiolated with 2-IT (29, ten equivalents) at O°C in reaction buffer 
for one hour. The sample was chromatographed on a G-25 column and eluted with the 
standard borate buffer. The column was monitored by a UV detector reading at A 254 nm, 
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and a peak eluting at the void volume was collected and reacted directly with five 
equivalents of y-maleimidobutyric acid (in minimal DMF). The reaction procedure was 
repeated a further four times, altering only the thiolation reaction time (5, 12, 24 or 48 
hours). Each of the samples was analysed by LC MS in the same manner as above. 
Thiolation by-products (see Section 2.8.1.4) became prominent after 24 hours (Figure 
3.7) with 'dead-end' peaks at 11,094 Da and 11,378 Da. 
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Figure 3.7: Neuttal-scale mass spectnun of reaction of CV-N (28) with 2-IT (29) and y-maleimidobutyric 
acid (40) after 24 hours at 0 'C, 
A thiolating reaction time of twelve hours, with ten equivalents of 2-IT (29), provided the 
optimum conditions to produce a singly-derivatised conjugate product, with no 
interference from the thiolation by-product. To test these conditions further, a second 
model maleimide was chosen. 
3.3.2 A Model System 2-IT (29) and F-150 (46) 
Fluorescein is perhaps the most popular of all fluorescent labeling agents. 154 The 
fluorescent properties are created by the multi-ring aromatic structure, and the planar 
nature of the upper, fused three-ring system (Figure 3.8). 
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Figure 3.8: The fluorescent labeling agent: F-150. 
Fluorescein-5-maleimide, F-150, (46) is a commercially available (Molecular Probes Inc.) 
fluorescent probe containing a maleimide functionality attached to the lower ring 
structure. This fluorescein derivative possesses characteristic properties with an excitation 
wavelength at 490 nm and an emission wavelength of 515 nm, in the green spectral 
region.154 F-150 (46) was chosen as a model maleimide to react with the thiolated CV-N. 
The fluorescent properties of F-150 (46) would allow for easy visualisation of CV-N 
conjugates, both by eye on a size exclusion column, or by diode array analysis. 
The target fluorescent conjugate ofCV-N (47) is illustrated in Figure 3.9. 
OH 
HO 
(47) 
Figure 3.9: CV-N-F-150 Conjugate. 
CV -N (28, 200 /-lg) was reacted with 2-IT (29, 10 equivalents) at O°C in reaction buffer 
for 12 hours. The thiolation mixture was chromatographed on a size-exclusion (G-25) 
column eluted with standard borate buffer. The protein component eluted at Vo and F-150 
(46, five equivalents, in minimal DMF) was added immediately and the reaction left to 
stand for two hours. The protein solution was concentrated to ~500 /-lL under nitrogen gas 
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flow and purified on a G-25 column as described previously. Two fluorescent bands 
eluted from the column, one at the void volume (~20 mL), indicative of fluorescently 
tagged protein, and one 15 mL later, suggestive of free 46. Both fluorescent bands were 
collected and analysed by LC MS (Agilent, Zorbax, C18) using the standard protein LC 
MS gradient The second fraction was confirmed to be unreacted maleimide, 46. The TIC 
chromatogram of the first fluorescent fraction is shown in Figure 3.10. 
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Figure 3.10: Total Ion Current chromatogram of a preparation of a CV-N-F-J50 conjugate (47). 
Two closely eluting broad peaks (~47 minutes and ~49 minutes) were present in the LC 
MS analysis. The ESI-data of the first peak was processed and was shown to be unreacted 
CV-N (28). The second peak demonstrated a strong absorbance at 450 nm in the diode 
array chromatogram, providing preliminary evidence that F-150 (46) was conjugated to 
CV-N (28). The MaxEnt deconvoluted ESI-mass spectral data for this peak is presented 
in Figure 3.11. As illustrated by Figure 3.11 (a), the expected singly derivatised 
conjugate, 47, (11,537 Da) had been formed. Interestingly though, a second product, 18 
mass units higher (11,555 Da), was also present. The conjugate sample was reanalysed by 
LC MS four hours later. This analysis (Figure 3.11 (b») revealed that this secondary 
product was becoming more prominent. Mter 24 hours, a final LC MS analysis (Figure 
3.11 (c») demonstrated that only the 'plus 18' product remained. Further analysis was 
required to determine the nature ofthis product (Section 3.4.3). 
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Figure 3.11: Deconvoluted ESI-mass spectra of CV-N-F-I50 conjugate (47): (a) two hours after 
preparation; (b) six hours after preparation; and (c) 24 hours after preparation. 
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3.4 Tryptic Digestion 
The results thus far have shown CV-N to be thiolated by 2-IT (29), but there has been no 
confirmation of the sites of modification. 2-IT (29) has, however, been shown to react 
preferentially with exposed lysine 8-amino groups but also at the N-terminal a-amino 
group of other proteins. 158 There are a number of complexities involved in achieving a 
successful conjugation strategy and the design of site-directed modification is just one 
example. A knowledge of the modification site(s) is important. This information allows 
rational design that should ensure good retention of activity. In order to fully characterise 
and determine the chemical nature of the conjugates, definition of the site of attachment is 
essential. 
A solution to this problem was to produce fragments of the protein that are amenable to 
analysis by LC MS. The cleavage methods employed are usually enzymatic, but proteins 
can also be fragmented by chemical means, such as partial acid hydrolysis. Proteolytic 
enzymes offer an advantage in that they hydrolyse only specific peptide bonds, and this 
specificity immediately gives information about the peptide products if the protein amino 
acid sequence is known. 
The proteolytic enzyme trypsin is one of the most commonly used reagents for specific 
protein digestion. 198 Trypsin specifically hydrolyses peptide bonds on the carboxyl side of 
lysine or arginine residues. 198 Therefore, in the case of CV -N (28), with five lysine and 
three arginine residues, nine peptide fragments would be expected if full digestion 
occurred. If a lysine residue has been modified then the residue is no longer recognisable 
as a substrate to trypsin and no cleavage occurs at that point. 198 
The initial commercial supply of trypsin was found to have chymotryptic activity. This 
complicated digests as fragments were produced with chymotryptic preferences. 
Hydrolysis of peptide bonds occurred on the carboxyl side of the aromatic amino acids, as 
well as leucine and histidine. To eliminate this problem, as much as possible, L-l-
tosylamido-2-phenylethylchloromethyl ketone (TPCK) treated trypsin was utilised. TPCK 
inactivates chyrnotryptic activity.199 
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3.4.1 Tryptic Digestion of Native CV-N (28) 
A tryptic digest was first performed on a sample of pure native CV-N (28). This would 
allow for development of methodology without the complicating factor of derivatisation. 
CV-N (28, 100 flg, 100 flL of 1 mg/mL in 0.9% saline solution) was diluted in 
ammonium bicarbonate buffer (100 flL). TPCK treated trypsin (10% by weight to the 
analyte protein) was added in 1 % acetic acid. This trypsin enzyme-to-substrate ratio was 
used to avoid having to consider trypsin autolysis in the sample digests. The trypsin 
enzyme has been observed to cleave itself to a limited extent.187 The digest was left at 
37°C for 24 hours and analysed by reverse phase LC MS running a slow and gentle 
acetonitrile/water (0.5% formic acid) gradient (Section 2.8.1). The TIC chromatogram of 
the digestion mixture is presented in Figure 3.12. 
100 
undigested 
digestion fragments CV -N (28) 
A~~\I 
% 
obL~~~~~~~~~~~~~~~~~ 
5.00 15.00 25.00 35.00 45.00 55.00 65.00 75.00 85.00 
Time (mins) 
Figure 3.12: Total Ion Current (TIC) chromatogram of a tlyptiC digest of CV-N (28). 
The LC MS data from the chromatogram in Figure 3.12 was processed and the fragment 
molecular weights were calculated by considering the mlz values found, and the charge 
state ions observed (for example, (M + 2Hi+, (M + 3H)3+). The experimentally 
determined masses were searched for within the peptide structure using protein software 
developed by Lewis P31mel1.200 This program provides a list of all possible peptide 
fragments of a given amino acid sequence based on the proteolytic selectivity of a 
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selected digestion enzyme. A match was made if the experimental MW was within 0.05% 
of the predicted MW. Table 3.1 details the data collected from the LC MS of the CV-N 
(28) tryptic digest, and the peptide fragment assignments that were made. 
1182.2 
31.68 2292.6 
907.5 Da, peptide from 77 to 84. (R)A. ... K(I) 
1182.5 Da, peptide from 88 to 98. L D .... L K 
2292.0 Da, peptide from 4 to 24. (K)F .... R(T), 
intact disulfide 
35.04 1650.2 1650.8 Da, peptide from 85 to 99. (K)L .. K(Y) 
39.1~3--~--~2~89~8~.2---+2~8~98~.3~D~a~,p~e~pt~id~e~fr~om~49~t~o~5~9~~~d~670=to~7~4.~U=()~W~.-.. 7R~~)-an~d~(R~)7N~ .. ~ .. K~(T=)-,~ 
intact disulfide 
45.27 2496.8 2496.2 Da, e tide from 25 to 48. R)T.. .. K W 
Table 3.1: Data/rom LC MS a/tryptic digest a/native CV-N (28). MW molecular weight. 
Figure 3.16 (see three pages over) maps out the assigned peptide fragments against the 
template of the amino acid sequence ofCV-N (28).93% ofthe protein is identified. 
3.4.2 Tryptic Digestion ofCV-N-maleimidobutyric acid conjugate (45) 
A sample of the singly derivatised CV-N-maleimidobutyric acid conjugate (45) was 
digested with TPCK treated trypsin in the same manner as for the native CV-N (Section 
3.4.1). The singly derivatised conjugate was chosen for digestion so an understanding of 
the distribution of modifications on the protein would result The digested conjugate was 
analysed by LC MS, and experimental peptide fragment masses were determined (Table 
3.2) by processing the ESI data of the prominent peaks in the TIC chromatogram. If the 
fragment masses identified did not match a predicted fragment from the digest 
database,2oo the mass was converted to a calculated molecular weight without 2-IT /y-
maleimidobutyric acid attached. This generated series of calculated peptide molecular 
weights was then compared to the database. Table 3.2 shows the data collected for this 
digest, and the fragment assignments that were made as a result. A match was made if the 
experimentally determined MW was within ±0.05% of the predicted MW. Two fragments 
were found (retention time of21.20 minutes and 38.39 minutes) that had been derivatised, 
and matched an amino sequence that included both the N-terminus and the lysine residue 
at position 3. The assumption was made that derivatisation had occurred at the lysine 
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residue, as digestion had not occurred at this point, suggesting that it was no longer a 
recognisable substrate for the trypsin enzyme. If derivatisation had occurred at the N-
tenninus an enzymatic cut would have been seen at the lysine residue. 
310.1 
907.4 
........ 
748.0 463.1 
31.60 2292.4 
34.93 1650.9 
38.89 2873.6 2588.7 
38.90 2898.0 
39.22 3438.6 3153.7 
--_ ... -
40.60 2823.6 2538.7 
40.60 2226.6 1941.7 
45 2496.0 
46.21 5663.7 5378.8 
Table 3.2: Selected datafi'om LC MS OftlyptiC digest of the CV-N-maleimidobutyric acid conjugate (45). 
ITIMalei 2-iminothiolane (29) and r-maleimidobutyric acid (40), MW = molecular weight. 
The assigned peptide fragments for the digest of 45 are mapped out against the template 
of the amino acid sequence ofCV-N (28) in Figure 3.16{see two pages over). 
3.4.3 Tryptic Digestion ofCV-N-F150 (47) 
The same enzymatic digestion procedure, as discussed above, was used for a tryptic 
digest of the CV-N-F150 conjugate (47). It was hoped that the digestion might shed some 
light on the nature of the 'plus 18' product. Like the previous digests, the sample was 
analysed by LC MS (Figure 3.13). This time however, the derivatised fragments were 
very easily visualised with a strong absorbance at 450 nm in the diode array 
chromatogram (Figure 3.13). 
Chapter Three - Native CV-N Conjugates 103 
100 Diode Array A, 450 nm 
% 
-382~~~~~~~~~~~~~~~~~~~~~~~~~~ 
100 
TIC ES+ 
o 5.00 15.00 25.00 35.00 45.00 55.00 
Time (mins) 
Figure 3.13: TJyptic digest ofCV-N-F-150 conjugate (47); Diode Array trace at A 450 nm and Total Ion 
Current (TIC) ES+ trace. 
The ESI-data was analysed as described in Section 3.4.2, taking into account addition of 
2-ITIF-150. This time however, a second series of calculated molecular weights were also 
generated. These calculated masses allowed for the possibility that the 18 mass units had 
been incorporated in the 2-IT/F-l50 section of the conjugate. Table 3.3 itemises the 
fragments that were identified, and their points of derivatisation. Figure 3.16 (one page 
over) displays the assigned peptide fragments against the amino acid sequence of CV-N 
(28). 
39.05 
35.20 
42.50 
39:28 
2892.0 
3699.2 
3085.0 
2606.7 2588.6 Da. peptide from I to 24. L .... R(T). 
derivatised at L 83 
2898.3 Da, peptide from 491059 and 60 to 74. (K)W .... R(N) and (R)N .... K(T). 
intact disulfide 
3171.1 3153.1 3153.9 Da. peptide from 491059 and 60 10 76. (K)W .... R(N) and (R)N .... R(A). 
inlact disulfide, derivatised at Lvs74 
2556.9 2538.9 2538.3 Da. peptide from 77 to 99. (Rjii:::::K(Y). 
2487.6 
l~~~~+-.. __ =~ __ t----=~_-t;d~er~iv~atised at L"'s""84'-:::-;;-:--=::-;;;;::-;-::::--_______ --i 
1959.5 1941.5 194J.4 Da.peptide from 85 to 101 (K)I. ... E. 
2496.6 
5924.4 
derivatlsed at L.l's979:--~~==c-===-_______ ---i 
2496.2 Da. e tide from 25 to 48. R T .... K 
5396.3 5378.3 5378.5 Da. peptide from 25 to 59 and 60 10 74. (R)T.. .. R(N) and (R)N .... K(T), 
intact disulfide. derivatised at L s48 
Table 3.3: Selected data from LC MS of tJyptic digest of CV-N-F-150 conjugate (47). ITIMalei = 2-
iminothiolane (29) and F-150 (46), MW = molecular weight. 
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As demonstrated by the analysis of the ESI data of the tryptic digest, the extra 18 mass 
units were carried though to the derivatised peptide fragments and so were most likely 
associated with addition to the maleimide. 
A well-documented problem in the synthesis of aspartic acid-containing peptides IS 
aspartamide, cyclic imide (Figure 3.14) formation?01-204 This imide ring formed IS 
susceptible to opening by the nucleophilic attack of water on either of the carbonyl 
carbons, resulting in two aspartate regioisomers, but with the isomer containing the ~­
amide bond being the main by-product (Figure 3.14).203,204 
y~'Q0 N-1 
p 
o 
cyclic imide 
Y~yO OH 
phosphate buffer ~ .......s 
.. (? 
o 
Figure 3.14: Ring-opening hydrolysis of a cyclic imide. 204 
a-product 
~-product 
It is proposed that the thioetherlsuccinimidyl entity in the CV-N-F-lS0 conjugate is being 
hydrolysed in a similar manner (Figure 3.15), despite the mild buffer conditions. 
o 
YS'Q N-1 
p 
o 
standard borate buffer 
pH 7.2 
CV-N-F-lS0 conjugate (47) 
o 
YSY-HOH yN-{ 
o 
Figure 3.15: Proposed hydrolysis of the CV-N-F-J50 conjugate, 47. 
a-product 
~-product 
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Figure 3.16: Digest fragments identified, disulfide,l' in/ad. points of derivatisation in yellow. T =c1eavage 
points f or tfJ'psin (a) CV-N (28); (b) CV-N 2-iminothiolanelmaleimidobutyric acid conjugates (45); (c) 
CV-N 2-iminothiolaneIF-/50 conjugates (47). 
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Although singly derivatised CV-N conjugates had been produced, Figure 3.16 illustrates 
that there was evidence for reaction at all five lysine residues, with no initial apparent 
selectivity for any particular residue. No attempt has been made at this point however, to 
closer investigate the relative reactivity of the lysine residues. There was no evidence for 
thiolation at the N-terminus. 
The selectivity for the E-amino groups cannot be described based on theoretical pKa 
values. Each type of ionisable group in the protein will have a unique pKa based upon the 
theoretical value for the amino acid and modulated from that value by its own 
surrounding microenvironment. The fact that no reaction was observed at the N-terminus 
suggests that it is completely protected from reaction by spatially close neighbours and 
the folding design of the protein. 
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3.5 CV-N-tyrosinamide Conjugate (48) 
Reaction conditions had been optimised with model maleimides for the production of 
singly derivatised CV-N conjugates. However, the synthesis of the toxin conjugates 
needed to be addressed. The CV-N-tyrosinamide conjugate, 48, was selected to test the 
addition of the maleimido-tetrapeptide-toxin construct prepared in Chapter 2. 
OH 
H 0 ~N~N 
o H 
(48) 
Figure 3.17: CV-N-tyrosinamide Conjugate. 
CV-N (28,400 I-Lg, 400 I-LL of 1 mg/mL in 0.9% saline solution) was diluted with reaction 
buffer (150 I-LL) and placed in a O°C water bath. Ten equivalents of 2-IT (29, 50 JlL of a 
freshly made 1 mg/mL solution in reaction buffer) were added and the reaction vial was 
capped and left at O°C for 12 hours. The protein was purified from the thiolating reagent 
on a G-25 column, eluting with the standard borate buffer (as discussed previously). The 
fraction eluting at Vo was collected (fraction volume ~5 mL) and reacted immediately 
with two equivalents of y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37, Section 
2.4.3, in minimal DMF) at O°C. After two hours the sample was concentrated to ~600 I-LL 
by evaporation under nitrogen gas flow. This sample was reloaded onto the G-25 size 
exclusion column (once again eluting with the standard borate buffer) to separate 
unreacted maleimide from the protein components. The proteinaceous fraction was 
analysed by the reverse phase standard protein LC MS methodology (Agilent, Zorbax, 
C3). Figure 3.18 shows the TIC ESI chromatogram of this analysis. Two closely eluting, 
but base-line separated, peaks (~41 minutes and ~43 minutes) were seen. Deconvolution 
of the mass spectral data revealed that the first peak was unreacted protein and the second 
peak was the desired singly-derivatised tryosinamide conjugate (48,11,829 Da) ofCV-N. 
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% 
o 10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 
Time (mins) 
108 
Figure 3.18: Total Jon Current (TIC) ES+ chromatogram of the preparation of a CV-N-tyrosinamide 
conjugate (48). 
With chromatographic base-line separation (Figure 3.18), the conjugate product (48) 
could be purified from any underivatised CV-N (28) using the standard protein LC MS 
gradient. The protein sample was concentrated from to ~500 ilL under nitrogen gas flow. 
Aliquots ( 40 ilL) of this mixture were purified using the LC MS method with manual 
collection of the required peak. The purification was guided by MS analysis, with ~ 10% 
of the sample directed to the mass spectrometer, and 90% of the sample collected. 
100 
% 
o 10.00 20,00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 
Time (mins) 
Figure 3.19: Total Ion Current (TIC) ES+ chromatogram of the purified CV-N-tyrosinamide conjugate 
(48). 
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Figure 3.19 demonstrates the effectiveness of this purification method, with a single peak 
eluting at the retention time of the conjugate, 48. Analysis of the mass spectral data 
however, revealed that the conjugate now had a molecular weight of 11,848 Da (Figure 
3.20), 18 mass units higher than expected. It is believed that this is due to the hydrolysis 
of the succinimide functionality, as discussed in Figure 3.4.3. 
100 
% 
o 10500 11500 
11848.0 
±O.S 
Mass (Da) 
12500 13500 14500 
Figure 3.20: Deconvoluted, neutral-scale mass spectrum o/the CV-N-tyrosinamide conjugate (48). 
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3.6 Conclusions 
For the CV-N-toxin conjugates to be viable as therapeutic agents, homogeneity of product 
is of primary importance. Limited homogeneity was achieved with CV -N conjugates 
prepared using the thiollmaleimide methodology. A distribution of derivatisation over all 
the lysine residues, but not at the N-tenninus, was observed. While exact points of 
interaction between CV-N (28) and gp120 are still not known, the N-terminus is believed 
to be involved.96,lo6 By avoiding derivatisation at the N-tenmnal amino group, the chance 
of producing conjugates that do not interfere with the binding of CV-N to gp120 is 
increased. 
Ideally, a more selective and defined modification of the protein is needed. 
With reactivity at all lysine residues it is possible, nonetheless, to have some control over 
the loading of toxin derivatives onto CV-N (28). By creating a range of conjugate 
products, the optimum pharmacokinetic properties can be determined. 
A tyrosinamide-based conjugate has been produced. This conjugate can be radio-labelled, 
and will be useful in cellular and body distributi~n studies of the CV-N conjugates. 
111 
s 
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MUTANT CV-N CONJUGATES 
4.1 Introduction 
The heterogeneity of a therapeutic conjugate presents a regulatory challenge for the 
phannaceutical industry. By comparison with synthetic polymers, working with CV-N 
(28), as a defined entity, is helpful in this context. However, there still exists, within CV-
N (28) the potential for heterogeneity. Chapter 3 described a number of native CV-N (28) 
conjugates prepared by covalent linkages with lysine amino groups. Invariably, this gave 
a broad distribution of products. Five products are possible, even with mono-derivatised 
CV -N (28), and each of these are inseparable from each other. The heterogeneity of the 
product mixture can be significantly reduced by using a very high excess of the 
modifYing reagent, resulting in complete modification of all available amino groups. 
However, in this case, the problem of site-selective attachment of toxin remains unsolved. 
The goal of the following chapter of work was to produce conjugates of CV-N; 
selectively, controllably, and unifonnly modified with the biolinker-toxin constructs 
prepared in Chapter 2. In rare cases, selective protein modification and fonnation of a 
homogeneous bioconjugate can be achieved if the protein happens to have only a single 
reactive amino acid residue targeted by the modifying agent. In general, however, 
strategies relying on a single attachment point on the protein molecule can hardly be 
considered a general method of preparation of homogeneous conjugates because proteins 
typically bear multiple reactive groups on their surface. 
A solution to the problem of the site-specific preparation of homogeneous bioconjugates 
of CV-N (28) was provided by a four recombinantly-produced mutant CV-N proteins. 
These proteins were supplied by NektarTM Therapeutics. Through site-directed 
mutagenesis, each of these new proteins had varying numbers of the lysine residues in 
CV-N (28) replaced by arginine residues. Arginine does not have the E-arnino functional 
group, and is therefore not reactive to the thiolating reagent, 2-IT (29). The mutant 
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proteins provided were: CV-N: K3R (49); CV-N: K3R, K48R (50); CV-N: K3R, K48R, 
K74R (51); and CV-N: K3R, K48R, K74R, K84R (52). Protein 52, for example, has only 
one lysine residue at position 99. This is advantageous as it allows for only a single 
attachment point on the protein. 
This chapter describes the synthesis of homogeneous samples of singly- and doubly-
substituted toxin conjugates of CV-N, through modification of CV-N: K3R, K48R, 
K74R, K84R (52), and CV-N: K3R, K48R, K74R (51), respectively. 
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4.2 Recombinant Mutant CV -N Proteins 
4.2.1 Purification 
The four mutant proteins (49, 50, 51, 52) were supplied as partially purified samples and 
each needed further purification before conjugate preparation could continue. Each 
protein was purified using a semi-preparative polymeric reverse phase (PRP-3) HPLC 
system. A PRP column was chosen as this type of column had previously been shown to 
have good recovery of protein samples.205 A 45-minute method (Section 8.4), with 
monitoring at 'A 210 nm, was utilised. The major component eluted at 28 minutes in each 
case and was collected using a fraction collector. LC MS (Agilent 11 00, see Section 8.4 
for method) confirmed the exact mass and purity of each sample, and a representative 
TIC ES+ chromatogram of a purified protein is presented in Figure 4.1. A single 
component eluted at ~21.5 minutes in each case. The purified proteins were all taken to 
dryness under nitrogen gas flow, and reconstituted in distilled water (1 mg/mL) for 
storage. 
300 
250 
QJ 200 y 
= <:<j 
"C 
= :;:I 150 < 
100 
50 
0 
5 10 15 20 25 30 
Time (mins) 
Figure 4.1: TIC ES+ Chromatogram of purified CV-N: K3R, K48R, K74R, K84R (52). 
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A deconvoluted mass spectnun (prepared using HP ChemStation) of each of the mutant 
proteins is shown in Figure 4.2. The expected molecular weight was obtained in each 
case. 
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Figure 4.2: Deconvoluted mass spectra of mutant CV-N proteins: (a) CV-N: K3R (49); (b) CV-N: 
K3R,K48R (50); (c) CV-N: K3R, K48R, K74R (51); and (d) CV-N: K3R, K48R, K74R, K84R (52). 
Two of the mutant proteins were chosen for further conjugate development. CV-N: K3R, 
K48R, K74R, K84R (52) was a particularly attractive protein. With just a single lysine 
residue remaining, at postion 99, this protein presented an ideal opportunity to selectively 
modify CV-N as discussed in Chapters 2 and 3. A single, defined product would be 
produced. CV-N: K3R, K48R, K74R (51) was chosen as it presented two available lysine 
residues (at positions 84 and 99), and offered the prospect of producing doubly-
substituted protein-toxin conjugates that were also well defined and characterised. The 
production of a doubly-substituted protein would allow investigations to determine the 
optimum pharmacokinetics of the CV-N conjugates to begin. 
The two remaining mutant proteins may be of use in future experimental design. 
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4.2.2 Tryptic Digestion 
A tryptic digest was performed on both CV-N: K3R, K48R, K74R, K84R (52) and CV-N: 
K3R, K48R, K74R (51) to confirm the respective amino acid sequences, and the 
replacement of the appropriate lysine residues by arginine. The digestions followed the 
same procedure discussed in Section 3.4 and were analysed by LC MS (standard protein 
LC MS gradient). A list of predicted peptide fragments was created using the digest 
software200 and these fragments were compared to the experimentally determined masses 
after processing the ESI MS data. The relevant ESI MS digest data, and the resultant 
fragment assignments, for CV-N: K3R, K48R, K74R, K84R (52) and CV-N: K3R, K48R, 
K74R (51) is presented in Table 4.1 and 4.2 respectively. 
Retention ... Experquental 
..•••••.•.•••.. ·····••••.• •• ··.'l'fr~!ic/9~~1l1()trr~~i~.. ••• · ••.. I ..•..• < ...... MW(Da) ". ;' .'. Time (mins) I .. Cleavage Sites and Fragments .... 
11.9 935.6 936.0 Da, peptide from 77 to 84. (R)A .... R(I) 
14.4 1019.8 1019.1 Da, peptide from 60 to 69. (R)N .... L(A) 
15.9 747.5 747.8 Da, peptide from 4 to 9. (R)F .... YeN) 
21.3 1187.8 1188.2 Da, peptide from 19 to 29. (L)T .... YeN) 
21.9 1549.0 1549.7 Da, peptide from 60 to 74. (R)N .... R(T) 
1565.2 1565.7 Da, peptide from 10 to 24. (Y)N .... R(T) 
548.3 548.6 Da, peptide from 70 to 74. (L)A .... R(T) 
27.3 1651.2 1651.8 Da, peptide from 85 to 99. (R)I .... K(Y) 
29.2 1379.8 1380.5 Da, peptide from 49 to 59. (R)W .... R(N) 
2294.4 2295.5 Da;peptide from 4 to 24. (R)F .... R(T) 
37.8 2524.8 2525.7 Da, peptide from 25 to 48. (R)T .... R(W) 
41.4 11119.4 undigested protein 
Table 4.1: Selected ESJ-MS data from LC MS oftlyptic digest ofCV-N: K3R, K48R, K74R, K84R (52). 
MW = molecular weight. 
i~~t~Iit!?~C E*p~riipellt~! 1'\// .. ···~Trypti~/ChymQt:ryptie· I' ..... ..;........ i/.>·· ' ..••. 
. Time (mins) MW(Da) ;' I" Cleavage Sites and Fragmeuts " 
13.2 907.6 908.0 Da, peptide from 77 to 84. (R)A .... K(I) 
15.8 747.4 747.8 Da, peptide from 4 to 9. (R)F .... YeN) 
22.6 1549.0 1549.7 Da, peptide from 60 to 74. (R)N .... R(T) 
1565.0 1565.7 Da, peptide from 10 to 24. (Y)N .... R(T) 
548.3 548.6 Da, peptide from 70 to 74. (L)A .... R(T) 
28.0 1651.2 1651.8 Da, peptide from 85 to 99. (K)I .... K(Y) 
1310.8 1311.4 Da, peptide from 88 to 99. (L)D .... K(Y) 
29.8 1379.8 1380.5 Da, peptide from 49 to 59. (R)W .... R(N) 
38.7 1505.0 1505.7 Da, peptide from 75 to 87. (R)T .... L(D) 
2524.5 2525.7 Da, peptide from 25 to 48. (R)T .... R(W) 
40.5 2508.6 2508.8 Da, peptide from 2 to 24. (L)G .... R(T) 
Table 4.2: Selected ESJ-MS data from LC MS of tryptic digest of CV-N:K3R, K48R, K74R (51). MW = 
molecular weight. 
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All peaks in the TIC chromatograms of the digests were matched with a predicted 
fragment (or fragments). Some chymotryptic activity was also seen, with cleavage after 
leucine and tyrosine residues in some instances. A map of both proteins was created, 
providing confirmation ofthe amino acid sequence in each case. 
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4.3 CV -N: K3R, K48R, K74R,K84R (52) 
4.3.1 CV-N: K3R, K48R, K74R, K84R-F-150 Conjugate (53) 
The model maleimide, F-150 (46), was employed again for initial reactivity and method 
development studies. The target (53); a singly-derivatised, conjugate of CV-N: K3R, 
K48R, K74R, K84R (52) is illustrated in Figure 4.3. 
OH 
Figure4.3: CV-N: K3R, K48R, K74R, K84R-F-150 Conjugate. 
CV-N: K3R, K48R, K74R, K84R (52, 200 flg) was thiolated with 2-IT (29, 25 
equivalents) in reaction buffer at O°C in an ice bath for 12 hours. The protein was 
separated from 2-IT (29) on a G-25 column eluting with standard borate buffer, while 
monitoring at Iv 206 nm. The peak that eluted at ~20 minutes was collected and reacted 
directly with F-150 (46, two equivalents in minimal DMF) for five hours at O°C. The 
reaction mixture was concentrated (~200 flL) and purified on a further G-25 column, this. 
time eluting with distilled water. A fluorescent yellow band eluted at the void volume 
(Yo). This fraction was collected and analysed by LC MS (Waters/Micromass, Zorbax-
C3, standard protein LC MS gradient). Two primary peaks eluted in the TIC 
chromatogram (Figure 4.4). The second peak is visible at 450 nm, suggesting that it has 
been tagged by 150 (46). Analysis of the ESI MS data demonstrated that unreacted 
protein (11,119 Da) was eluting at 42.6 minutes and that the conjugate 53 (11,648 Da) 
was eluting at 44.5 minutes (Figure 4.5). A doubly-substituted product was not observed. 
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Figure 4.4: Expansion of a section of the chromatogram of the preparation of CV-N: K3R, K48R, K74R, 
K84R-F-150 Conjugate (53). Diode Array trace at A 450 nm and Total Ion Current (TIC) ES+ trace. 
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Figure 4.5: ESI deconvoluted mass spectrum ofCV-N: K3R, K48R, K74R, K84R-F-150 Conjugate (53). 
The succinimide ring-opened component (11,666 Da), as discussed in Section 3.4.3, was 
also present and increased in proportion over time until it became the sole product. 
Increasing the amount of 2-IT (29), or an increase in thiolation reaction time, served only 
to introduce the thiolation by-product. A 100% yield of the conjugate product was never 
obtained. However, with base-line chromatographic separation of the unreacted protein 
(52) and the conjugate (53), the conjugate could be readily purified. 
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4.3.2 CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B Conjugate 
The ultimate goal of this project was to combine the potent toxicity of homohalichondrin 
B (22) with the anti-HIV targeting ability of CV-N (28). This section of work set out to 
prepare the mono-derivatised CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin 
conjugate (54) illustrated in Figure 4.6. 
Figure 4.6: CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B Conjugate. 
Protein 52 (4.5 mg) was dissolved in degassed reaction buffer (4.5 mL) and thiolated with 
2-IT (29,25 equivalents) at O°C for 12 hours. The reaction mixture was chromatographed 
on a G-25 column (2.5 cm x 40 em) with standard borate buffer at a flow rate of 3 
mLimin, and visualised with a diode array detector set at 280 nm. The protein fraction 
was collected after 19 minutes. This fraction was concentrated to -4 mL by centrifugation 
in a centriprep concentrator (YM-3 regenerated cellulose 3000MW). y-Maleimidobutyric-
Gly-Phe-Leu-Gly-norhomohalichondrin B (32, Section 2.4.1, one equivalent, in miminal 
DMF) was added, and the reaction left to stand at O°C overnight. LC MS analysis 
confirmed that the reaction was complete at this point and that a single, mono-derivatised 
product (54) had been produced (Figure 4.7). Disappointingly, it appeared only -10% of 
the mutant protein had been derivatised (Figure 4.7). However, with unreacted protein 
eluting at 15.7 minutes, and a small proportion of thiolation by-product eluting at 17.1 
minutes, conjugate 54 (21.2 minutes) could be purified using analytical reverse phase 
HPLC. A solvent gradient comprising the following steps was used: a linear gradient 
from 20-45% CH3CNIH20 (0.5% acetic acid) over 25 minutes; a linear gradient to 100% 
CH3CN over five minutes; isocratic at 100% CH3CN for five minutes; and then a return 
to 20% CH3CN/H20 over five minutes. Despite concerns of the stability of the 
halichondrin component of the sample, the acid modifier was essential for 
chromatography; no conjugate was observed without it. Conjugate 54 eluted at 21.2 
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minutes, and was collected manually and dried down under nitrogen immediately to avoid 
any possible degradation ofthe halichondrin by acetic acid. 
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Figure 4.7: Diode Array chromatogram (It 280 nm) for the preparation of CV-N: K3R, K48R, K74R, 
K84R-norhomohalichondrin B Conjugate (54). 
After collection, 54 was reanalysed by LC MS to assess the final purity of the sample. 
The sample was essentially a single component. This component had a mass 18 Da higher 
(12,870 Da) than that expected for 54. (Figure 4.8) This mass difference had been 
observed previously with model systems (Section 3.4.3). 
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Figure 4.8: Neutral-scale deconvoluted mass spectrum for purified CV-N' K3R, K48R, K74R, K84R-
norhomohalichondrin B conjugate (54). 
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A number of analytical experiments were undertaken to quantify 54, and to confirm the 
exact site of derivatisation. 
4.3.2.1 Amino Acid Analysis 
Conjugate 54 was submitted for amino acid analysis. This gave a protein quantitation of 
50.8 Ilg. This quantity of conjugate, though small, would be enough for preliminary 
investigations. Amino acid analysis also confirmed a ratio of one Gly-Phe-Leu-Gly 
biolinker to each protein molecule. 
4.3.2.2 Amino Acid Sequencing 
Conjugate 54 (0.846Ilg) was submitted for ammo acid sequencmg by an Applied 
Biosystems Procise Sequencer. The sequencer chemically cleaves amino acids one by one 
from the N-terminus of the protein and identifies them chromatographically. The first 
nine amino acids from the N-terminus were sequenced correctly. This suggests that the 
primary product being sequenced had not been derivatised at the N-terminal amine. The 
sequencer would not have recognised the N-terminus otherwise. This consolidates 
previous results. 
4.3.2.3 Tryptic Digest 
Conjugate 54 (4.2 Ilg) was digested with TPCK-treated sequencing grade trypsin in the 
same manner as discussed in Section 3.4 and analysed by LC MS after 12 hours. A 
reverse phase (Zorbax-C3) system was used for the analysis. The solvent elution gradient 
consisted of the following timetable; a very long linear gradient from 100% H20 (5% 
acetic acid) to 40% CH3CNIH20 over 135 minutes, and then an increase in CH3CN 
concentration to 100% over 15 minutes. A small amount of dithiothreitol (DTT) was 
added to the LC MS sample just before analysis to break any disulfide bonds that might 
be binding two fragments together. All peaks in the resultant LC MS trace (Figure 4.9) 
were accounted for with a peak eluting at 123 minutes being particularly notable. This 
peak represented the amino acid residues, 85 to the C-terminus of 52, derivatised by 2-IT 
(29) and y-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32). Since 
trypsin cleaves on the carboxyl side of lysine, the lack of cleavage of this fragment at 
residue 99 is also indicative of derivatisation of lysine at this point. Other fragment 
assignments can be seen in Table 4.3. 
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Figure 4.9: Total ion current chromatogram of the tlyptic digest of CV-N:K3R, K48R, K74R, K84R-
norhomohalichondrin B Conjugate (54). 
Retention E):JlerlmeJJ.tltl i, .... 9al~ulatedMW.(Da>' ; ···/·'frypticlG.brDlotrypt,c \} . .... 
Time (mins) MW(Da>.· .. Without ITlMalei WitiIout H20 . CleaYage Sites and Fragments 
....... 
..... ' 
48.75 1549.0 1549.7 Da, peptide from 60 to 74. (R)N .... R(T) 
65.89 1380.0 1380.5 Da, peptide from 49 to 59. (R)W .... R(N) 
68.00 935.7 936.0 Da, peptide from 77 to 84. (R)A .... R(I) 
68.79 1018.8 1019.1 Da, peptide from 60 to 69. (R)N .... L(A) 
70.51 2294.9 2295.5 Da, peptide from 4 to 24. (R)F .... R(T) 
97.05 2525.5 2525.7 Da, peptide from 25 to 48. (R)T.. .. K(W) 
123.61 3676.3 1944.3 1944.1 Da, peptide from 85 to 101 (K)I.. .. E, 
derivatised at Lys99 
3694.2 1944.2 1944.1 Da, peptide from 85 to 101 (K)I....E, 
derivatised at Lys99 
Table 4.3: Selected ESI MS data from the LC MS of the tlyptic digest ofCV-NK3R, K48R, K74R, K84R-
norhomohalichondrin B conjugate (54). MW = molecular weight. IT/Malei = 2-IT (29)/ 
y-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32). 
The biological testing of this conjugate is discussed in Chapter 6. 
4.3.3 CV-N: K3R, K48R, K74R, K84R-Doxorubicin Conjugate (55) 
Over the past 33 years, doxorubicin (34) unquestionably has proven to be of considerable 
medical value because of its outstanding anti-cancer activity. The importance of 
doxorubicin (34) is well documented in a huge number of publications. 135,171,175,206-209 
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Spurred on by the positive results reported by Kratz et al. with transferrin135 and 
albumin144,210 protein conjugates of doxorubicin (34), and the traverse of the polymer 
therapeutics of doxorubicin (34) (PK1 142,171 and PK2143 ,211) through clinical trials, the 
goal of this section of work was to combine doxorubicin (34) and CV-N (28) in a unique 
therapeutic (55, Figure 4.10) for HIV. 
K'--', NH 0 ~: 
I 52 )--, j~s~ H 0 H 0 H ~H 
\",( ) ,j' ~ N~(N~~N NY~Nl(N/('Q' .. ,\\\ 
"~ 0 H 0 - H 0 0 
o Y Q OH 0 OCH3 
(55) HOH'C~ 
o OH 0 
Figure 4.10: CV-N.' K3R, K48R, K74R, K84R-Doxorubicin Conjugate. 
CV-N: K3R, K48R, K74R, K84R (200 )lg) was reacted with 2-IT (29) in reaction buffer 
at ODC for 12 hours. A size-exclusion column (G-25), eluted with standard borate buffer, 
was utilised to separate the protein from excess thiolating reagent. This column was 
monitored at 206 nm with a diode array detector. A peak eluting at 20 minutes was 
collected and reacted directly with y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin 
(35, two equivalents in minimal DMF) for two hours. The reaction mixture was 
concentrated (~200 IlL) and purified on a further G-25 column, this time eluting with 
distilled water. A pale pink band eluted at 20 minutes. This fraction was collected and 
analysed by LC MS (Micromass/Waters, Zorbax-C3, standard protein LC MS gradient) 
(Figure 4.11). 100 
% 
\. t~~ ______ --o~~~~~~~~~::~~::::::::::~~~ 
10,00 20,00 30.00 40.00 50.00 60.00 70.00 80.00 
Time (mins) 
Figure 4.11: Total Ion Current chromatogram of the preparation of CV-N: K3R, K48R, K74R, K84R-
doxorubicin conjugate (55). 
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Two peaks were predominant in the LC MS analysis. The second peak demonstrated a 
strong absorbance at 480 run in the diode array, indicative of a doxorubicin derivative. 
Analysis of the TIC data showed that umeacted protein (11,120 Da) was eluting at 42.05 
minutes and that 55 (12,304 Da) was eluting at 46.20 minutes (Figure 4.12). 
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FiguI'e 4.12: ESI MS deconvoluted data Ji'om the preparation of CV-N: K3R, K48R, K74R, K8R-
doxorubicin conjugate (55), (a) retention time 42.05 minutes; (b) retention time 42.75 minutes; (c) retention 
time 43.42 minutes; and (d) retention time 46.20 minutes. 
A small peak elutes closely to the umeacted protein (42.75 minutes) and this was 
confirmed to be the thiolation by-product (Figure 4.12) as previously discussed. With 
good separation from the product conjugate, the formation of this by-product does not 
present purification issues. There were two significant elements of concern however. 
Deconvolution of the product peak (46.20 minutes, Figure 4.12) presents two products: 
the expected conjugate (12,304 Da) and a peak with a mass of 11,890 Da. This appears to 
be loss of the anthracyline, and water, from the conjugate, perhaps in the mass 
spectrometer. Significantly more alerting was the presence of small peak (Figure 4.12) 
eluting at 43.42 minutes. Deconvolution of the ESI MS data showed that this compound 
had a mass of 11,908 Da. This compound does not absorb at 480 nrn in the diode array 
indicating a loss of the anthracycline functionality. Based on the mass, this peak appears 
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to be loss of the anthracycline from the conjugate. Interestingly, a peak of 11,890 Da is 
also present in this spectrum, and is possibly loss of water from the degraded conjugate in 
the mass spectrometer. The sample was analysed with further LC MS runs, and an 
overlay of the resultant chromatograms is presented in Figure 4.13. The conjugate (55, 
46.20 minutes) degrades over time, and the peak at 43.42 minutes grows. Within 24 hours 
the conjugate (55) was no longer present. 
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Figure 4.13: TIC chromatogram overlay of the degradation of conjugate 55. 
A literature search reveals that doxorubicin (34) is far from an ideal drug. It interacts with 
all kinds of ions, chelates strongly with divalent and trivalent metal ions, adsorbs onto 
various materials, particularly glass surfaces, tends to self-associate in concentrated 
solutions, and is liable to photolytic degradation, and to oxidation?12-214 A number of 
systematic studies into the chemical degradation processes have been completed. The 
studies have focused on the kinetics of doxorubicin degradation, primarily in aqueous 
solution, as a factor of pH, buffers, temperature, lomc strength and drug 
concentration.212-214 There are a number of degradation conditions that are particularly 
important in relation to this project. Firstly, the degradation rate of doxorubicin is 
strongly influenced by the pH of the medium, decomposing under both acidic and basic 
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conditions. The compound shows maximum stability at pH 4.213 Secondly, in the region 
of up to pH 9.5, catalysis by acetate, phosphate and carbonate buffer components have 
been demonstrated?13,2l4 And fmally, it has also been shown that in the presence of light; 
even room light, or light from photodiode array detectors, degradation of doxorubicin 
(34) occurs.2l2 
In acidic solution (pH < 4) the initial degradation step of doxorubicin (34) is conversion 
into the 7-hydroxyaglycone, doxorubicinone (56, Figure 4.14) and the amino sugar, 
daunosamine (57, Figure 4.14). At pH > 4 the degradation pattern of doxorubicin (34) has 
not been elucidated completely, but compound 58 appears as the main degradation 
prodUCt.213 
o OH o 
o OH 
OH OH 
doxorubicinone (56) 
Figure 4.14: Doxorubicin, and structures of the doxorubicin degradation products, 
Beijnen et al.2l3 proposed a degradation mechanism. Enolisation of the a-ketol side chain 
is assumed to be the first step in the degradation reaction of doxorubicin (34). Abstraction 
of a benzylic proton, and cleavage of the side chain and the amino sugar (57) yields 
doxorubicinone (56). The high stability of the resulting degradation product is the driving 
force of the full aromatisation of the A ring (58) after cleavage of the side chain. 
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We assume that the degradation product observed in our case is the conjugate (59) 
illustrated in Figure 4.15. The sugar remains attached to the biolinker, while the 
anthraquinone functionality is expelled. 
~s~o H 0 
H N~N~N 
o H 
o 
(59) 
Figme 4.15: Degradation product of the CV-N: K3R, K48R, K74R, K84R-Doxorubicin conjugate (55). 
This degradation probably occurs as a function of interrelated factors, particularly of pH, 
buffers, and light conditions. The degradation product (59) was seen at the same retention 
time as the conjugate product (55) in the LC MS analysis, perhaps due to fragmentation in 
the mass spectrometer, but was also seen at an earlier retention time, suggesting 
degradation in the sample vial. 
This raises a complex issue. The authors of publications reporting the preparation of 
polymeric142,143,171,172,215 and protein135,144,210 constructs of doxorubicin (34) claim that the 
conjugate systems increase the therapeutic index of the drug: that cardiotoxicity 
decreases, while the cytostatic action is preserved. The publications make no mention of 
degradation products, or in fact complete degradation (as in our case). Interestingly, the 
preparation of the albumin144,210 and transferrin135 conjugates of doxorubicin (34) utilise 
very similar reaction conditions to those used in this project, and stock solutions of the 
conjugates were kept in a standard borate buffer (0.0025 M sodium borate, 0.15 M NaCI, 
pH 7.5). The lack of reported degradation of these conjugates raises questions about the 
cytotoxic action of the parent compound and the degradation products. More research will 
need to be done to evaluate this further. 
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4.4 CV-N: K3R, K48R, K74R (51) 
Potency of the therapeutic agent, and the clinical dose required must be considered in the 
development of a drug. One of the most important limiting factors when designing a drug 
delivery system is its drug carrying capacity, not only in terms of the theoretical 
possibilities for chemical conjugation, but also practical issues such as water solubility of 
the product and the influence of high drug substitution on the pattern of biodistribution of 
the conjugate. This latter issue is of primary importance with the binding specificity of 
CV-N to gp120. Research has shown a maximum drug loading does not always yield a 
product with maximum efficacy.12l The issue of increased toxin loading on CV -N was 
addressed with modification of the mutant protein CV-N: K3R, K48R, K74R (51). 
4.4.1 CV-N: K3R, K48R, K74R-F-150 Conjugate (60) 
The doubly-substituted fluorescent conjugate (60, Figure 4.16) was selected as the initial 
target. 
OH 
N~s0· 
H ~N 
o 
HO 
o 2 
(60) 
Figul'e4.16: CV-N: K3R, K48R, K74R-F-J50 Conjugate. 
CV-N: K3R, K84R, K74R (200 ~g) was thiolated with 2-IT (28, 35 equivalents) in 
reaction buffer for 12 hours at O°C. Like after most previous thiolation reactions, the 
reaction mixture was chromatographed on a G-25 column. The protein component eluted 
at 20 minutes and this solution was reacted directly with F-150 (46, four equivalents in 
minimal DMF) for five hours. The sample was concentrated and purified on a further 
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size-exclusion column, this time eluting with distilled water. The fluorescent yellow band 
that eluted at ~20 minutes was collected and analysed by LC MS (Micromass/Waters, 
Zorbax-C3, standard protein LC MS gradient). 
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Figure 4.17: Expansion of a section of the chromatogram of the preparation ofCV-N:K3R, K48R, K74R-
F-150 conjugate (60). Diode Array trace at }, 450 nm, and Total Ion Current (rIC) ES+ trace. 
The spectrum max diode array, and the TIC chromatogram (Figure 4.17) showed three 
peaks, eluting at 41.7 minutes, 43.4 minutes and 45.4 minutes. The second and third 
peaks appeared to be tagged with F -150 as they absorbed at 450 nm in the diode array. 
Analysis of the TIC data showed that unreacted protein (11,119 Da) was eluting at 41.7 
minutes and that 60 (12,149 Da) was eluting at 45.4 minutes (Figure 4.18). The 
compound eluting at 43.4 minutes was a singly-derivatised CV-N: K3R, K84R, K74R. 
Better product ratios were never achieved. However, purification of the doubly-
substituted conjugate (60) was possible with collection of the desired peak after HPLC 
separation using the standard protein LC MS gradient. The mass spectrometer was used 
as a guide of retention time, with a 1:9 split of sample to the mass spectrometer and the 
collection vial. 
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Figure 4.18: ESI deconvoluted spectrum ofCV-N: K3R, K48R, K74R-F-J50 conjugate (60). 
4.4.2 CV-N: K3R, K48R, K74R-norhomohalichondrin B (61) 
131 
12750 
The final goal of this section of work was to create the doubly-substituted 
norhomohalichondrin B conjugate ofCV-N (61), illustrated in Figure 4.19. 
(61) 
Figure 4.19: CV-N: K3R, K48R, K74R-norhomohalichondrin B Conjugate. 
CV-N: K3R, K84R, K74R (200 Ilg) was thiolated with 2-IT (28, 35 equivalents) in 
reaction buffer, for 12 hours at ODC. The reaction mixture was purified on a G-25 column. 
The protein component eluted from the column at 20 minutes and this solution was 
reacted directly with y-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32, 
four equivalents in minimal DMF) for ten hours. The sample was concentrated, and then 
Chapter Four - Mutant CV-N Conjugates 132 
purified on a further size-exclusion column with distilled water as the eluant. A peak: 
absorbing at A 206 run was detected at ~20 minutes and this was collected and analysed 
by LC MS (Micromass/Waters, Zorbax-C3). Figure 4.20 presents the TIC chromatogram 
of the protein fraction. The halichondrin family of compounds are unstable in acid 
conditions, so for this reason LC MS analysis was attempted without an acid additive. It 
was found, however, that fonnic acid (0.1%), was required to achieve good 
chromatography. 
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Figure 4.20: Total Ion Current chromatogram of the preparation of CV-N: K3R, K48R, K74R-
norhomohalichondrin B Conjugate (61). 
Figure 4.20 shows the TIC chromatogram of the LC MS analysis. MaxEnt deconvolution 
of the ESI MS data of each peak revealed that the desired conjugate, (61, 14,557 Da) was 
eluting at 58.5 minutes (Figure 4.21). This product was accompanied by two further 
products, 14,574 Da, and 14,593 Da, which demonstrate one and two, hydrolysed 
succinimides, respectively. 
A singly-derivatised norhomohalichondrin B conjugate ofCV-N: K3R, K48R, K74R (12 
723 Da) was seen to be eluting ~52 minutes. It was followed by a closely eluting 
derivative (12,807 Da) that showed a second addition of 2-IT (29) that had cyclised into 
the unreactive 'dead end' by-product. Unreacted protein (11,092 Da) and protein showing 
addition of the thiolation by-product (11,176 Da and 11,260 Da) were present at 43.1 
minutes and 44.2 minutes respectively. 
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Figure 4.21: Neutral-scale deconvoluted mass spectrum of the purified CV-N: K3R, K48R, K74R-
norhomohalichondrin B conjugate (61). 
The conjugate, 61, was purified from the other protein components using the standard 
protein LC MS gradient in the same manner as described in Section 4.4.1. As Figure 4.20 
illustrates, good chromatographic separation is achieved between the various components 
with this method. The collected fraction was taken to dryness immediately and reanalysis 
by LC MS confirmed that the halichondrin. component had not degraded in the 
purification steps. The conjugate sample has not been quantified. 
The purified CV-N: K3R, K48R, K74R-norhomohalichondrin B conjugate (61) has been 
submitted for biological testing to assess its cytotoxicity, and its binding affinity to 
gp120. 
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4.5 Conclusions 
Two recombinantly produced mutant CV-N proteins, CV-N: K3R, K48R, K74R (51) and 
CV-N: K3R, K48R, K74R, K84R (52), allowed for the production of two selectively 
modified double- and single-norhomohalichondrin B conjugates of CV-N. Somewhat 
disappointingly, the production was not high yielding, but both conjugates could be 
readily purified. The toxin-conjugate preparations presented in this thesis were one off 
experiments. With a greater availability of the toxin construct, conjugate yield may be 
optimised in the future. However, the preparation of these conjugates had addressed the 
problem of being able to produce highly defined and characterised protein products that 
could be utilised in a therapeutic application. 
Doxorubicin proved to be a troublesome drug, with the conjugate degrading rapidly. The 
instability of this compound raises questions as to the nature of other published drug 
preparations. 
135 
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HSA CONmGATES 
5.1 Introduction 
Human serum albumin (HSA) IS the most prevalent circulating protein in the 
bloodstream.216 Albumin plays numerous important biological roles, including 
involvement in regulating osmotic blood pressure and transporting fatty acids from the 
liver to tissues.216 Serum albumin possesses a unique capability to bind, covalently and 
reversibly, a great number of endogenous and exogenous compounds (for example, 
bilirubin, the breakdown product of heme, therapeutic drugs such as aspirin, penicillins 
and sulfonamides, and the metal ions, copper(II), nickel(II) and calcium(II)).119,217 This 
blood serum protein also serves as an important source of amino acids for cells. 119,216 
HSA is a single-chain protein synthesised and secreted from liver cells. The protein is 
produced at a rate of approximately 10-12 g daily and exhibits an average half-life of 19 
days.217 HSA has 585 amino acids and has a molecular weight of 66,500 Da.217 Albumin 
lacks prosthetic groups and covalently bound carbohydrate and lipid. According to X-ray 
crystallographic analyses (Figure 5.1) of HSA, the polypeptide chain forms a heart-
shaped protein with approximately 67% a-helix but no ~_sheet.217 All but one (Cys-34) of 
the 35 cysteine residues are involved in the formation of stabilising disulfide 
bonds. 144,217,218 
In the middle of last century the first reports appeared in the literature that tumours might 
be able to trap plasma proteins.219 In the following 30 years only a small number of 
investigations addressed the role of albumin in tumour growth. 119 The reason for 
neglecting the significance of albumin for tumour proliferation and metabolism may be 
due to a reluctance to believe that such an abundant protein should show a selective 
uptake in tumour tissue. Matsumura and Maeda coined the expression "EPR" (Section 
1.5) in 1989 after they studied the uptake of macromolecules, including serum albumin, 
by mouse tumours.220 Since that time, an increasing number of distribution studies 
concerning the uptake of labeled albumin in animal tumours have appeared in the 
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literature. 1 19,130 These studies showed that between 3-25% of the applied dose was found 
in the tumour. 1 19 In contrast to the EPR effect as an explanation for the accumulation of 
HSA in tumours, Stehle et al. have also proposed that plasma proteins such as albumin 
are major energy and nutrition sources for tumour growth. With the increased metabolism 
and proliferation of cancer cells, this could explain the high rate of serum albumin 
turnover in tumours. 119.2 11i 
Figure 5.1: C,ystal structure of human serum albumin. Cysteine-34 is shown in ball and stick 
representation (inset). The disulfide bonds are highlighted in yellow, The diagram was produced with 
Protein Explorer from the RCSB PDB, entry IA06. 
The preferential uptake of HSA in tumour tissue, the good biological stability of the 
protein, and its non-toxic, non-immunogenic nature, has provoked the development of a 
number of HSA conjugates. The anthracyclines, doxorubicin210,221 and daunorubicin,222 
the folate antagonist methotrexate,223 and further anti-cancer agents such as 
camptothecin224 and chlorambuci 1134 have been conj ugated to HSA via a number of 
methods. Many of these conjugates have shown high anti-tumour activity in in vitro and 
in vivo models. These conjugates also demonstrated a prolonged half-life of the drug in 
the plasma, and increased water solubility of the cytotoxin. 134 
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Of particular relevance to this project was the development of albumin conjugates of the 
anti-cancer drug chlorambucil. 134 Maleimido derivatives of chlorambucil were bound to 
HSA that had been thiolated with 2-iminothiolane. The average number of introduced 
thiol groups was 3.0. 134 In vitro and preliminary in vivo studies demonstrated positive 
anti-tumour efficacy. The conjugates also exhibited an increased serum stability 
compared to the free chlorambucil.134 
As discussed and demonstrated in Chapter 2, 3 and 4, 2-iminothiolane reacts with primary 
amines. HSA has 59 lysine residues (and therefore 59 8-amino groups), and allows very 
little control over the number and distribution of thiol derivatives. This presents 
difficulties in characterising the resultant conjugates. 
Approximately 70% of circulating albumin in the blood stream is mercaptalbumin that 
contains an accessible free thiol at cysteine-34 (Figure 5.1) that is not blocked by 
endogenous sulfhydryl molecules such as cysteine or glutathione. 144,218 Commercially 
available albumins are a mixture of mercaptalbumin and non-mercaptalbumin, containing 
approximately 20-60% of the free sulfhydryl compound.221 The X-ray structure of the 
protein (PDB entry lA06, Figure 5.1) reveals that cysteine-34 is located in a hydrophobic 
crevice on the surface of the protein.144 
Kratz et al. have paid considerable attention to developing anti-cancer albumin conjugates 
that exploit the availability of cysteine_34.218,221,224 The advantage of these conjugates is 
that only one product can be formed, and the thiolating step is avoided. Maleimido 
derivatives of doxorubicin have been synthesised and coupled to exogenous serum 
albumin through cysteine-34.221 Several ofthese conjugates demonstrate anti-proliferative 
activity in in vitro studies. 
To avoid the ex vivo synthesis and characterisation of drug albumin conjugates, Kratz et 
al. have also proposed the use of in situ binding of a maleimido-derivatised drug to the 
cysteine-34 position of circulating albumin after intravenous administration. 144,218,224 An 
acid-sensitive (maleimidophenylacetyl)hydrazone derivative of doxorubicin bound 
preferentially and rapidly to cysteine-34 of endogenous albumin and demonstrated 
superior anti-tumour efficacy in murine renal cell carcinoma compared to doxorubicin.218 
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Similar albumin-binding derivatives of camptothecin have also been produced. These 
constructs were well tolerated and showed enhanced anti-tumour efficacy when compared 
to camptothecin.224 
This chapter describes the synthesis and characterisation of protein conjugates designed 
to act as anti-cancer therapeutics, by attaching low-molecular-weight cytotoxic 
compounds to HSA. The target structure is shown schematically in Figure 5.2. The 
rationale was that HSA would deliver the drug to cancerous cells. Selective cleavage of 
the biolinker, within diseased cells, would release the drug and the inherent cytoxicity. 
selective cleavage for 
controlled dmg release 
~ 
" 
low-molecular-weight 
carrier/targeting agent cytotoxic compound 
Figure 5.2: Schematic of a human serum albumin conjugate. 
The positive results demonstrated by Kratz et ai. encouraged the exploitation of the free 
thiol at cysteine-34 to create these conjugates. The goal was to take advantage of the 
maleimido-tetrapeptide derivatives of homohalichondrin B (32), doxorubicin (35); and 
tyrosinamide (37), prepared in Chapter 2, to selectively bind to the cysteine-34 position of 
exogenous human serum albumin (Figure 5.3) 
cysteille-34 
Figure 5.3: Preparation of a human serum albumin conjugate utilising HSA-cysteine-34 and a 
maleimido activated drug derivative. 
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5.2 LC MS of HSA 
The characterisation of the HSA conjugates generated in this project depended solely on 
LC MS analysis. Human serum albumin, at 66,500 Da, is a considerably larger protein 
than lysozyme or cyanovirin-N (28). Because of the greater molecular weight, the ESI-
mass spectrum of HSA is more complex. A larger series of peaks are observed 
representing a greater number of charge states. 
Initial analyses of HSA proved difficult to decipher. Direct injection of analyte, or the 
coupling of a LC system employing a short solvent gradient method (Zorbax 300SB-C3, 
20-50% CH3CN/H20 (0.5% formic acid) over 15 minutes) to the mass spectrometer, 
generated a low-intensity, poorly resolved series of peaks such as the spectrum presented 
in Figure 5.4. 
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Figure 5.4: A low intensity, poorly resolved ESJ-mass spectrum of HSA. 
As discussed in Chapter 2.8.1, impurities and buffer-related cations inherently cause a 
reduction in the mass spectral response of a protein. With the large number of charge 
states possible for HSA, the cation effect was such that the resultant spectra were 
impossible to interpret. For this reason it was essential to desalt the protein from any 
storage or reaction buffers before ESI analysis. Online coupling of the mass spectrometer 
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to an HPLC, running a long gentle solvent gradient system, served to both desalt/purify 
and separate the analytes. The gradient comprised of a 105 minute run with a flow rate of 
200 )lL/min, and consisted of the following solvent gradient timetable: a slow gradient 
from 0% - 60% CH3CNIH20 (0.5% formic acid) over 80 minutes to free the protein of 
any salts, followed by ramp in concentration to 100% CH3CN over five minutes, an 
isocratic hold on 100% CH3CN for five minutes and then a restoration to 0% CH3CN 
over five minutes. The method was finished with an isocratic hold on 0% CH3CN over 
five minutes (Zorbax 300SB-C3). A broad peak eluted at ~47-51 minutes. This peak 
represented a well-resolved, decipherable mass spectrum of HSA, presented in Figure 5.5. 
An organic modifier, formic acid (0.5%), or acetic acid (5%), in the solvent system was 
essential for good spectral results. This method became known as the standard protein 
LC MS gradient. 
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Figure 5.5: The ESJ-mass spectrum of human serum albumin (supplied by Sigma@). The inset shows the 
deconvoluted, neutral-scale mass spectrum. 
Initial analyses of human serum albumin employed a lyophilised and crystallised form 
supplied by Sigma®, quoted at being 97-99% pure. Deconvolution of the ESI-mass 
Chapter Five - HSA Conjugates 142 
spectrum for this supply of HSA (inset, Figure 5.5) revealed the presence of 
approximately five protein forms with similar masses to HSA. The principal peak was at 
66,4 79 Da. Some of the components may represent non-mercaptalbumin, with cysteine-
34 bound to various thiol-containing compounds, such as cysteine or homocysteine. It 
was decided not to attempt to eliminate these components by reducing this bond, for fear 
of reducing some of the 17 stabilising disulfide bonds. This would destroy the advantage 
of just one free thiol available for reaction. Since approximately 30% of circulating 
albumin is non-mercaptalbumin, and considering the non-immunogenic, biodegradable, 
non-toxic nature of HSA, 119 it was believed that the presence of these components would 
not be a problem in the development ofHSA as a drug carrier. 
The maleimido fluorescein dye, F150 (46), was chosen as a model maleimide. It would 
test the feasibility of reaction at HSA-cysteine-34 before commitment of the toxin 
derivatives. Fluorescently-Iabelled HSA would have the added advantage of being 
chromatographically distinct by UV profile (and by eye). HSA (Sigma®, 400 Jlg) was 
dissolved in a borate buffer (pH 7.2). F-150 (46, 5 equivalents, in minimal DMF to aid 
water solubility) was added and the reaction was left at RT for 24 hours. The reaction 
mixture was then separated on a size-exclusion (G-25) column with distilled water. Two 
fluorescent yellow bands eluted off the column, one at the void volume (Vo), suggestive 
oflabelled protein, and the other 15 mL later, suggestive of 'small molecule' unreacted F-
150 (46). Both fluorescent bands were collected and analysed by LC MS (Agilent, 
Zorbax, C3) using the standard protein LC MS gradient. The first fraction showed a 
single broad peak at ~50 minutes with an absorbance at A 440 nm. HSA is not visible at 
this wavelength normally. The ESI-mass spectrum of this peak was unable to be 
deconvoluted with MaxEnt. It appeared that several of the protein components had 
reacted with F-150, creating a large number of overlapping charge states. An alternative, 
purer, more homogeneous, supply of HSA needed to be sought. The second fraction off 
the G-25 column was confirmed to be excess, unreacted F-150. 
After consultation with Felix Kratz on the most suitable commercially available form of 
HSA, a sample, "Dessau", was obtained from Pharma Dessau, FRG. This was a 20% 
solution of HSA prepared in 16 mM sodium octanoate. This new sample of HSA was 
analysed by LC MS using the standard protein LC MS gradient. Deconvolution of the 
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ESI data collected produced the spectrum in Figure 5.6. This spectrum demonstrated that 
there were just two main protein components. The principal peak had a mass of 66,445 
Da. 
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Figure 5.6: The deconvoluted ESI-mass spectrum of human serum albumin (supplied by Pharma Dessau). 
The HSA supplied by Pharma Dessau was a considerably purer sample than the protein 
obtained from Sigma®. For this reason "Dessau" was employed for the continuation of 
the construction of the HSA conjugates. No step was taken to eliminate any non-
mercaptalbumin. 
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5.3 A Model System - HSA-F150 Conjugate (62) 
OH 
o 
~N 
o 
(62) o 
Figure 5.7: HSA-F 150 conjugate. 
F-150 (46) was again chosen as a model maleimide because of its fluorescent properties 
and the ease of which derivatised protein could be traced. HSA (Phanna Dessau, 400 ).tg, 
60 ).tL of the commercially prepared solution) was diluted in a borate buffer (PH 7.2). 
150 (46, 2 equivalents, in minimal DMF) was added and the reaction was left at RT for 
12 hours. At this time the sample was analysed by LC MS using the standard protein LC 
MS gradient (Figure 5.8). 
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Figure 5.8: Chromatogram of the preparation of an HSA-F150 conjugate (62); Diode Array trace at }" 440 
mn alld Total Ion Current (TIC) ES+ trace. 
As Figure 5.8 demonstrates, one large broad peak, with a retention time of 47 to 52 
minutes, is visible in the TIC spectrum. This peak represents protein, and as evidenced by 
the analysis at A 440 nm in the diode array spectrum, has been tagged by F-150 (46). The 
sharp peak at 34.4 minutes, visible at a wavelength of 440 nm, was unreacted F-150 (46). 
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The protein was purified from the excess F-150 (46) by passing the sample through a 
size-exclusion (G-25) column, eluting with distilled water. The fluorescent yellow band 
eluting at the void volume was collected and reanalysed by reversed phase LC MS to 
confirm the purity of the sample. This analysis showed one broad peak, with a retention 
time of 47 to 52 minutes, in both the diode array at A 440 urn and the TIC spectra. 
Analysis of the mass spectral data showed that the broad peale encompassed both 
unreacted albumin (67,572 Da) and the conjugate product 62 (67,008 Da, approximately 
50% yield). (Figure 5.9) Clearly, a mass of approximately 427 (F-150, 46) had been 
added onto HSA, but further analysis of the sample was required to confirm the nature of 
the product. 
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Figure 5.9: Deconvoluted, neutral-scale mass spectrum o/the HSA-F150 Conjugate (62). 
HSA presents problems for analysis by mass spectrometry because of the high molecular 
weight (~66500 Da) and hence the large number of possible charge states. Derivatisation 
of the protein results in products that are inseparable from unreacted protein. The 
conjugation ofF-150 (46) to HSA for example, does not change the polarity of the protein 
significantly, so the components are unable to be separated by chromatography. The 
problem is compounded when there are several protein forms already present in the 
sample. The charge state peaks in the mJz spectra become very broad and overlap, 
creating difficulties in resolving the charge distributions of the compounds present. 
Further, a small shift in the calibration of the mJz data, results in a significant shift ofthe 
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absolute molecular weight detennined in the deconvoluted spectrum. For example, a shift 
of 0.5 on the mJz scale at the 53rd charge state will result in a mass difference in the 
deconvoluted spectra of approximately 25 Da. 
A tryptic digest was perfonned on the sample containing 62 to confinn that F -150 (46) 
had tagged HSA and to confinn the expected site of derivatisation. Conjugate 62 (100 f-tg) 
was taken up in ammonium bicarbonate buffer (10 mM, pH 8). TPCK treated trypsin 
(10% by weight to analyte protein) was added in 1% acetic acid. The digest was left at 
37°C for 24 hours and assessed by a reverse phase LC MS system running the standard 
protein LC MS gradient (Figure 5.10). A small amount of dithiothreitol (OTT) was added 
to the sample, just before analysis, to break any disulfides that might be binding two 
fragments together. 
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Figure 5.10: Tryptic digest of HSA-F-J50 Conjugate (62); Diode An'ay trace at A 440 nm and Total Ion 
Current (TIC) ES+ trace. 
Analysis of a tryptic digest of HSA is not trivial. According to the peptide and protein 
software set up by Lewis Pannell,2oo there are 3,569 possible tryptic fragments, and over 
20,000 possible enzymatic cuts if one takes chymotryptic activity into account. To 
simplify the analysis of the tryptic digest of 62, only those peaks representing fragments 
that were visible at 440 nm (and hence likely to have been derivatised by F-150 (46)) 
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were processed (Figure 5.10). Table 5.1 shows the data collected for this selection of 
peaks. In each case the fragment masses identified at each retention time (experimental 
MW) were converted to a calculated MW without F-150 (46) attached. A further 18 mass 
units were subtracted from these fragments to generate a second series of possible 
fragments. An increase of 18 mass units had been seen in the case of the CV-N 
conjugates. This was attributed to hydrolysis of the succinimide ring of the biolinker, and 
the assumption was made that this could also be occurring in the case of these HSA 
conjugates. The two generated series of calculated molecular weights were compared 
against the predicted digest fragments. Of the possible digest fragments (as determined by 
the peptide and protein software200 and with the assumption that the amino acid sequence 
ofthe employed Pharma Dessau HSA sample matched the sequence in the database), only 
those containing cystcine-34 were searched for mass matches. Therefore, this does not 
discount derivatisation at another site in the protein. 
1080.7 653.3 635.3 
1051.4 624.1 606.1 
29.72 2163.1 1735.8 1717.8 
374.1 356.1 
31.09 1426.6 1408.6 
1182.5 1164,5 
31.85 1173.0 155.0 
1109.5 1091.5 
32.42 2609.9 2182.5 2164.5 2162.4 Da, e tide from g to 49. (L) .... F(A) 
2273.9 1846.5 1828.5 1825.2 Da, e tide from 21 to 3§JK)A .... F(E) 
33.34 1874.4 1447.0 1429.0 1428.7 Da, eptide from 25 to 36. (L)I .... F(E) 
1341.4 914.0 896.0 
851.5 424.1 406.1 
33.94 2722.1 2294.8 2276.8 
3405.1 2977.8 2959.8 
34.74 2151.6 1724.3 1706.3 
1472.2 1044.8 1026.8 
742.4 315.0 297.0 
Table 5.1: Selected E51-MS datafrom LeMS oftlyptic digest ofHSA-F-150 (62). MW molecular weight 
A match was made if the calculated MW was within ±O.2% of the predicted MW. There 
are four possible peptide matches, which contain the cysteine-34 residue, for the 
fragments seen. 
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5.4 HSA-norhomohalichondrin B Conjugate (63) 
(63) 
Figure 5.11: HSA-norhomohalichondrin B Conjugate. 
HSA (Phanna Dessau, 200 flg) was dissolved in borate buffer (PH 7.2) and reacted with 
two equivalents of y-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32, 
Section 2.4.1, in a minimal volume ofDMF) for three days. The protein component was 
separated from excess 32 by passing the sample through a G-25 size exclusion column. 
Unlike in the case ofF-ISO, the derivatised protein could not be tracked by fluorescence, 
so a single beam UV detector set at 'A 206 nm was used to monitor the column. The peak 
that eluted at the void volume was collected and analysed by LC MS. This analysis 
showed a single broad peak, at a retention time of 47-51 minutes, in both the spectrum 
max diode array and TIC traces. Figure 5.12 shows the ESI-mass spectrum of this peak:. 
On an initial glance at the spectrum it does not appear that any conjugation has taken 
place. This is because the addition of 1,631 Da (32) to HSA shifts the charge envelope up 
so that the product charge states almost overlap completely with those of unreacted 
albumin. However, at the 47th charge state, for example, the product is separated from 
unreacted HSA by approximately 4 Da on the mlz scale. An expansion of several charge 
state peaks shows this fine detail (inset, Figure 5.12), The 46th and 4th charge states of 
component A (umeacted HSA) are shown to almost overlap the 4th and 48th charge states 
of component B (conjugate product, 63). 
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Figure 5.12: The EST-mass spectrum of the HSA-norhomohalichondrin B conjugate (63). The inset shows 
an expansion of the 46th and 47th charge states of component A (unreacted HSA), and the 47th and 48th 
charge states of component B (conjugate product, 63). 
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Figure 5.13: Deconvoluted, neutral-scale mass spectrum of the HSA-norhomohalichondrin B conjugate 
(63). 
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Deconvolution of the mass spectral data with MaxEnt confirms that the broad peak in the 
LC MS trace encompassed both unreacted albumin and the conjugate product (63,68,144 
Da, approximately 33% yield). (Figure 5.13) It is believed that the unreacted albumin is 
nor-mercaptalbumin, with the cysteine-34 blocked by thiol containing compounds. This 
sample was not purified further; LC MS demonstrated only protein was present, and that 
these components could not be chromatographically separated. 
This conjugate (63) was not digested by trypsin because of the limited supply of 
homohalichondrin B, and the requirement to submit the conjugate for biological assay. 
For anti-cancer biological assay results of 63, see Chapter 6. 
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5.5 HSA-doxorubicin Conjugate (64) 
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Figure 5.14: HSA-doxorubicin conjugate. 
HSA (Phanna Dessau, 200 ilg) was dissolved in borate buffer (pH 7.2) and reacted with 
two equivalents of y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35, Section 2.4.2, 
in minimal DMF) for 24 hours. The protein component was then separated from excess 
35 by passing the reaction mixture down a G-25 size-exclusion column with distilled 
water. The pink: fraction that eluted at the void volume was collected and analysed by LC 
MS. 
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Figure 5.15: Expansion of a section of the chromatogram of the preparation of an HSA-doxorubicin 
conjugate (64); Diode Array trace at A 254 mn, Diode Array trace at A 480 nm and Total Ion Current (TIC) 
ES+ trace. 
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This analysis (Figure 5.15) showed one broad peak, with a retention time of 47 to 52 
minutes, in both the diode array at A 254 run and TIC spectra. Analysis at A 480 run also 
presents a peak at this retention time, evidence that 35 had tagged HSA. HSA is not 
visible at this wavelength normally. Closer examination of this peak at A 480 run 
demonstrated that the conjugate product was concentrated in the latter half of the total 
protein peak. 
Unlike with the HSA-norhomohalichondrin B conjugate (64), the ESI-mass spectrum of 
the protein fraction of the doxorubicin conjugation quite clearly showed two series of 
charge state peaks. These two series of peaks have been highlighted in Figure 5.16. 
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Figure 5.16: The ESI-mass spectrum of the HSA-doxorubicin conjugate (64). A section of charge states is 
highlighted, series 1: circles, and series 2: triangles. 
Analysis of the mass spectral data showed that the broad peak encompassed both 
unreacted albumin and the conjugate product (64) (67,531 Da, approximately 25% yield). 
(Figure 5.17) Disappointingly, however, the peak also encompassed a degradation 
product (67,115 Da). This product represented the loss of the anthracycline portion (56) 
of doxorubicin from the conjugate (as discussed in Chapter 4). A small sample of this 
protein mixture was left at room temperature in distilled water for 48 hours. Within this 
period the conjugate had completely degraded to the product mentioned above. 
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Figure 5.17: Deconvoluted, neutral-scale mass spectrum o/the HSA-doxorubicin conjugate (64) 
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Due to the problems of degradation, conjugate 64 was kept dry, and in the dark, until 
further analysis and biological assays could be completed. No further purification steps 
were taken, for unlike the CV-N conjugate (55), this HSA conjugate could not be 
separated from umeacted protein. This minimised handling, and would hopefully extend 
the half-life of the protein conjugate. 
A tryptic digest was performed on the sample containing 64 to confirm that y-
maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35) had indeed tagged HSA, and that 
derivatisation had occurred at cysteine-34. The enzymatic digest was performed in a 
similar fashion to the previous digests, but in this case analysis took place after just 12 
hours of reaction time. It was hoped, optimistically, that a fraction of the doxorubicin in 
the sample remained intact, and that peptide fragments could be found bound to 35. 
Figure 5.18 shows the analysis of the digest by LC MS using the standard protein LC MS 
gradient. To simplify the analysis of the tryptic digest of 64, only those peaks 
representing fragments that were visible at A., 480 run (and hence likely to be derivatised 
by 35) were processed. 
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Figure 5.18: Tlyptic digest o/the HSA-doxorubicin conjugate (64); Diode An'ay trace at It 480 nm and 
Total Ion Current (TIC) ES+ trace. 
Table 5.2 shows the data collected from this selection of peaks. In each case the fragment 
masses identified at each retention time (experimental MW) were converted to a 
calculated MW without 35 (Dox) attached. A further 18 mass units were subtracted from 
these fragments to generate a second series of possible fragments, for the reasons 
discussed in Section 5.3. The two generated series of calculated molecular weights were 
compared to the predicted digest fragments?OO Of the possible digest fragments, only 
those containing cysteine-34 were searched for mass matches. As before, this does not 
discount derivatisation at another site in the protein. 
A match was made if the calculated MW was within ±O.2% of the predicted MW. There 
are three possible peptide matches, which contain the cysteine-34 residue, for the 
fragments seen. 
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Tiffie.(mills) '. MW(I)a) ···With6ul:06x WithoutlliO •... . CleavageSitt!s.an~.Fraglri.WtsY 
39.42 2917.6 1819.1 Da, peptide from 28 to 42. (F)A .... L(V) 1835.2 1817.2 
3363.1 2280.7 2262.7 
39.93 2508.4 1426.0 1408.0 1428.7 Da, peptide from 25 to 36. (L)I .... F(E) 
2542.5 1460.1 1442.1 
3893.5 2811.1 2793.1 
40.56 4047.7 2965.3 2947.3 
44.64 3543.6 2461.2 2443.2 
46.26 6622.0 5539.6 5521.6 
6992.0 5909.6 5891.6 
47.76 2433.2 1350.8 1332.8 
2559.2 1476.8 1458.8 1456.7 Da, peptide from 31 to 42. (Y)L .... L(V) 
49.11 2403.8 1321.4 1303.4 
49.71 9125.9 8043.5 8025.5 
50.56 9126.0 8043.6 8025.6 
54.12 11389.0 10306.6 10288.6 
54.95 3102.9 2020.5 2002.5 
Table 5.2: Selected ESJ-MS data from LC MS of the tlyptic digest of the HSA-doxorubicin conjugate (64), 
Dox = y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35), MW = molecular weight. 
The biological assay results for 64 are discussed in Chapter 6. 
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5.6 HSA-tyrosinamide Conjugate (65) 
OH 
Figure 5.19: HSA-tyrosinamide Conjugate, 
HSA (200 Ilg, Pharma Dessau) was combined with two equivalents of y-
maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37, Section 2.4.3, in minimal DMF to 
aid solubility) in a borate buffer (PH 7.2). After 24 hours at room temperature, the 
reaction mixture was placed on a G-25 column. This column was eluted with distilled 
water and detection was with a diode array detector set at 206 nm. This wavelength was 
selected as the tyrosinamide construct lacked a distinctive UV absorbance, like that in the 
case of F -150 (46) and doxorubicin (34). The peale that eluted at Vo was collected, and 
analysed by LC MS using the same method that had been utilised for the other HSA 
derivatives. This analysis showed one broad peak, with a retention time of 47 to 53 
minutes, in both the spectrum max diode array and TIC spectra. 
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Figure 5.20: Expanded region of the ES[-mass spectrum of the HSA-tyrosinamide conjugate (65). Three 
series of peaks can be seen, A, Band C. 
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Three series of charge states (A, B and C), very clearly resolved, were visible in the ESI-
mass spectrum. Figure 5.20 provides an expansion of a small region of the ESI -mass 
spectrum to demonstrate this. Deconvolution of the mass spectral data collapses the 
charge state series' to A: 66,480 Da, B: 67,079 Da and C: 66,390 Da (Figure 5.21). 
Unreacted albumin and the conjugate product 65 (67,079 Da) were both present in the 
sample. 
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Figure 5.21: Deconvoluted, neutral-scale mass spectrum of the HSA-tyrosinamide conjugate (65). 
The sample containing 65 was enzymatically digested with trypsin, in a similar manner to 
the previous digests. This would identify if y-maleimidobutyric-Gly-Phe-Leu-Gly-
tyrosinamide (37) had been conjugated to HSA at cysteine-34. The analysis of this digest 
was somewhat more time consuming than the previous tryptic digests. For the F-150 and 
doxorubicin conjugates, distinctive UV absorbances had been relied on to highlight 
significant derivatised fragments. Tyrosinamide (36) lacks this useful property, so each 
peak in the LC MS of the digest had to be analysed. 
Table 5.3 shows the data collected from the LC MS of the tryptic digest of the sample 
containing 37. Fragments smaller than 37 in molecular weight were ignored, as these 
peptides had obviously not been modified. In each case the fragment masses identified at 
each retention time (experimental MW) were converted to a calculated MW without 37 
(Tyro) attached. A further 18 mass units were subtracted from these fragments to generate 
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a second series of possible fragments (see Section 5.3). The two generated series of 
calculated molecular weights were compared to the predicted digest fragments.zoo Of the 
possible digest fragments, only those containing cysteine-34 were searched for mass 
matches. Again, this does not discount derivatisation at another site in the protein. 
Table continued on next page .... 
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1334.8 
1710.1 
1728.1 
1761.4 1743.4 
1746.1 1728.1 
44.4 2353.5 2335.5 
45.3 975.7 957.7 
2669.7 2651.7 
4755.7 4737.7 
45.9 1714.7 1696.7 
4309.7 4291.7 
46.4 1456.0 736.7 718.7 
4368.0 3648.7 3630.7 
47.5 1451.0 731.7 
1603.0 883.7 
~-........ ~-
4352.0 3632.7 
49.5 1683.0 963.7 
3367.0 2647.7 
Table 5.3: ESI-MS dataji-om LCMS oftlyptic digest of the HSA-tyrosinamide conjugate (65), 
Tyro y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37), MW = molecular weight. 
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A match was made if the calculated MW was within ±O.2% of the predicted MW. There 
are two possible peptide matches, which contain the cysteine-34 residue, for the 
fragments seen. It was noted that a peptide fragment of approximately 1428 Da (amino 
acid residues 25-36) was produced in both this digest and in the previous digests of the 
HSA conjugates (Sections 5.3 and 5.5). This was taken as evidence that derivatisation has 
occurred at the same place, at cysteine-34, in eaoh case. 
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5.7 Conclusions 
Among naturally occurring proteins, albumin is a potential carrier of anti-cancer drugs 
because it demonstrates significant uptake by tumour cells and due to its biocompatibility. 
This chapter outlined the synthesis and characterisation of four human serum albumin-
based conjugates. The syntheses exploited the availability of a free thiol moiety at 
cysteine-34 of HSA, and the specific and selective reaction of this thiol with a maleimide 
functional group. The generation of these conjugates took advantage of the maleimido-
tetrapeptide derivatives of homohalichondrin B (32), doxorubicin (35), and tyrosinamide 
(37) synthesised in chapter 2. The fluorescent maleimide, F-150 (46), was also conjugated 
to HSA to establish the feasibility of this preparation method, and to develop analytical 
methodologies for characterising the resultant conjugates. The HSA conjugate syntheses 
were simple and required very little protein manipulation. Much lilce its CV-N 
counterpart, the HSA-doxorubicin degraded under gentle conditions. 
LC MS was essential to the analysis of the conjugates. A long, gentle, LC solvent 
gradient system was critical to achieving good mass spectral results as it served to both 
purify and desalt the protein derivatives. Tryptic digestion of the HSA-based conjugates 
demonstrated that conjugation of the maleimido-tetrapeptide-drug constructs with HSA 
had indeed occurred at cysteine-34 ofHSA. 
Complete reaction of HSA was not seen in the production of the HSA conjugates. This 
was ascribed to the cysteine-34 residue being unavailable for reaction in some cases, as a 
proportion of the sample of HSA has this residue blocked by disulfide bond formation 
with other thiol containing molecules, such as glutathione. The high molecular weight of 
HSA presented difficulties when it came to purifying the conjugate product away from 
unreacted protein. As HSA is biodegradeable, non-immunogenic and non_toxic,119,144 the 
inseparable mixture of unreacted protein and toxin conjugate will not be a problem in the 
development of HSA as a drug carrier. 
Chapter 6 describes the anti-cancer biological assay results for the HSA conjugates. 
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BIOLOGICAL TESTING 
6.1 Introduction 
The goal of this study was to establish the feasibility of the use of protein-toxin 
conjugates to target, deliver, and release cytotoxins for the elimination ofHN-infected or 
cancerous cells. Although the synthesis of various CV-N- and HSA-toxin conjugates was 
successful, the determining factor in deciding their therapeutic potential can only be 
evaluated with extensive biological testing. This chapter explores preliminary biological 
analyses of several of the conjugates. 
The tetrapeptide, Gly-Phe-Leu-Gly, was designed as a substrate for the cathepsin 
enzymes (see Section 2.2).128,146,147 The linker was tailored to allow drug/toxin liberation 
at an appropriate rate intracellularly. The following work sought to provide proof that the 
toxin could be released from the conjugate, an essential principle ofthe conjugate design. 
CV-N (28) is a novel anti-HN protein due to its ability to bind with high affinity to the 
viral envelope glycoprotein gp120. To utilise CV-N (28) as a gpI20-targeting, and 
therefore HN-targeting, moiety, the covalent linkage of cytotoxic agents to CV-N (28) 
must not diminish the protein's gp 120 binding affinity. An Enzyme Linked 
Immunosorbent Assay (ELISA) was employed to assess the ability of the conjugates to 
bind gp120. 
The ultimate test, for both the CV -N conjugates and the HSA conjugates, is to determine 
if the cell-killing ability of the toxin moiety can be selectively applied to diseased cells. 
Preliminary in vitro cytotoxicity assays have been completed and are presented in this 
chapter. 
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6.2 Biological Testing of CV -N Conjugates 
6.2.1 Cathepsin B Digest 
Attachment of a drug to a macromolecule restricts its mode of uptake by cells to the 
process of pinocytosis and thus provides an opportunity to direct an otherwise freely 
permeating drug specifically to the cell type where the cytotoxic action is required. 149,150 
Such a delivery system can only be effective if the drug is firmly bound to its carrier 
during transport to cells and if controlled release of drug occurs after its arrival within the 
cell. To fulfil this role, a tetrapeptide, Gly-Phe-Leu-Gly, was selected to link the proteins 
to the toxins. This oligopeptide had previously been shown to be susceptible to specific 
hydrolysis by the intralysosomal cathepsin enzymes (as discussed in section 2.2).149,150 
In vitro release ofnorhomohalichondrin B amine (31) and degradation of the tetrapeptide, 
Gly-Phe-Leu-Gly, from the CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B 
conjugate (54), by cathepsin B has been demonstrated using a method adapted from that 
developed by Pechar et al. 146,147 CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin 
B (54, 1 Jlg) was incubated with cathepsin B (3 Jlg, 4 x 10-7 M) in a phosphate buffer 
(0.05 M KH2P04, 0.001 M EDTA, 0.005 M glutathione, pH 6.0) at 3rC. 
The degradation of the conjugate (54) was monitored by reverse phase (C18) LC MS after 
5, 24 and 48 hours of incubation with cathepsin B. A solvent gradient (200 JlL/min) 
comprising the following steps was used: a slow linear gradient from 0-60% CH3CNIH20 
(5% acetic acid) over 60 minutes; a linear gradient to 100% CH3CN over two minutes; 
isocratic at 100% CH3CN for five minutes; a return to 100% H20 over five minutes; and 
finally an isocratic hold on 100% H20 for 2 minutes. The progress of the digestion can be 
seen in the LC MS traces pictured in Figure 6.1. Conjugate 54 elutes at 42 minutes. 
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Figure 6.1: Overlay a/the total ion current traces of the Cathepsin B digest ofCV-N K3R, K48R, K74R, 
K84R-norhomohalichonJrin B Conjugate (54) . 
After five hours, a digestion product could be seen eluting at 37 minutes. This had a mass 
of 12,871 Da and is equivalent to the thioether glycine derivative ofCV-N: K3R, K48R, 
K74R, K84R (66), as illustrated in Figure 6.2. Cleavage of the oligopeptide linker had 
occurred between the glycine and the phenylalanine residues . After 24 hours, further 
digestion of the conjugate could be seen. Significantly, norhomohalichondrin B amine 
(31) with a mass of1 ,092 Da, and a glycine derivative (67) with a mass of 1,149 Da, were 
visible, both eluting at 39 minutes. No intact conjugate could be resolved after 48 hours. 
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Figure 6.2: Degradation products of a cathepsin B digest of the CV-N: K3R, K48R, K74R, K84R-
l1orhomohalichol1dril1 B Conjugate (54). 
These results support the hypothesis of using Gly-Phe-Leu-Gly as a biodegradable linker 
and as a substrate for cathepsin B. This confinns the results of Pechar et al. on their 
development of a conjugate of doxorubicin. 146 These researchers found that during the 
incubation of their conjugate with cathepsin B, a glycine derivative of doxorubicin was 
released together with the free drug. The glycine derivative was further degraded to free 
doxorubicin when tritosomes (mixture of rat-liver lysosomal enzymes) were used instead 
of cathepsin B. 
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6.2.2 Enzyme Linked Immunosorbent Assay 
Low nanomolar concentrations of CV-N (28) irreversibly inactivate isolates of HN-l. 
Furthermore, CV-N (28) prevents in vitro fusion and transmission between cells.95 The 
anti-HN activity of CV-N (28) is mediated, at least in part, through high-affinity 
interactions with the viral envelope protein gp120. Therefore, conjugate development 
must not interfere with the essential, and unique, binding of the protein to gp 120. With 
the attachment of large molecules, such as the toxin constructs prepared in Chapter 2, 
there is the potential to block CV -N binding to gp 120. This was presumed to be the case 
for the CV-N-PE38 conjugate previously constructed and tested by Mori et al. 95 where 
the gp 120 binding affinity of the conjugate was significantly reduced. The same method 
of testing, and using, an ELISA system developed by the LDDRD, was used to determine 
the relative affinity of the conjugates prepared in this project for gp 120. This assay was 
critical in determining if the modification of the lysine B-amino groups had resulted in 
loss of binding affinity. 
The Enzyme Linked Immunosorbent Assay (ELISA) is a sensitive and precise method 
used to detect the presence of antigens or antibodies of interest in a wide variety of 
biological samples.225 Many variations in the methodology of the ELISA have evolved 
since its development in the 1960s.225 An ELISA has been applied for the detection and 
quantification of the binding ofCV-N to gp120. 
This assay is based on the Sandwich ELISA design with indirect detection of binding.225 
A schematic of this methodology is shown in Figure 6.3. The assay is performed in a 96-
well plate. Gp120 is initially bound to the plate itself. After two hours of incubation, the 
plate is thoroughly washed. Any sites unfilled by gp 120 are capped by incubating 
overnight with bovine serum albumin (BSA). Once again, the plate is thoroughly washed. 
CV -Nand its derivatives are introduced and incubated for one hour so that they can 
selectively bind to the gp120. Those molecules not bound are washed away and CV-N 
antibodies (Rabbit-anti-CV-N Ab) are added to the plate. These are in tum bound by a 
second antibody (anti-Rabbit-IgG-Ab-AP) which has a terminal alkaline phosphatase 
(AP) enzyme. Finally the substrate buffer (10% diethanolamine, 10 mM MgCh, 4 mglmL 
p-nitrophenylphosphate (pNPP), pH 9.8) is loaded on the plate. This buffer develops a 
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yellow colour on reaction with the AP enzyme. The plate can be read at 405 run in a plate 
reader. The intensity of the colour is prop0l1ionai to the degree of binding. Hence, any 
change in the binding affinity of the CV -N derivatives to gp 120 results in fewer 
antibodies binding at each step, and therefore was a less intense yellow colour. 
plate 
CV- / 
conjugate 
gp 120 
anti-Rabbit IgG-Ab-AP 
y 
rabbit-anti-CV- Ab 
~ 
substrate buffer 
containing 
colouring reagent 
Figure 6.3: Schematic of the ELISA methodology for testing the binding ofCV-N. 
Figure 6.4 shows the typical layout of a 96-well plate. The outer wells of the plate are not 
loaded with gp 120. This provides a background reading for the assay and ensures that the 
assay is working correctly. Rows B, C and D are used as a standard reference for each 
plate, and are loaded with native CV-N, or with a mutant CV-N. In tum, the CV-N 
conjugates are placed in rows E, F and G. The concentration of CV -N placed in each cell 
increases from column two to 11 in a logarithmic fashion. Each concentration is measured 
in triplicate to ensure uniformity of readings. The large range of concentrations results in 
a precise and quantitative measurement of the binding affinity of the CV-N to gp120. 
This data can be graphically represented as a sigmoidal curve. A comparison of the data 
for the standard reference versus the CV -N conjugates at the point where half the gp 120 
are bound gives an indication of their relative binding affinities. 
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Figure 6.4: Layout oJthe 96-we// plate in the CV-N ELISA assay. 
The CV -N: K3R, K48R, K74R, K84R-norhomohalichondrin B conjugate (54) and the 
parent mutant protein, CV-N: K3R, K48R, K74R, K84R (52), were both assayed using 
the process described above. Figure 6.5 shows a graphical representation of the results 
obtained. 
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Figure 6.5: Plot oj the ELISA assay results Jor the mutant protein (52), and norhomohalichondrin B 
conjugate (54). 
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1.42 ng of 54 was required for half the gp120 to be bound. In comparison, 0.71 ng of 52 
was required. This shows the unmodified protein (52) has a two-fold better binding 
affmity for gp120 over the conjugate (54). This may be due to steric hindrance of the CV-
N-gp120 interactions and/or to changes in the tertiary structure of the CV-N moiety. This 
small reduction in binding affinity is not thought to be particularly significant, 
however. 205 
The mutant protein (52) and wild-type CV-N (28) had been shown previously to have 
comparable binding affinities for gp120 in a similar ELISA assay procedure.205 
6.2.3 Cytotoxicity Assays 
The anti-HN assay is a relatively simple method to determine the ability of a drug to 
protect cells against the cytopathic effects of HIV. T -lymphocyte-derived CEM-SS cells 
are added to 96-well microtitre plates along with cell-free HIV (RF strain) and the test 
agent at Y2-log dilutions over a multi-dose range. Six days after infection, a tetrazolium 
reagent, XTT, is added to the wells. In the presence of viable cells, XTT is metabolized 
to an orange coloured formazan, such that the quantity of viable cells, and thus the 
protective ability of the test agent, is proportional to the depth of the colour. Uninfected 
cells are also treated with the drug in order to determine the cytotoxicity of the drug, if 
any, to the CEM-SS cells. 
The CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B conjugate (54) and free 
norhomohalichondrin B amine (31) were submitted for the above HIV cytotoxicity assay 
at the NCI-Frederick. A graphical illustration of the cytotoxicity results is presented in 
Figure 6.6. The IC50 values obtained from this data were expressed in units of pg/mL. 
These values were converted to pmollmL so that a more accurate comparison between the 
toxicities of the conjugate and the free drug could take place (Table 6.1). 
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Figure 6.6: XTT assay for the detection of cell killing of HI V-infected cells (CEM SSu/.) and uninfected 
(CEM SS) cells (expressed in pg/mL), by norhomohalichrondrin B amine (3/, halimamine) and C V-N: KJR, 
K48R, K74R, K84R-norhomohalichondrin B Conjugate (54). 
CEMSS CEMSSRF 
Compound ICso a (pg/mL) ICsoa (pmollmL) ICso a (pg/mL) ICso a (pmollmL) 
haliamine (31) 7.2 0.0066 71.1 0.0651 
malei-tet-hali (32) 13.5 0.0083 116.1 0.0712 
Conjugate (54) 2.4 0.0002 43.2 0.0036 
a Inhibition Concentration 
Table 6./: C:vtotoxicity of norhomohalichondrin B amine (31, haliamine), y-maleimido-Gly-Phe-Leu-Gly-
norhomohalichondrin B (32, malei-tet-hali) and CV-N: KJR, K48R, K74R, K84R-norhomohalichondrin B 
Conjugate (54, conjugate) against H/V infected (CEM SS/u) and uninfected (CEM SS) cells. IC,I) expressed 
in both pg/mL and pmol/mL. 
Surprisingly, the conjugate shows quite the opposite cytotoxicity results to that predicted 
from the previous studies by Mori el at. 95 The conjugate does not show selective toxicity 
for the HIV -infected cells. It is interesting to note that both the free drug (31) and the 
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conjugate (54) demonstrate higher toxicity to the non~infected cell line (CEM~SS) over 
the HN~infected cells (CEM-SSRF). This may be due to the HN infection interfering the 
cellular mechanisms of uptake in this cell-line. The conjugate (54) was significantly more 
toxic to both cell lines (33 fold for uninfected cells and 18 fold for infected cells) over the 
free drug. It is not known why this is the case, and further investigations are required, 
however there are a number of hypotheses that may offer an explanation. 
Norhomohalichondrin B amine (31) has limited aqueous solubility. Attachment of the 
toxin to the hydrophilic protein may have resulted in improved solubility of the conjugate 
over the free halichondrin. Further, conjugation to the protein may allow for improved 
membrane permeability and uptake into the cell. Active transport of the CV-N carrying 
norhomohalichondrin B (in both infected and uninfected cells) may also be occurring. 
Mori et al. 95 evaluated the CV-N-PE38 conjugate against HN infected H9/HlV-lIIIb cells 
and uninfected H9 cells using the XTT -tetrazolium cell viability assay. The human T-cell 
line H9 chronically infected with HN -1 IIIb (H9/HlV -1 IIIb) is lmown to express viral 
envelope glycoprotein gp 120 on the cell surface.95 No steps have been taken to quantify 
the amount of gp120 being expressed on the surface of the HlV infected CEM SS cell-
line at this stage. The CV -N conjugates prepared in this thesis will be also be tested 
against H9/HN -1 IIIb cells to establish whether selective toxicity is cell-line dependent. 
Further developments on the assay, the cell line, and quantitation of gp120 on the cells in 
question, are in progress at the NCt 
Once assay procedures are established, the doubly-derivatised CV-N 
norhomohalichondrin B conjugate (61) will also be tested. This will evaluate the effect of 
toxin loading on the pharmacokinetics of the conjugates. 
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6.3 Biological Testing of HSA Conjugates 
6.3.1 Cytotoxicity Assays 
The HSA-based conjugates, and the various individual components of the constructs, 
were screened in the Marine Chemistry Group's in-house anti-tumour assay. This in vitro 
'anti-tumour' assay uses the P388 cell line (murine leukaemia cells). A two-fold dilution 
series of the sample of interest is incubated with P388 cells. Sample, media, cel] and 
solvent controls are also run. After 72 hours of incubation, MTT, a yellow tetrazolium 
salt is added. After a further two hours the concentration ofthe sample required to reduce 
the number of viable cells by fifty percent relative to a control is calculated. The 
mitochondria of viable leukaemia cells reduce the yellow MTT dye to a purple formazan 
derivative?26 By measuring the light absorbance at 540 nm in each well, a direct 
quantification of formazan formation, and therefore the number of viab Ie cells, is able to 
be determined. The absorbance is expressed as a percentage cell viability relative to the 
control, and is plotted against sample concentration in the well to generate a sample 
concentration vs cell viability curve. The concentration producing a fifty percent 
reduction in the number of viable cells gives the ICso result, which is usually expressed in 
units ofnglmL. 
The cytotoxicity results of the HSA-norhomohalichondrin B conjugate (63) and the HSA-
doxorubicin conjugate (64) are presented in Table 6.2. The maleirnido-tetrapeptide (30), 
norhomohalichondrin B amine (31), doxorubicin (34), and the maleimidobutyric-
tetrapeptide-toxin constructs (32 and 35) were also tested (Table 6.2). The ICso values 
obtained were expressed in units of ngimL. These values were converted to nmollmL so 
that a more accurate comparison could take place. Several assumptions were made in the 
analysis of this data. From mass spectrometric analysis of the protein conjugates, it 
appeared that there was approximately one-third conjugate to two-thirds umeacted HSA 
in each of the samples. This factor of three was taken into account in the assay data. 
Instability issues had been experienced with doxorubicin and the doxorubicin conjugates 
(see Section 4.3.3). The samples tested here were stored dry, in the dark, and in the 
freezer until just before analysis. The assumption was made that doxorubicin had not 
degraded at this point. 
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P388 
Compound ICso
B (ng/mL) ICso B (nmollmL) 
malei-tet (30) NA NA 
haliamine (31) 9.5 0.009 
malei-tet-hali (32) 16.3 0.01 
HSA-hali (63) 183 0.0027 
doxorubicin (34) 707.3 1.3 
malei-tet-dox (35) 5315 4.9 
HSA-dox (64) 4429 0.067 
a Inhibition Concentration 
NA = not active at highest concentration 
Table 6.2: Cytotoxicity of r-maleimidobutyric-Gly-Phe-Leu-Gly-OH (30, malei-tet), norhomohalichondrin 
B amine (31, haliamine), r-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32, malei-tet-
halt), HSA-norhomohalichondrin B conjugate (63, HSA-hali), doxorubicin (34). r-maleimidobutyric-Gly-
Phe-Leu-Gly-doxorubicin (35, malei-tet-dox) and HSA-doxorubicin conjugate (64, HSA-dox) against the 
P388 murine leukaemia cell line. 
The maleimido-tetrapeptide (30) showed no toxicity at the highest concentration tested. 
As expected, both the free toxins demonstrated good toxicity, with norhomohalichondrin 
B amine (31) proving to be especially potent. Derivatisation of norhomohalichondrin B 
amine (31) with the maleimido-tetrapeptide (30) to form y-maleimidobutyric-Gly-Phe-
Leu-Gly-norhomohalichondrin B (32) did not result in any significant loss of toxicity. y-
Maleimido-Gly-Pbe-Leu-Gly-doxorubicin (35) demonstrated a 3.8 fold loss of cytoxicity 
over free doxorubicin (34). 
What is especially interesting about these results is that both conjugates show an 
increased cytotoxicity, in the P388 anti-tumour assay, over the free toxin. Factors such as 
increased membrane permeability, active transport of the HSA conjugates into the cells, 
and increased solubility of the conjugate compared to the free toxin, may also come into 
play here. Further biological testing is required to test these hypotheses. 
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6.4 Conclusions 
In vitro release ofnorhomohalichondrin B amine (31) and degradation of the tetrapeptide, 
Gly-Phe-Leu-Gly, from the CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B 
conjugate (54) by cathepsin B has been demonstrated. These results support the 
hypothesis of using Gly-Phe-Leu-Gly as a biodegradable linker that would allow 
controlled release of a drug within diseased cells. 
The ability of the conjugate, CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B 
(54), to bind gp120 was assessed in an ELISA assay. Both the conjugate (54) and the 
mutant protein (52) showed comparable binding affinities to gp120. These results 
demonstrate the feasibility for further pursuit of the concept of CV -N-based conjugates, 
through modification of the lysine e-amino groups with low-molecular-weight 
compounds. 
The concept behind drug targeting, and controlled drug release formulations, is to design 
a conjugate which will reduce the peak plasma concentration of the drug and in theory 
prolong exposure to an effective drug concentration, leading to both a reduction in 
toxicity and also increased efficacy.121 It was encouraging to see that the HSA and CV -N-
based conjugates demonstrated potent cytotoxicity. However, disappointingly, these 
conjugates exhibited an increased cytotoxicity over the free toxins, and no selectivity has 
been demonstrated at this point. This increased cytotoxicity may be beneficial provided 
selectivity for diseased cells can be achieved. Selectivity may not be demonstratable in a 
cell-based assay and a move to in vivo studies may be appropriate. Further investigations 
to clarify the mechanisms behind these results, and the implementation of alternative 
assay systems, are underway. 
175 
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CONCLUSIONS 
The aim of this project was to create protein-based drug delivery systems delivery 
systems that would package, target, and deliver cytotoxins to diseased cells. Primarily, 
this project explored the use of the protein CV-N (28) to actively target and deliver 
cytotoxic natural products to HIV-infected cells. This project also investigated the use of 
human serum albumin as a protein carrier to passively target and deliver cytotoxic natural 
products to cancerous cells. 
Chapter 2 outlined a strategic approach to the development of these therapeutics. Of 
primary importance was the judicious selection of the protein-toxin linker, a tetrapeptide 
Gly-Phe-Leu-Gly, which would allow for the site and rate of drug liberation in vivo to be 
controlled by enzymatic means. Maleimido-activated tetrapeptide toxin constructs were 
prepared in readiness for selective reaction with proteins carrying thiol functionalities. 
Native CV-N conjugates were prepared by thiolation of the lysine amino groups, and the 
subsequent reaction with maleimido-activated compounds. A distribution of products, 
with reaction across all lysine residues, introduced the issue of heterogeneity and the 
difficulties this presents in defining a therapeutic. A singly substituted, but randomly 
distributed, tyrosinamide conjugate of CV-N was prepared. This conjugate can be radio-
labelled and could then be used as a tracer in cellular and body distribution studies. 
Two recombinantly produced mutant CV-N proteins, CV-N: K3R, K48R, K74R (51) and 
CV-N: K3R, K48R, K74R, K84R (52), allowed for the preparation of two selectively 
modified double- and single-norhomohalichondrin B conjugates ofCV-N. This section of 
work addressed the issue of preparing homogeneous bioconjugates that could be utilised 
in a therapeutic application. 
Digestion of the CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B conjugate 
(54) with the enzyme cathepsin B, and subsequent release of norhomohalichondrin B 
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amme (31), provided proof-of-principle that the toxin would be released from the 
conjugate once it was internalised within affected cells. 
Homohalichondrin B, doxorubicin, and tyro sin amide conjugates of HSA were prepared. 
The syntheses exploited the availability of a free thiol moiety at cysteine-34 of HSA, and 
the specific and selective reaction of this thiol with the maleimido-activated tetrapeptide 
derivatives of the toxins. Although unreacted protein and the conjugate products could 
not be separated, the biodegradable and non-immunogenic nature of HSA suggests that 
this will not present a significant problem. 
No matter what modifications are made to CV-N, the critical issue is whether those 
alterations interfere with the unique binding affinity of the protein to gp120. The results 
for the CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B conjugate (54), in the 
gp120-based ELISA assay, clearly indicate that no discernable inhibition of gp120 
binding was taking place. However, the ultimate goal is to show targeted delivery of the 
conjugate to HIV -infected cells. Although the conjugate demonstrated potent toxicity, 
there is doubt over whether it is demonstrating selective toxicity. This could be a factor of 
the whole cell-based assay system, and a move to animal models may be appropriate. 
However, homohalichondrin B (22) may simply be too toxic. With ehemical attachment 
to the construct at a point distant from the biologically active portion of the moleeule, 
homohalichondrin B (22) is possibly not acting as a prodrug. The entire construct may be 
a toxic entity, even before drug release. 
Similarly, the HSA-based eonjugates exhibited excellent toxicity in the P388 murine 
leukaemia biological screen. Whether this is targeted toxicity however, remains a point of 
further investigation. 
The three basic components of a protein-drug conjugate (protein, linker and toxin) must 
be optimally matched to maximise therapeutic potential. Potency of the agent to bc 
delivered (and therefore the clinical dose) is one factor that must be taken into 
consideration. Realising that a relatively small proportion of the dose administered may 
reach the infected site, high doses (500 mglkg) of polymer carriers of methotrexate (of 
mild potency) are routinely administered.121 This concept seems fraught with possible 
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problems, with issues such as additional toxicological burden, immunogenic responses, 
and problems with metabolism/excretion from the body. For this reason, in this initial 
study, we chose to combine the particularly potent toxins, homohalichondrin B (22) and 
doxorubicin (34), with CV-N (28) and HSA. Homohalichondrin B (22) was available in-
house and showed potent in vitro and in vivo cytotoxicity. Doxorubicin (34) was available 
commercially. By operating on a proof-of-concept approach, these compounds have 
provided an excellent starting point for the preparation of the anti-HIV and anti-cancer 
therapeutics discussed in this thesis. The CV-N- and HSA-norhomohalichondrin B 
conjugates that were prepared have yet to be fully evaluated in vitro and in vivo, but there 
is the distinct possibility that their extreme potency and chemical sensitivity might limit 
their further development. Somewhat suprisingly, doxorubicin (34) too, proved to be a 
difficult drug due to instability problems. 
From the experience gained in this project I would conclude that for these innovative CV-
N (28) and HSA therapeutics to be viable, a more suitable toxin needs to be incorporated 
into the construct. The toxin should be more suitable in terms of: 
1) Reduced toxicity. 
2) Behaving as a prodrug until the conjugate was internalised and the "active" drug 
was released within the affected cell. 
3) Chemical stability. The toxin should be amenable to easy synthetic modification 
and incorporation into the conjugate, and be stable within systemic circulation. 
4) Supply, with a requirement to be readily available on a commercial scale. 
Of course it will be very difficult to identify a toxin, be it natural or synthetic, which is 
ideal in every respect, but a literature search for an alternative revealed large numbers of 
possible candidates. Five interesting cytotoxic compounds that show potential for further 
development have been selected for discussion below. 
Although homohalichondrin B (22) might never progress further as a potential drug, in 
part due to supply problems, and in part due to toxicity problems, the synthesis of 
structurally simplified synthetic halichondrin analogues may result in a commercially 
viable exploitation of the extraordinary cytotoxicity of the polyether macrolide. The 
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synthetic ketone analogue (27)88 retains the exceptional in vitro and in vivo activity of the 
parent halichondrins, but with substantially lower toxicity in in vivo trials. The amine 
functionality could be readily attached to the maleimido-tetrapeptide construct (40, 
prepared in Section 2.4) via an amide bond. However, with the knowledge that the 
cytotoxic activity resides in the macrocyc1e, the problem of harnessing the cytotoxicity 
might remain a problem under a prodrug rationale. 
H3cq 
OH ~ 
H2N~\\\\\ 
ER-086526 (27) 
Figure 7.1: Ketone analogue ofhalichondrin B, ER-086526. 
Maintaining a New Zealand focus in conjugate 'development, pateamine A (66), a novel 
sulfur-containing heteroaromatic macrolide with potent in vitro cytotoxic activity, is 
another possibility. This compound was isolated originally from the marine sponge, 
Mycale sp., off the South-West coast of the South Island of New Zealand?27 Several 
groups have published synthetic routes towards pateamine A (66) and a number of 
simplified derivatives.228,229 Interestingly, C3-amino acylated derivatives display a 
reduced activity from the parent. This suggests that pateamine A (66) may well be 
efficacious as a prodrug in the acylation strategy employed in this project. 
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pateamine A (66) 
Figure 7.2: The thiazole-containing macrolide, pateamine A. 
At the other end of the spectrum, in tenns of structural complexity, 5-fluorouracil (5-
fluoro-pyrimidine-2,4-dione) (67) is an antimetabolite with a broad spectrum of activity 
against solid tumours. 
Figure 7.3: 5-Fluomuracil. 
o HN:yF 
oAN 
H 
5-fluorouracil (67) 
Various conjugates of 5-fluorouracil (67) and poly(ethylene glycol),23o dextran230 or N-(2-
hydroxypropy1)methacrylamide-based copolymers,231 have been reported. In these 
conjugates, 5-fluorouracil (67) is linked to the polymer carriers at the a-position of a C-
tenninal glycine residue of peptide spacers of different amino acid sequences. These 
conjugates are reported to act as prodrugs and are able to cause a site-specific release of 
free 5-fluorouracil (67) under the action of enzymes occurring in the vicinity of, or inside 
tumour cells. The release mechanism of 5-fluorouracil (67) from the glycine a-carbon 
stems from the inherent instability of a-substituted glycines.231 5-Fluorouracil might be 
attached to the tetrapeptide construct (40, prepared in Section 2.4) in a similar manner. 
Squalamine (68) was the first aminosterol isolated from tissues of dogfish shark Squalus 
acanthias.232 Squalamine (68) inhibits angiogenesis and tumour growth in several animal 
models and is currently in Phase II clinical trial for treatment of non-small cell lung 
cancer.
233 
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Several syntheses of squalamine (68) and simplified squalamine analogues have been 
published. The stereoselective syntheses of squalamine dessulfate analogues that use 7a-
aminocholesterol as an intermediate were reported very recently.233 Compound 69, for 
example, exhibits comparable cytotoxicity to the parent compound. The simplicity of the 
synthetic strategy, and the simplicity of the molecule itself, lends squalamine (68), and 
69, to being very attractive options for incorporation into constructs, like those prepared 
in this proj ect. 
H2N~N~N 
H H 
squalamine (68) 
HO "'IN~N~NH2 
H H 
7 a-N-[3N-( 4-aminobutyl)aminopropyIJaminocholesterol (69) 
Figure 7.4: Structures of squalamine (68) and a dessulfate analogue, 69, 
Targeted delivery of drugs is one of the most actively pursued goals in anti-HIV and anti-
cancer chemotherapy. It is evident from the preliminary studies presented in this thesis 
that both CV -N (28) and HSA show enormous potential as macromolecular carriers of 
toxins, for the targeted treatment ofHIV-infected and cancerous cells, respectively. Their 
further success will hinge upon the selection of a suitable toxin, and a focused effort to 
understand the details of the biological fate of the conjugates. 
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EXPERIMENTAL 
8.1 General Methods 
8.1.1 Nuclear Magnetic Resonance 
NNIR spectra were recorded at 23°C on a Varian Unity INOVA-500 spectrometer, 
operating at 500 MHz and 125 MHz for IH and 13C, respectively. Other NMR 
experiments described in this thesis viz COSY, and the reverse detected HSQC and 
CIGAR experiments were recorded on the INOV A 500 spectrometer, at 500 MHz. The 
spectrometer was fitted with a pulsed field MLD driver with a 5 mm Indirect Detection 
Probe. 
Chemical shifts in this thesis are described in parts per million (ppm), on the 0 scale, and 
were referenced to the appropriate solvent peaks: Chloroform (with 0.1 % pyridine for 
halichondrin-based compounds); CDCh (d1) referenced to CHCb at OH 7.26 ppm eH) 
13 . 
and CHCh at Oc 77.0 ppm ( C); Methanol; CD30D (d4) referenced to CHDzOD at OH 
3.31 ppm eH) and CD30D at Oc 49.3 ppm (13C); Dimethylsulphoxide; (CD3)zSO (d6) 
referenced to (CH3)2S0 at OH 2.60 ppm eH) and (CH3)zSO at Oc 39.6 ppm (13C). 
Tetramethylsilane (TMS) was used as an internal reference. 
IH NMR spectra were recorded using an acquisition time (AT) of 1.892 s; BC NMR 
spectra were recorded using an AT of 1.3 s. COSY experiments were recorded using an 
AT of typically 0.215 s and a relaxation delay (D 1) of 1.0 s. HSQC experiments were run 
with an AT of typically 0.14 s, a Dl of 1.0 sand IJCH of 140 Hz. CIGAR experiments 
were recorded with an AT of typically 0.250 s, Dl of 1.0 sand nJCH of 8.3 Hz. 
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8.1.2 Mass Spectrometry 
Electrospray ionisation mass spectra (ESI MS) were recorded from a Micromass LCT 
TOF mass spectrometer, with a probe voltage of 3,200 V at 150DC, a source temperature 
of 80°C, nebuliser gas flow of 160 Llhr and desolvation gas flow of 520 Llhr. Direct 
injection used 10 I!L of a 10 l!g/mL solution. The carrier solvent was 50% CH3CN/lhO at 
a flow rate of 20 I!Llmin. The cone voltage was typically 25 V unless otherwise stated. 
This system was controlled by MASSLYNX (Version 4.0) software. 
The majority of LC MS samples were analysed with a Waters 2790 HPLC system and a 
Waters 996 photo diode array (PDA) detector coupled in parallel to a Micromass LCT 
mass spectrometer equipped with an electro spray ionisation (ESI) probe. Samples were 
analysed at the same operating conditions as above. Protein samples were analysed with 
a cone voltage of typically 45 V unless otherwise stated. Non-protein samples were 
analysed with a cone voltage of 25 V unless otherwise stated. This system was controlled 
by MASSL YNX (Version 4.0) software. LC MS analysis used one of the following two 
columns (as stated): Agilent, Zorbax 300SB-C3, 51!, 2.1 x 150 mm; or Agilent, Zorbax 
SB-CI8, 51!, 2.1 x 250 mm. A flow rate of 200 I!Llmin and varying solvent profiles of 
acetonitrile (Scharlau, Acetonitrile, Multisolvent®, HPLC grade) with water (purified 
using a MilliQ deionising system), or water with 0.5% formic acid was ultilised. A 9:1 
solvent split was employed to deliver 20 I!Llmin solvent to the mass spectrometer and 
180 I!Llmin solvent to the diode array detector. 
A standard HPLC solvent gradient was developed to analyse protein samples on the 
Zorbax 300SB-C3 column. This was known as the standard protein LC MS gradient. 
The gradient comprised of a 105 minute run with a flow rate of 200 I!Llmin, and 
consisted of the following solvent gradient timetable: a slow gradient from 0% - 60% 
CH3CN/H20 (0.5% formic acid) over 80 minutes, followed by ramp in concentration to 
100% CH3CN over five minutes, an isocratic hold on 100% CH3CN for five minutes and 
then a restoration to 0% CH3CN over five minutes. The method was finished with an 
isocratic hold on 0% CH3CN over five minutes. 
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LC MS analysis also took place while a guest at the MTDDP, NCI, Frederick, Maryland, 
USA (as stated in text). This analysis used an Agilent 1100 series LC MS with an 
electrospray interface. This system was set with a capillary voltage of 4,000 V, a gas 
temperature of 350°C, and a drying gas flow of 10 L/min. A fragmentor of 50 V was 
typically used unless otherwise stated. One of two columns was utilised (as stated), a 
Zorbax 300SB-C3 (511,2.1 x 150 mm), or a Zorbax SB-C18 (5~t, 2.1 x 150 mm). A flow 
rate of 200 ilL/min and varying solvent profiles of acetonitrile (Scharlau, Acetonitrile, 
Multisolvent®, HPLC grade) with water (purified using a MilliQ deionising system), or 
water with acetic acid (varying concentrations, stated) was ultilised. 
8.1.3 High Perfonnance Liquid Chromatography 
Semi-preparative reverse phase HPLC work described in this thesis was perfonned on 
one of two machines (stated). A Shimadzu LC-4A instrument equipped with a Shimadzu 
UV Spectrotometric Detector SPD-2AS and Hewlett Packard 3390A integrator was used 
at the Chemistry Department, University of Canterbury, Christchurch, New Zealand. A 
Phenomenex, Luna column (C18, 100A, 511, 10 x 250 mm) with a flow rate of 5 mL/min 
and varying solvent profiles consisting of acetonitrile (Scharlau, Acetonitrile, 
Multisolvent®, HPLC grade) with water (purified using a MilliQ deionising system), or 
water with 0.5% fonnie acid was ultilised. Solvents were degassed using a flow of 
helium. 
HPLC purification of CV-N mutant proteins took place while a guest at the MTDP, NCI-
Frederick, Frederick, MD, USA and used a BioCAD® Sprint Chromatography System 
(Applied Biosystems, Inc.) with a reversed phase PRP-3 column (Hamilton, 7 x 305 mm). 
A flow rate of 2 mL/min and a solvent gradient consisting of acetonitrile (Scharlau, 
Acetonitrile, Multisolvent®, HPLC grade) (0.1% TFA) with water (purified using a 
MilliQ deionising system) (0.1 % TF A), was used. 
Analytical and small-scale preparative work was perfonned on one of two HPLC systems 
(stated). The first system was a Shimadzu VP. The complete setup involved a Shimadzu 
LC-IOAC VP liquid chromatograph coupled to a SIL-I0A VP auto-injector, aCTO-lOA 
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VP column oven set to 40°C, and a SPD-M10A VP diode array detector. A Shimadzu 
degasser was utilised for the degassing of all solvents used in this machine. This system 
was controlled by Shimadzu CLASS-VP (Version 5.023) software. 
A Dionex HPLC system was also used. (P680 HPLC pump, ASI 100 automated sample 
injector, TCC 100 column oven operating at 40°C, UVD 340U diode array detector and 
an ELSD 800 light scattering mass detector.) A Dionex degasser was utilised for the 
degassing of all solvents used in this machine. This system was controlled by Chromeleon 
(Version 6.50 SP3 Build 980) software. 
A Phenomenex Prodigy reverse phase column (C18, 5f.t, 4.6 x 250 mm) with a flow rate 
of 1 mL/min and variable concentration gradients of acetonitrile (Scharlau, Acetonitrile, 
Multisolvent®, HPLC grade) with water (purified using a MilliQ deionising system), or 
water with 0.05% TFA was ultilised for both analytical HPLC systems. 
A standard HPLC gradient was used to analyse samples on these columns. This was 
known as the standard HPl,C gradient. The gradient consisted of a 40 minute run with 
a flow rate of lml/min, following a solvent gradient comprised of the following steps: 
two minutes at 10% CH3CN/HzO followed by a linear gradient to 75% CH3CN!HzO over 
a period of 12 minutes, an isocratic hold at 75% CH3CN!HzO for ten minutes then a linear 
gradient to 100% CH3CN!HzO over two minutes. 100% CH3CN!HzO was maintained for 
four minutes before the solvent ratio was returned to 10% CH3CN!HzO in two minutes. 
The 10% CH3CN/HzO was held for eight minutes to allow the column to re-equilibrate. 
Depending on the sample (stated) the water was modified with 0.05% TFA. 
8.1.4 Other Chromatography 
Reverse phase CI8 chromatography of doxorubicin and halichondrin containing 
compounds used Bakerbond spe™ Octadecyl (C18) disposable extraction cartridges. 
(Reversed phase octadecylsilane bonded to silica gel (40 f.tm APD, 60A), 3 mL solid 
phase extraction column, 500 mg per column.) 
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Chromatography of proteins used Sephadex® G-25 in glass columns with the dimensions 
and appropriate solvents stated. The chromatography was visualised by a single beam UV 
monitor LKB 2238 Uvicord S II (A 206 mn, time constant = 1, absorbance range = 0.1). 
Analytical reverse phase thin layer chromatography (TLC) was carried out on Merck RP-
18 R254 TLC plates (0.2 mm thickness). Normal phase TLC was performed using Merck 
silica gel 60 F254 aluminium backed sheets (0.2 mm thickness) and Merck DIOL F254 
glass backed plated (0.2 mm thickness). Some TLC plates were initially visualised under 
a short-wave UV lamp (A 254 run) and then further developed with iodine (12), potassium 
permanganate dip (3 g KMn04, 20 g K2C03 and 5 mL 5% NaOH in 300 mL H20), 
phosphomolybdic acid (PMA) spray (10% PMA in EtOH, w/v) or ninhydrin spray (5% 
ninhydrin in EtOH, w/v). 
8.1.5 Solvents 
All technical grade solvents were distilled prior to use. Methanol (MeOH) was distilled 
twice. Dry solvents were obtained using the following standard methods. MeOH was 
distilled from magnesium metal and iodine and stored over activated molecular sieves (4 
A). Pyridine was refluxed over CaH2 before distillation. Tetrahydrofuran (THF) was 
refluxed over sodium metal and benzophenone before distillation directly prior to use. 
Dichloromethane (DCM) was refluxed over calcium hydride before distillation. DMF was 
dried by treating twice overnight with 4 A molecular sieves, followed by storage over 4 A 
sieves. Isopropyl alcohol (IP A) was refluxed over calcium hydride for 3 hours before 
distillation and stored over 4 A sieves. 
The pH 8.0 thiolation 'reaction buffer' was prepared in distilled water, and consisted of 
0.1 M sodium borate, 0.15 M NaCI, and 0.001 M EDTA. Size exclusion columns and 
maleimide-based reactions were carried out in a 'standard borate buffer' (PH 7.2, 
0.0025 M sodium borate, 0.15 M NaCl). Both the above buffers were degassed 
thoroughly for 1 hour before use by bubbling argon through the solutions. 
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8.1.6 Kaiser Testl64 
For SPPS of peptides the Kaiser test was used to detennine the presence (or not) of free 
amines. Several beads from the resin synthesis were removed and washed with 3 x 1 mL 
EtOH in a small glass vial. The following three stock solutions were made and 3 drops 
from each were added to the resin ensuring all beads were completely covered in solution. 
1) 2.5 g of ninhydrin in 50 mL of EtOH 
2) 40 g phenol in 10 mL of EtOH 
3) 0.001 M KCN (6.5 gin 100 mL water) and 12 mL of pyridine 
The vial was capped and placed in an oven (100°C) for approximately 5 min. A positive 
result that is, the presence of a free amine - was indicated by the beads turning blue, 
while a negative result - no free amine - was shown by no change in colour (beads 
remain yellow). 
Chapter Eight Experimental 189 
8.2 Work Described in Chapter 2 
8.2.1 Fmoc-G1y-Resin 
All amino acids used in the following preparations were of L-configuration. Wang resin 
(4-Benzyloxybenzyl alcohol polystyrene, 100-200 mesh, 2 g, 1.5 meq/g, 3 mmol 
hydroxymethyl groups) and Fmoc-Gly-OH (0.98 g, 3.3 mmol) were dissolved/suspended 
in dry DMF (20 mL) at RT for 15 minutes. Pyridine (1.67 mL, 20.70 mmol) and 2,6-
dichlorobenzoyl chloride (2,6-DCBC, 1.48 mL, 10.35 mmol) were added successively 
and the suspension was shaken for 15 hours at RT. Fmoc-Gly-Resin was filtered and 
washed with DMF (3 x 10 mL), IPA (3 x 10 mL) and DCM (3 x 10 mL) before being 
dried in vacuo for 12 hours. 
8.2.2 Capping Resin 
Fmoc-Gly-Resin was benzoylated with benzoyl chloride (1.35 mL, 12 mmol) and 
pyridine (1.46 mL, 18 mmol) by shaking in dichloroethane (DCE, 20 mL) for three hours 
at RT. The resin was filtered and washed with DCE (3 x 10 mL) and DCM (3 x 10 mL), 
and dried under high vacuum for 12 hours. 
8.2.3 Determination of Amino Acid Loading ofFmoc-G1y-Resin 
Dry Fmoc-Gly-Resin (0.46 mg) and 20% piperidine in DMF (3 mL) were mixed for two 
minutes. The absorbance at 290 nm was read in a UV -visible spectrophotometer (Varian 
Cary 50 Probe). Absorbance 0.6468. This was repeated with a second sample ofFmoc-
Gly-Resin (0.97 mg). Absorbance 1.4307. 20% piperidine in DMF was used as a 
solvent blank. The degree of resin loading was determined on basis of a linear 
relationship between absorbance at 290 nm and the quantity of Fmoc-amino acid present, 
with one mmol of Fmoc-amino acid giving an absorbance of 1.650. Average loading = 
0.873 mmol Fmoc/g resin. 
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8.2.4 Synthesis ofy-Maleimidobutyric-Gly-Phe-Leu-Gly-OH, (30) 
<:t
o 46H~20 
N~~~N 
~ 2 0 H 0 
1 0 
o 
18 
16 ~Tr0H 
28 0 
27 
y-maleimidobutyric-Gly-Phe-Leu-Gly-OR (30) 
The SPPS of 30 was perfonned in a glass apparatus fitted with a frit (porosity 3) that 
allowed bubbling of the resin with N2 gas from below, and subsequent removal of the 
solvent by vacuum after each reaction step. 
Fmoc-Gly-Resin (2 g, 1.746 mmol) was bubbled with dry DMF (20 mL) for 30 minutes, 
drained, and bubbled with 20% piperidinelDMF solution (20 mL) for 10 minutes. The 
resin was filtered by suction for 15 minutes, and then washed with DMF (3 x 20 mL) and 
IPA (3 x 20 mL). Several beads were removed and analysed using the Kaiser Test (see 
General Methods, section 7.1.6). A positive result was recorded, so the resin was washed 
with further DMF (3 x 20 mL) and the collection flask was replaced to remove filtrate. 
Fmoc-Leu-OR (1.234 3.492 mmol) , HBTU .(1.324 g 3.492 mmol), ROBt (0.472 g, 
3.492 mmol) and DIPEA (1.22 mL, 6.984 mmol) were combined in DMF (10 mL) for 
two minutes. This solution was then bubbled with the resin for 60 minutes. The resin was 
filtered and washed with DMF (3 x 20 mL) and IPA (3 x 20 mL). Several beads were 
removed and analysed using the Kaiser Test, and a negative result was recorded. The 
resin was washed again with DMF (3 x 20 mL). The above procedure of coupling and 
deprotection was repeated for the sequential addition of Fmoc-Phe-OR (1.352 g, 3.492 
mmol) , Fmoc-Gly-OH (1.038g, 3.492 mmol) and y-maleimidobutyric acid (0.640 g, 
3.492 mmol) , with all other reagents remaining the same. The sample was left to dry 
overnight in vacuo inside the glass apparatus, in the presence ofP20s. The resin was then 
bubbled for 20 minutes with 40 mL 95% TF A, 2.5% TES, and 2.5% water, drained and 
rinsed with TFA (2 x 15 mL). The acidic fractions were combined and alternately 
concentrated under vacuum and precipitated with water to remove TF A from the solution. 
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Semi-preparative reverse phase HPLC (Shimadzu LC-4A) was used to purify 30 from the 
sample. A solvent gradient comprising the following steps was used: an isocratic hold on 
15% CH3CNIH20 (0.05% TFA) for two minutes; a linear gradient to 50% CH3CNIH20 
over 20 minutes; a return to 15% CH3CNIH20 over one minute; and finally an isocratic 
hold on 15% CH3CNIH20 for two minutes. The system was monitored at 213 nm and a 
peak eluting at 15.6 minutes was collected manually and the solvent removed under 
nitrogen gas flow to give 30. Yield 535 mg (55%) HRESIMS MH+ 558.2563 
(C27H36N50S requires 558.2564) IH NMR (500 MHz, CD30D) (5 0.89 (d, JHH = 6.5 Hz, 
3H, H28), (5 0.93 (d, JHH = 6.5 Hz, 3H, H27), (5 1.62 (m, 3H, H25, H26), (5 1.84 (m, 2H, 
H5), (5 2.21 (t, JHH = 7.5 Hz, 2H, H6), (5 2.96 (dd, JHH = 8.5, 13.5 Hz, 2H, H20a), (5 3.15 
(dd, JHH = 8.5, 13.5 Hz, 2H, H20~), (5 3.50 (m, 2H, H4), (5 3.72 (d, JHH = 16.5 Hz, 2H, 
H9a), (5 3.80 (d, JHH = 16.5 Hz, 2H, H9~), (5 3.86 (s, 2H, HI8), (54.41 (m, IH, HI5), (5 
4.62 (m, IH, HI2), (5 6.80 (s, IH, HI), (5 7.23 (m, 3H, H22, H23, H24) amide protons not 
observed. 13C NMR (CD30D) as determined by 2D IH NMR experiments: (5 174.4 (C7), 
(5 173.6 (CI9), (5 172.4 (C13), (5 171.5 (C2, CI6), (5 171.0 (CI0), (5 137.2 (C21), (5 134.3 
(Cl), (5 129.1 (C22), (5 128.3 (C23), (5 126.7 (C24), (5 55.0 (CI2), (5 51.9 (CI5), (5 42.5 
(C9), (5 40.6 (CI8), (5 40.4 (C25), (5 37.0 (C20), (5 36.8 (C24), (5 36.6 (C4), (5 32.2 (C6), (5 
24.5 (C26), (5 24.1 (C5), (5 22.3 (C27), (5 20.5 (C28). 
8.2.5 Norhomohalichondrin B aldehyde, (33) 
H H 
H H 
",C(--', 
" 'I/ 
I" 0 
'" 
norhomohalichondrin B aldehyde (33) 
Homohalichondrin B (22, 2 mg, 1.8 ~mol) was dissolved in MeOH (3 drops) and stirred 
with aqueous sodium periodate (NaI04, 1 mL, 30mM) at RT. TLC (DIOL, 5% 
MeOHIDCM, PMA) was used to monitor the reaction and indicated the reaction was 
complete after 24 hours by the disappearance of 22 (Rf 0.1) and the appearance of a new 
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spot (Rf 0.6). The aqueous reaction mixture was extracted with ethyl acetate (3 x 1 mL). 
The organic fractions were combined and evaporated under nitrogen to give 
norhomohalichondrin B aldehyde (33) in quantitative yield. IH NMR (500 MHz, CDCh) 
was identical to that previously reported (Figure 2.9).89 HRESIMS MW 1091.5607 
(C6oH83018 requires 1091.5579) 
8.2.6 Norhomohalichondrin B amine, (31) 
H 
H H 
H 
H H \"C(-", 
\\ 'II 
I, 0 
III/ norhomohalichondrin B amine (31) 
Norhomohalichondrin B aldehyde (33, 1.7 mg, 1.6 /lmol) and NH4CH3COO (12 mg, 160 
/lmol) were stirred with crushed activated 3 A molecular sieves in dry MeOH (1 mL, 
saturated with (NH4)2C03) for 30 minutes. NaCNBH3 (489 /lg, 8 /lmol) in dry MeOH 
(l00 /lL, saturated with (NH4)2C03) was added. A TLC (Si02, 10% MeOHIDCM, PMA 
and ninhydrin) taken after 12 hours of reaction showed the disappearance of the aldehyde 
(33, Rf 0.8, PMA) and the appearance of a spot closer to the baseline (Rf 0.2) that was 
positive to both ninhydrin and PMA. The reaction solution was diluted with water (10 
mL) and passed through a C18 cartridge (see Section 8.1.4) pre-equilibrated with water, 
washed with further water (10 mL) and eluted with MeOH (5 mL). The methanol fraction 
was dried down to provide crude 31 as confirmed by HRESIMS (MNai+ 557.7884 
(C60H8SN017 requires 557.7897). Yield 1.5 mg (88%). 31 was acylated (see below) 
without further purification. 
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8.2.7 y-Maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B, (32) 
30 (858 /lg, 1.54 /lmol) was activated by stirring, under nitrogen atmosphere, for two 
minutes with N-hydroxysuccinimide (NHS, 322 /lg, 2.8 /lmol) and 
dicyclohexylcarbodiimide (DCC, 578 /lg, 2.8 /lmol) in 1 mL dry THF. (Refluxed over 
sodium wire and benzophenone.) Norhomohalichondrin B amine (31, 1.5 mg, 1.4 /lmol) 
was added to the reaction in dry THF (1 mL). The reaction was left to stir under nitrogen 
atmosphere for 60 hours at which time analytical HPLC established the reaction was 
complete. Compound 32 was purified using an analytical reverse phase HPLC system 
(Agilent 1100) on a Zorbax SB-C18 column (5/l, 2.1 x 150 mm) at a flow rate of 200 
!1L/min. A solvent gradient comprising the following steps was used (note: no acid used): 
an isocratic hold on 20% CH3CNIH20 for two minutes; a linear gradient to 60% 
CH3CN/H20 over 40 minutes; a linear gradient to 100% CH3CNIH20 over two minutes 
followed by a return to 20% CH3CNIH20 over three minutes; and finally an isocratic hold 
on 20% CH3CNIH20 for five minutes. A peak eluting at 33.7 minutes was collected 
manually and the solvent removed under nitrogen gas flow to give 32. Insufficient sample 
(0.4 mg) was obtained for NMR analysis but ESI MS analysis confirmed the preparation 
of32. HRESIMS (MH)2+ 816.4157 (C87Hll9N6024 requires 816.4177). 
8.2.8 Doxorubicin, (34) 
A reversed phase C 18 cartridge (Reversed phase octadecylsilane bonded to silica gel (40 
/lm APD, 60A) 3 mL solid phase extraction column, 500 mg per column.) was pre-
equilibrated with 0.05% NH40HlH20 (6 mL). 0.05% NH40HlH20 (1.5 mL) was added to 
doxorubicin hydrochloride (3 mg), resulting in a dark purple solution that was 
immediately loaded onto the cartridge. The cartridge was washed with 0.05% 
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NH40HIH20 (5 mL). Washing with acetone (5 mL) eluted 34 in quantitative yield after 
drying under nitrogen gas flow. lH NMR (500 MHz, (CD3)2S0) was identical to that 
previously reported.234 Confirmation was obtained by HRESIMS MH+ 544.1836 
(C27H29NOll requires 544.1819) 
8.2.9 y-Maleimidobutyric-Gly-Phe-Leu -Gly-doxorubicin, (35) 
o OH 0 
y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35) 
30 (2.26 mg, 4.1 flmol) was activated by stirring, under nitrogen atmosphere, for two 
minutes with N-hydroxysuccinimide (NHS, 0.82 mg, 7.2 flmol) and 
dicyc1ohexylcarbodiimide (DCC, 1.49 mg, 7.2 flmol) in 1 mL dry THF. Doxorubicin (34, 
2 mg, 3.6 flmol) was added to the reaction in dry THF (1 mL). The reaction was left to 
stir under nitrogen atmosphere for 24 hours at which time analytical HPLC established 
the reaction was complete. Compound 35 was purified using an analytical reverse phase 
HPLC system (Shimadzu VP) at a flow rate of 1 mUmin. A solvent gradient comprising 
the following steps was used: an isocratic hold on 55% CH3CNIH20 (0.05% TFA) for 
two minutes; a linear gradient to 69% CH3CNIH20 over eight minutes; a return to 55% 
CH3CNIH20 over one minute; and finally an isocratic hold on 55% CH3CNIH20 for two 
minutes. A peak eluting at 4.3 minutes was collected manually and the solvent removed 
under nitrogen gas flow to give 35 as a red solid. HRESIMS MNa+ 1105.4034 
(Cs4H62N6018Na requires 1105.4018) The lH NNIR spectrum in CD30D was assigned as 
far as possible through comparison with the spectra of 30 and 34 (Figure 2.14). 
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8.2.10 y-Maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide, (37) 
o H~O 24 Ct 4 6 N N~8 ION ~ 2 0 H 0 
1 0 
o H 
18 N 16 ~l(20 
32 0 2 
H2N 
23 
31 
y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37) 
OH 
195 
30 (3 mg, 0.0054 mmol) was activated by stirring under argon atmosphere for two 
minutes with N-hydroxysuccinimide (NHS, 1.12 mg, 0.0098 mmol) and 
dicyc1ohexylcarbodiimide (DCC, 2.02 mg, 0.0098 romol) in 2 mL dry THF. 
Tyrosinamide (36, 0.88 mg, 0.0049 mmol) was added to the reaction in dry THF (1 mL). 
The reaction was left to stir under argon atmosphere for 24 hours at which time analytical 
HPLC established the reaction was complete. Compound 37 was purified from the 
reaction mixture using a semi-preparative reverse phase HPLC system (Shimadzu LC-
4A) at a flow rate of 5 mLimin. A solvent gradient comprising the following steps was 
used: an isocratic hold on 15% CH3CNIH20 (0.05%TFA) for two minutes; a linear 
gradient to 50% CH3CNIH20 over 20 minutes; a return to 15% CH3CNIH20 over one 
minute; and finally an isocratic hold on 15% CH3CNIH20 for two minutes. The system 
was monitored at 213 nm and a peak eluting at 13.8 minutes was collected manually and 
the solvent removed under nitrogen gas flow to give 37. HRESIMS MNa+ 742.3152 
(C36H4SN709Na requires 742.3176) IH NMR (CD30D) 0 0.88 (d, JHH 6.2 3H, H32), 
00.92 (d, 6.2 Hz, 3H, H31), 0 1.28 (m, 2H, H29), 0 1.61 (m, IH, H30), 0 1.83 (m, 
2H, H5), 0 2.20 (t, JHH = 7.2 Hz, 2H, H6), 0 2.85 (dd, J HH 9.0, 14.0 Hz, 2H, H33a), 0 
2.98 (dd, JHH 9.0, 14.3 Hz, 2H, H33~), 0 3.08 (dd, JHH = 5.1, 13.8 Hz, 2H, H24a), 0 
3.16 (dd, JHH 5.4, 14.2 Hz, 2H, H24~), 0 3.49 (m, 2H, H4), 0 3.65 (d, J HH 16.5 Hz, 
2H, H9a*), 0 3.76 (dd, JHH 13.6, 16.5 Hz, 2H, H18*), 0 3.86 (d, JHH 16.5 2H, 
H9~*), 04.22 (dd, JHH = 4.8, 10.2 Hz, IH, HI5), 04.50 (dd, JHH 5.0,9.3 Hz, IH, H21), 
04.60 (dd, JHH 5.6, 9.1 Hz, lH, HI2), 06.68 (d, JHH = 8.5 Hz, IH, H36), 0 6.79 (s, lH, 
HI), 0 7.07 (d, 8.8 Hz, IH, 3H, H35), 0 7.23 (m, H26, H27, H28) amide protons 
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not observed, *interchangeable. l3C NMR (CD30D) as detennined by 2D IH NMR 
experiments. 8 134.5 (Cl), 8 130.2 (C35), 8 129.1 (C26),8 128.4 (C27), 8 126.8 (C28), 8 
115.0 (C36), 8 55.2 (C12), 8 55.2 (C2l), 8 52.8 (C15), 842.7 (C18*), 8 42.5 (C9*), 836.8 
(C24), 8 36.7 (C33), 8 36.6 (C4), 8 32.1 (C6), 8 29.4 (C29), 8 27.3 (C30), 8 25.0 (C5), 8 
22.3 (C3l), 8 20.5 (C32). 
8.2.11 Reaction of ~-a1anine (39) with 2-IT (29) and y-Ma1eimidobutyric 
acid (40) 
~-alanine (39, 1 mg, 0.01 mmol) was dissolved in reaction buffer (1 mL). 2-IT (29, 2.0 
mg, 0.015 mmol) was added, the reaction was flushed with argon, capped and left for one 
hour. y-maleimidobutyric acid (40,2.7 mg, 0.015 mmol) was added in minimal DMF and 
the reaction was left for 10 minutes. The reaction mixture was analysed by direct infusion 
ESIMS. 
8.2.12 Size-exclusion Purification of Lysozyme 
Lysozyme (200 )lg) was dissolved in reaction buffer (200 IlL) and chromatographed on a 
G-25 column (1 x 40 cm) with standard borate buffer. The column was monitored by UV 
detector set at A 206 nm, and a peak eluting at Vo (20 mL, as detennined by calibration 
with blue dextran) was collected (total volume ~4 mL). The sample was concentrated (~l 
mL) by evaporation under nitrogen gas flow. 
8.2.13 MS Analysis of Lysozyme 
Lysozyme solution (10 IlL), as prepared in Section 8.2.12, was directly infused in to the 
mass spectrometer. No useful MS result was obtained. 
Chapter Eight - Experimental 197 
Lysozyme solution (40 ilL), as prepared in Section 8.2.12, was analysed by a reversed 
phase (Agilent, Zorbax 300SB-C3, 5 Il, 2.1 x 150 mm) LC MS system 
(WaterslMicromass). The solvent gradient comprised of a 105 minute run with a flow rate 
of 200 ilL/min, and consisted of the following solvent gradient timetable: a slow gradient 
from 0% - 60% CH3CNIH20 (0.5% formic acid) over 80 minutes, followed by ramp in 
concentration to 100% CH3CN over five minutes, an isocratic hold on 100% CH3CN for 
five minutes and then restoration to 0% CH3CN over five minutes. The method was 
finished with an isocratic hold on 0% CH3CN over five minutes. A broad peak eluted at a 
retention time of ~41-43 minutes. The ESI-mass spectrum and the MaxEnt deconvoluted, 
neutral-scale mass spectrum of lysozyme, can be seen in Figure 2.20. 
8.2.14 Thiolation of Lysozyme 
Lysozyme (200 Ilg, 0.014 Ilmol) was dissolved in reaction buffer (200 ilL). 2-IT (29, 0.07 
Ilmol, 10 ilL of 1 mg/mL solution in reaction buffer, freshly made) was added and the 
mixture was flushed with argon, capped and left for five hours at room temperature. The 
sample was chromatographed on a G-25 column (1 x 40 cm) and eluted with standard 
borate buffer (1 mL/min). The column progress was monitored by a single beam UV 
detector set at A 206 nm. A peak eluting at Vo (20 mL) was collected and analysed by LC 
MS following the method established in Section 8.2.13. A broad peak eluted after 42 
minutes (visible in both TIC and diode array chromatograms). The deconvoluted mass-
spectrum of the thiolated protein is presented in Figure 2.22. 
8.2.15 Thiolated Lysozyme and y-maleimidobutyric acid. 
Immediately after LC MS analysis, the sample prepared in Section 8.2.14 was reacted 
with y-maleimidobutyric acid (40, 12.8 Ilg, 0.07 Ilmol, 12.8 ilL of 1 mg/mL in DMF). 
After two hours the sample was concentrated (~1 mL) and analysed by LC MS following 
the method in Section 8.2.13. A broad peak eluted at a retention time of ~41 minutes. 
Analysis of this peak can be seen in Figure 2.23. 
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8.2.16 Thiolation Optimisation Time and Temperature Dependence 
Lysozyme (200 ~g, 0.014 ~mol) was dissolved in reaction buffer (200 ~L). 2-IT (29,0.07 
~mol, 10 ~L of 1 mglmL solution in reaction buffer, freshly made) was added and the 
mixture was flushed with argon, capped and left for one hour at room temperature. y-
maleimidobutyric acid (40, 12.8 ~g, 0.07 ~mol, 12.8 ~L of 1 mglmL in DMF) was added 
in situ and the reaction was left for a further two hours. This reaction was repeated a 
further four times, with the thiolation step left for 5, 12, 24 and 48 hours respectively, 
before the malemide was added. Each of the samples were analysed by LC MS following 
the method in Section 8.2.13. A broad peak eluted at a retention time of ~41 minutes in 
each case. Mass spectral results are depicted in Figure 2.24. 
The group of time dependent reactions above were repeated at OCC and analysed in the 
same manner by LC MS. Deconvoluted mass spectra of these samples are presented in 
Figure 2.25. 
8.2.17 Characterisation of Thiolation By-product 
Benzylamine (42, 10 mg, 0.09 mmol) was dissolved in degassed thiolation reaction buffer 
(1 mL). 2-IT (29,0.09 rnmol) was added and the reaction was left to proceed for 24 hours 
at room temperature. Oily droplets were seen in the reaction mixture. The oily droplets 
were extracted into ethyl acetate (3 x 2 mL). TLC (silica, 30% MeOH/EtOAc) showed a 
single UV active spot with Rf 0.83. Benzylamine standard, Rf 0.40. The ethylacetate 
fraction was evaporated in vacuo. HRESIMS, and a number of NMR experiments 
(CDCh, lH, l3C, HSQC, CIGAR) led to the assignment of the product 44. 
3 
~N£( 
llV 
(44) 
HRESIMS MH+ 192.0846 (CllH14NS requires 192.0847) lH NMR (CDCh, 500 MHz) (5 
2.14 (p, JHH = 5.0, 10.0 Hz, 2H, H3), (5 2.73 (t, JHH = 5.0 Hz, 2H, H2), (5 3.27 (t, JHH = 6.5 
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Hz, 2H, H4), () 4.40 (s, 2H, H7), () 7.34 (m, 5H, H9-l1). BC NMR (CDCh, 75 MHz) () 
139.5 (C8), () 128.4 (C9), () 128.0 (ClO), () 126.8 (Cll), () 61.5 (C7), () 39.0 (C2), () 33.9 
(C4), () 26.9 (C3). 
8.2.18 Thiolation Optimisation Ratio of 2-IT (29) 
Lysozyme (200 !-tg, 0.014!-tmol) was dissolved in reaction buffer (200 !-tL). 2-IT (29,0.07 
!-tmol, 10 !-tL of 1 mg/mL solution in reaction buffer, freshly made) was added and the 
mixture was flushed with argon, capped and left for 12 hours at O°C. y-Maleimidobutyric 
acid (40, 12.8 !-tg, 0.07 !-tmol, 12.8 !-tL of 1 mg/mL in DMF) was added in situ and the 
reaction was left for a further two hours. This reaction was repeated a further four times 
with 2-IT (29, 0.14 !-tmol, 0.35 !-tmol, 0.7 !-tmol and 1.4 !-tmol). Equal equivalents of y-
maleimidobutyric acid (40) were added after 12 hours. Each of the samples were analysed 
by LC MS following the method in Section 8.2.13. A broad peak eluted at a retention 
time of ~41 minutes in each case (Figure 2.27). Mass spectral results are depicted in 
Figure 2.28. 
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8.3 Work Described in Chapter 3 
8.3.1 LC MS ofCV-N (28) 
CV-N solution (10 J.LL of 1 mg/mL in 0.9% saline solution) was analysed by a reversed 
phase (Agilent, Zorbax SB-C18, 5 J.L, 2.1 x 250 mm) LC MS system (WaterslMicromass) 
employing the standard protein LC MS gradient. The resultant diode array and TIC 
chromatograms are presented in Figure 3.2. Analysis of the ESI -mass spectral data of the 
single peak (~46.5 minutes) is shown in Figure 3.3. 
8.3.2 Modification ofCV-N (28) 
8.3.2.1 A Model System 2-IT (29) and y-Maleimidobutyric acid (40) 
CV-N (28, 100 J.Lg, 100 J.LL of 1 mg/mL in 0.9% saline solution, 9.1 nmol) was diluted 
with reaction buffer (50 J.LL) and kept at O°C. 2-IT (29, 6 J..LL of 1 mg/mL in reaction 
buffer, 45.5 nmol) was added to the protein solution. The reaction vial was flushed with 
argon, capped, and held at O°C. y-Maleimidobutyric acid (40, 8.3 J.LL of 1 mg/mL in 
DMF, 45.5 nmol) was added in situ after 12 hours. This reaction procedure was repeated 
a further four times with varying amounts of 2-IT (29, 12.5 J..LL of 1 mg/mL in reaction 
buffer, 91 nmol; 31.5 J.LL of 1mg/mL in reaction buffer, 0.23 J.Lmol; 63 J..LL of 1 mg/mL in 
reaction buffer, 0.46 J..Lmol; and 125 J.LL of 1 mg/mL in reaction buffer, 0.91 J.Lmol). Equal 
equivalents ofy-maleimidobutyric acid (40, 16.7 J.LL of 1 mg/mL in DMF, 91 nmol; 21J.LL 
of2 mg/mL in DMF, 0.23 J.Lmol; 42 J..LL of2 mg/mL in DMF, 0.46 J.Lmol; and 42 J.LL of 4 
mg/mL in DMF, 0.91 J.Lmol) were added after 12 hours. Each of the samples were 
analysed by LC MS following the method in Section 8.2.13. The diode array 
chromatograms ofthe LC MS analyses are presented in Figure 3.5, with selected MaxEnt 
deconvoluted mass spectral data shown in Figure 3.6. 
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CV-N (28, 100 J.lg, 100 J.lL of I mg/mL in 0.9% saline, 9.1 nmol) was diluted with 
reaction buffer (87.5 J.lL) and the sample was kept at O°C. 2-IT (29, 12.5 J.lL of 1 mg/mL 
in reaction buffer, 91 nmol) was added and the mixture was flushed with argon, capped, 
and left for one hour at O°C. The sample was chromatographed on a G-25 column (1 x 40 
cm) and eluted with standard borate buffer (1 mLlmin). The column progress was 
monitored by a single beam UV detector ("- 206 nm). A peak eluting at Vo (20 mL) was 
collected and reacted directly with y-maleimidobutyric acid (40, 16.7 J.lL of I mg/mL in 
DMF, 91 nmol) for two hours. This reaction was repeated a further four times, with the 
thiolation step left for 5, 12, 24 and 48 hours respectively, before the maleimide was 
added. Each of the samples were analysed by LC MS following the method in Section 
8.2.13. An example mass spectral result is presented in Figure 3.7. 
8.3.2.2 A Model System - 2-IT (29) and F-lS0 (46) 
OH 
rN~ \ ~H s~O 
/H N 
o 
o (47) 
HO 
CV-N (28, 200 J.lg, 200 J.lL of I mg/mL in 0.9% saline, 18.2 nmol) was diluted with 
reaction buffer (187.5 J.lL) and the sample was kept at O°C. 2-IT (29, 25 J.lL of I mg/mL in 
reaction buffer, 182 nmol) was added and the mixture was flushed with argon, capped, 
and left for one hour at O°C. The sample was chromatographed on a G-25 column (1 x 40 
cm) and eluted with standard borate buffer (1 mLlmin). The column progress was 
monitored by a single beam UV detector ("- 206 nm). A peak eluting at Vo (20 mL) was 
collected and reacted directly with F-150 (46,39 J.lL of2 mg/mL in DMF, 182 nmol) and 
for two hours. The reaction mixture was concentrated under nitrogen gas flow (~500 J.lL) 
and purified on a G-25 column as described above. The two fluorescent bands eluting 
from the column (~20 minutes and ~35 minutes) were collected and analysed by reverse 
phase LC MS (Agilent, Zorbax, C18) using the standard protein LC MS gradient. The 
TIC chromatogram is presented in Figure 3.10, and mass spectra of the conjugate are 
shown in Figure 3.11. 
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8.3.3 Tryptic Digestion of Native CV-N (28) 
CV-N (28, 100 Ilg, 100 )..lL of 1 mg/mL in 0.9% saline solution) was diluted with 
ammonium bicarbonate buffer (8mM, pH 8, 100 )..lL). TPCK treated trypsin (10% by 
weight to analyte protein, 10 )..lg, 10 )..lL of 1 mg/mL in 1 % acetic acid) was added and the 
digest was left at 37°C for 24 hours. The digest was analysed by LC MS 
(Waters/Micromass, Zorbax, SB-C18, standard protein LC MS gradient). See Figure 3.12 
for the TIC ES+ chromatogram. The ESI MS data was processed as discussed in Section 
3.4.1. The relevant ESI MS data from this digest, and the assignment of peptide fragments 
can be seen in Table 3.1. The assigned peptide fragments are mapped against the amino 
acid sequence of CV -N (28) in Figure 3.16. 
8.3.4 Tryptic Digestion ofCV-N-Maleimidobutyric acid Conjugate (45) 
The singly-derivatised CV -N-maleimidobutyric acid conjugate (45) prepared in Section 
8.3.2.1 was concentrated to ~ 1 00 ilL by evaporation under nitrogen gas flow. TPCK 
treated trypsin (10% by weight to analyte protein, 10 )..lg, 10 )..lL of 1 mg/mL in 1 % acetic 
acid) was added and the digest was left at 37°C for 24 hours. The digest was analysed by 
LC MS (Waters/Micromass, Zorbax, SB-C18, standard protein LC MS gradient). The ESI 
MS data was processed as discussed in Section 3.4.2. The relevant ESI MS data from this 
digest, and the assignment of peptide fragments can be seen in Table 3.2. The assigned 
peptide fragments are mapped against the amino acid sequence of CV -N (28) in Figure 
3.16. 
8.3.5 Tryptic Digestion of CV-N-FI50 Conjugate (47) 
The CV-N-F-150 conjugate (47) prepared in Section 8.3.2.2 was concentrated to ~100 )..lL 
by evaporation under nitrogen gas flow. TPCK treated trypsin (10% by weight to analyte 
protein, 10 )..lg, 10 )..lL of 1 mg/mL in 1 % acetic acid) was added and the digest was left at 
37°C for 24 hours. The digest was analysed by LC MS (Waters/Micromass, Zorbax, SB-
C18, standard protein LC MS gradient). The ESI MS data was processed as discussed in 
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Section 3.4.3. The relevant ESI MS data from this digest, and the assignment of peptide 
fragments can be seen in Table 3.3. The assigned peptide fragments are mapped against 
the amino acid sequence ofCV-N (28) in Figure 3.16. 
8.3.6 Preparation ofCV-N-Tyrosinamide Conjugate (48) 
OH 
CV-N (28, 400 Ilg, 400 ilL of 1 mg/mL in 0.9% saline solution, 36 nmol) was diluted 
with reaction buffer (150 ilL) and held at O°C. 2-IT (29, 50 I-iL of 1 mg/mL in reaction 
buffer, 360 nmol) was added. The reaction was flushed with argon, capped and left at O°C 
for 12 hours. The sample was chromatographed on a G-25 column (1 x 40 cm), eluting 
with standard borate buffer (1 mLlmin), and monitored by a diode array detector (A. 206 
nm). The protein component eluting at the void volume (-20 mL) was collected and 
reacted directly with y-maleimidobutyric-Gly-Phe-Leu-Gly-tyrosinamide (37, 52 JlL of 1 
mg/mL in DMF, 72 nmol) at O°C. After two hours the sample was concentrated (-600 
ilL) by evaporation under nitrogen gas flow, and chromatographed on G-25 as above. The 
protein component, eluting at Vo (-20 mL) was collected and analysed by LC MS 
(Waters/Micromass, Zorbax, SB300-C3, standard protein LC MS gradient). The TIC 
chromatogram of this analysis is shown in Figure 3.18. The protein sample was once 
again concentrated (-500 ilL) under nitrogen gas flow. Aliquots (40 ~LL) of this mixture 
were purified using the LC MS method above, with manual collection of the required 
peak. The purification was guided by MS analysis, with -10% of the sample directed to 
the mass spectrometer, and -90% collected. The TIC ES+ chromatogram and the 
deconvoluted mass spectrum of the purified CV-N-tyrosinamide conjugate (48), are 
shown in Figure 3.19 and 3.20 respectively. 
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8.4 Work Described in Chapter 4 
8.4.1 Purification of Mutant CV-N Proteins 
Four recombinantly produced mutant CV-N proteins were supplied by Nektar™ 
Therapeutics. These were CV-N: K3R (49, 6.5 mg/mL); CV-N: K3R, K48R (50, 3.63 
mg/mL); CV-N: K3R, K48R, K74R (51,4.55 mg/mL); and CV-N: K3R, K48R, K74R, 
K84R (52, 10.58 mg/mL). 
The four proteins samples (49, 50, 51, 52) were each diluted with double distilled H20 
(0.1 % TF A, 1 mg/mL). These samples were purified using semi-preparative reverse phase 
(PRP-3, 305 x 7mm) HPLC. This was completed at a flow rate of 2 mLimin using a 
solvent gradient comprised of the following steps: a five minute wash with 100% H20 
(0.1 % trifluoroacetic acid (TF A)), followed by a slow linear gradient to 60% CH3CNIH20 
(0.1 % TFA) over 28 minutes, then a linear gradient to 100% CH3CN (0.1 % TFA) over 5 
minutes, with a final hold on 100% CH3CN (0.1 % TF A) 7 minutes; and monitored at A 
210 nm and A 280 nm. The sample was purified over multiple injections (1 mL aliquots). 
The major component eluted at 27 minutes in each case and was collected using a fraction 
collector (1/minute). The fractions containing the major component were combined and 
taken to dryness under a flow of nitrogen gas. Purified mass: 49, ~26.3 mg; 50, ~3.7 mg; 
51, ~7.4 mg; 52, 9.9 mg. Each protein was reconstituted in distilled water (1 mg/mL) for 
storage. 
LC MS (Agilent 1100, Zorbax-C3, 2.1 x 150 mm) confirmed the exact mass and purity of 
each sample (See Section 4.2.1, Figure 4.1 and Figure 4.2). The method comprised of a 
40 minute run with a flow rate of 200 f-l,Llmin, and consisted of the following solvent 
gradient timetable: a linear gradient from 0% - 60% CH3CNIH20 (5% acetic acid) over 
30 minutes, followed by ramp in concentration to 100% CH3CN over two minutes and an 
isocratic hold on 100% CH3CN for three minutes, followed by a restoration to 0% 
CH3CN over five minutes. 
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8.4.2 Tryptic Digestion ofCV-N: K3R, K48R, K74R (51) 
CV-N: K3R, K48R, K74R (51, 100 )lg, 100 ilL of 1 mg/mL in distilled H20), purified in 
Section 8.4.1, was diluted with ammonium bicarbonate buffer (8 mM, pH 8, 100 ilL). 
TPCK treated trypsin (10% by weight to analyte protein, 10 )lg, 10 ilL of 1 mg/mL in 1 % 
acetic acid) was added and the digest was left at 37°C for 24 hours. The digest was 
analysed by LC MS (WaterslMicromass, Zorbax, SB-C18, standard protein LC MS 
gradient). The ESI MS data was processed as discussed in Section 3.4. The relevant ESI 
MS data from this digest, and the assigmnent of peptide fragments can be seen in Table 
4.2. 
8.4.3 Tryptic Digestion ofCV-N: K3R, K48R, K74R, K84R (52) 
CV-N: K3R, K48R, K74R, K84R (52, 100 )lg, 100 IlL of I mg/mL in distilled H20), 
purified in Section 8.4.1, was diluted with ammonium bicarbonate buffer (8 mM, pH 8, 
100 )lL). TPCK treated trypsin (10% by weight to analyte protein, 10 )lg, 10 IlL of 1 
mg/mL in 1% acetic acid) was added and the digest was left at 37°C for 24 hours. The 
digest was analysed by LC MS (WaterslMicromass, Zorbax, SB-C18, standard protein 
LC MS gradient). The ESI MS data was processed as discussed in Section 3.4. The 
relevant ESI MS data from this digest, and the assigmnent of peptide fragments can be 
seen in Table 4.1. 
8.4.4 CV-N: K3R, K48R, K74R, K84R (52) and F-150 (46) 
OH 
(53) 
CV-N: K3R, K48R, K74R, K84R (52,200 )lg, 200 IlL of 1 mg/mL in distilled H20, 18.0 
nmol) was diluted with reaction buffer (138 IlL) and the sample was kept at O°C. 2-IT 
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(29, 62 ilL of 1 mg/mL in reaction buffer, 450 nmol) was added and the mixture was 
flushed with argon, capped, and left for 12 hours at O°C. The sample was 
chromatographed on a G-25 column (1 x 40 cm) and eluted with standard borate buffer (1 
mLlmin). The column progress was monitored by a single beam UV detector (A 206 run). 
A peak eluting at Vo (20 mL) was collected and reacted directly with 150 (46, 15 ilL of 
1 mg/mL in DMF, 36.0 nmol) for two hours. The reaction mixture was concentrated 
under nitrogen gas flow (~200 ilL) and purified on a G-25 column as described above. 
The two fluorescent bands eluting from the column (~20 minutes and -35 minutes) were 
collected and analysed by reverse phase LC MS (Agilent, Zorbax, C18) using the 
standard protein LC MS gradient. An expanded region of the TIC chromatogram, and the 
diode array at A 450 nm, is presented in Figure 4.4, and mass spectrum of the conjugate is 
shown in Figure 4.5. The protein sample was once again concentrated (-200 ilL) under 
nitrogen gas flow. Aliquots (40 ilL) of this mixture were purified using the LC MS 
method above, with manual collection of the peale at 44.5 minutes. The purification was 
guided by MS analysis, with -10% of the sample directed to the mass spectrometer, and 
-90% collected. 
8.4.5 CV-N: K3R, K48R, K74R, K84R (52) and y-Maleimidobutyric-Gly-
Phe-Leu-Gly-norhomohalichondrin B (32) 
(54) 
CV-N: K3R, K48R, K74R, K84R (52, 4.5 mg, 450 ilL of 1 mg/mL in distilled H20, 0.4 
!-Lmol) was taken to dryness by evaporation and then reconstituted in reaction buffer (4.5 
mL) and kept at O°C. 2-IT (29, 1.4 mg, 10 !-Lmol) was added, the mixture was flushed with 
argon, capped, and left for 12 hours at O°C. The sample was chromatographed on a G-25 
column (2.5 x 40 cm) and eluted with standard borate buffer (3 mLlmin), and visualised 
with a diode array detector (A 280 nm). The protein fraction was collected after 19 
minutes. This fraction was concentrated (-4 mL) by centrifugation in a centriprep 
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concentrator (YM-3 regenerated cellulose 3000 MW). y-Maleimidobutyric-Gly-Phe-Leu-
Gly-norhomohalichondrin B (32, Section 2.4.1, 0.4 /lmol, 65 IlL of 10 mg/mL in DMF) 
was added, and left at O°C overnight. LC MS analysis (Agilent 1100, Zorbax C3, 2.1 x 
150 mm) confirmed that the reaction was complete at this point. A solvent gradient 
comprising the following steps was used: a linear gradient from 20-45% CH3CNIH20 
(0.5% acetic acid) over 25 minutes; a linear gradient to 100% CH3CN over five minutes; 
isocratic at 100% CH3CN for five minutes; and then a return to 20% CH3CNIH20 over 
five minutes. The TIC chromatogram is presented in Figure 4.7. Unreacted protein 
eluted at 15.7 minutes, and the conjugate, 54, eluted at 21.2 minutes (Figure 4.8). The 
sample was concentrated by evaporation under nitrogen flow (~1 mL). Conjugate 54 was 
purified by disconnecting the mass spectrometer, and following the diode array 
chromatogram (280 nm), collecting the peak at 21.2 minutes. Multiple injections (50 IlL) 
were made. The collected fraction was dried down under nitrogen immediately (~300 j.tg), 
and reconstituted in double distilled H20 (750 j.tL). Reanalysis of the purified sample 
(LC MS method above) demonstrated a single component was present. 
8.4.6 Amino Acid Analysis of 54 
Amino acid analysis and protein quantitation was performed by staff in the Protein 
Chemistry Laboratory at the NCI-Frederick, MD, USA. 
Conjugate 54 (50 ilL of 750 j.tL solution prepared in Section 8.4.5) was submitted for 
analysis. Using the amino acid concentrations, the conjugate was quantitated at 50.8 j.tg in 
the 750 IlL solution. This analysis also confirmed the ratio of one biolinker (Gly-Phe-
Leu-Gly) to one protein molecule. 
8.4.7 Amino Acid Sequencing of 54 
Amino Acid sequencing was performed by an Applied Biosystems Procise Sequencer at 
the MTDP, NCI-Frederick, Frederick, MD, USA. Conjugate 54 (12.5 ilL of 750 IlL 
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solution prepared in Section 8.4.5, 65.7 pmol as detennined above) was submitted for 
analysis. The first nine amino acids were sequenced as LGRFNQXA YN. 
8.4.8 Tryptic Digest of 54 
CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B (54, 4.2 Ilg, 62.5 ilL of750 ilL 
solution from Section 8.4.5) was diluted with ammonium bicarbonate buffer (8 mM, pH 
8, 100 ilL). TPCK treated trypsin (2.5 Ilg, 2.5 ilL of 1 mg/mL in 1% acetic acid) was 
added and the digest was left at 37°C for 24 hours. DTT (20 Ilg) was added to the digest. 
The digest was analysed by LC MS (Agilent, Zorbax, SB-C18 2.1 x 150 mm, 200 
ilL/min) using the following solvent gradient: 100% H20 (0.5% acetic acid) for 15 
minutes; a linear gradient to 40% CH3CN (0.5% acetic acid) over 135 minutes followed 
by a gradient to 100% CH3CN (0.5% acetic acid) over 15 minutes. The EST MS data was 
processed as discussed in Section 3.4. The relevant EST MS data from this digest, and the 
assignment of peptide fragments can be seen in Figure 4.9 and Table 4.3. 
8.4.9 CV-N: K3R, K48R, K74R, K84R (52) and y-maleimidobutyric-Gly-
Phe-Leu-Gly-doxorubicin (35) 
CV-N: K3R, K48R, K74R, K84R (52,200 Ilg, 200 ilL of 1 mg/mL in distilled H20, 18.0 
nmol) was diluted with reaction buffer (138 ilL) and the sample was kept at O°C. 2-IT 
(29, 62 ilL of 1 mg/mL in reaction buffer, 450 nmol) was added and the mixture was 
flushed with argon, capped, and left for 12 hours at O°C. The sample was 
chromatographed on a G-25 column (1 x 40 cm) and eluted with standard borate buffer (1 
mLlmin). The column progress was monitored by a single beam UV detector (A 206 nm). 
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A peak eluting at Vo (20 mL) was collected and reacted directly with y-maleimidobutyric-
Gly-Phe-Leu-Gly-doxorubicin (35, 39 ilL of 1 mglmL in DMF, 36.0 nmol) for two hours. 
The reaction mixture was concentrated under nitrogen gas flow (~200 ilL) and purified on 
a G-25 column as described above. A pale pink band (~20 minutes) was collected and 
analysed by LC MS (Micromass/Waters, Zorbax-C3, standard protein LC MS gradient). 
The TIC chromatogram is illustrated in Figure 4.11. The sample was analysed by LC MS 
in the same manner, 10 and 24 hours after preparation. An overlay of the TIC 
chromatograms from these analyses is shown in Figure 4.13. Selected MaxEnt 
deconvoluted ESI MS data is presented in Figure 4.12. 
8.4.10 CV-N: K3R, K48R, K74R (51) and F-150 (46) 
OH 
IN~s0 
./ H ~N 
o 
(60) 
CV-N: K3R, K48R, K74R (51, 200 Ilg, 200 ilL ·of I mg/mL in distilled lhO, 18.0 nmol) 
was diluted with reaction buffer (114 ilL) and the sample was kept at oce. 2-IT (29, 86 
ilL of 1 mg/mL in reaction buffer, 630 nmol) was added and the mixture was flushed with 
argon, capped, and left for 12 hours at OCC. The sample was chromatographed on a G-25 
column (1 x 40 cm) and eluted with standard borate buffer (1 mLlmin). The column 
progress was monitored by a single beam UV detector (A 206 nm). A peak eluting at Vo 
(20 mL) was collected and reacted directly with F-150 (46, 15 ilL of 2 mglmL in DMF, 
72.0 nmol) for two hours. The reaction mixture was concentrated under nitrogen gas flow 
(~200 ilL) and purified on a G-25 column as described above. The two fluorescent bands 
eluting from the column (~20 minutes and ~35 minutes) were collected and analysed by 
reverse phase LC MS (Agilent, Zorbax, C18) using the standard protein LC MS gradient. 
An expanded region of the TIC chromatogram, and the diode array at A 450 nm, is 
presented in Figure 4.17, and the mass spectrum of the conjugate is shown in Figure 4.18. 
The protein sample was once again concentrated (~200 ilL) under nitrogen gas flow. 
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Aliquots (40 ilL) of this mixture were purified using the LC MS method above, with 
manual collection of the peak at 45.4 minutes. The purification was guided by MS 
analysis, with ~ 10% of the sample directed to the mass spectrometer, and ~90% collected. 
The mass of purified conjugate was not determined. 
8.4.11 CV-N: K3R, K48R, K74R (51) and y-Maleimidobutyric-Gly-Phe 
Leu-Gly-norhomohalichondrin B (32) 
CV-N: K3R, K48R, K74R (51, 200 Ilg, 200 ilL of I mglmL in distilled H20, 18.0 nmol) 
was diluted with reaction buffer (114 ilL) and the sample was kept at O°C. 2-IT (29, 86 
ilL of 1 mglmL in reaction buffer, 630 nmol) was added and the mixture was flushed with 
argon, capped, and left for 12 hours at O°C. The sample was chromatographed on a G-25 
column (1 x 40 cm) and eluted with standard' borate buffer (1 mLlmin). The column 
progress was monitored by a single beam UV detector (A 206 nm). A peak eluting at Vo 
(20 mL) was collected and reacted directly with y-Maleimidobutyric-Gly-Phe-Leu-Gly-
norhomohalichondrin B (32, Section 2.4.1, 72 nmol, 59 ilL of 2 mg/mL in DMF) for 10 
hours. The sample was concentrated (~200 ilL) under nitrogen gas flow and purified on a 
G-25 column in the same manner as above, using distilled H20 as the eluant. A peak (~20 
minutes) was collected, concentrated (~200 ilL), and analysed by LC MS (standard 
protein LC MS gradient, 0.1% formic acid). The TIC chromatogram is presented in 
Figure 4.20. Aliquots (40 ilL) of this mixture were purified using the LC MS method 
above, with manual collection of the peak at 58.5 minutes. The purification was guided 
by MS analysis, with ~ 10% of the sample directed to the mass spectrometer, and ~90% 
collected. The mass of purified conjugate was not determined. The mass spectmm of the 
purified conjugate (61) is shown in Figure 4.21. 
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8.5 Work Described in Chapter 5 
8.5.1 MS analysis ofHSA (Sigma®) 
HSA was initially sourced from Sigma® (97-99%, Lyophilized powder, purified by Ix 
crystallisation). 
HSA (Sigma®, 2 nmol, 10 flL of a 13.3 mg/mL solution in borate buffer (0.0025 M 
sodium borate, 0.15 M NaCI, pH 7.2)) was directly infused into the mass spectrometer. 
No useful MS result was obtained. 
HSA (Sigma®, 0.6 nmol, 40 flL of a I mg/mL solution in borate buffer (0.0025 M sodium 
borate, 0.15 M NaCI, pH 7.2)) was analysed by a reversed phase (Agilent, Zorbax 300SB-
C3, 5 fl, 2.1 x 150 mm) LC MS system (WaterslMicromass) employing a short solvent 
gradient method (20-50% CH3CNIH20 (0.5% formic acid)) over 15 minutes. A broad 
peak eluted at a retention time of ~ 10-13 minutes. No useful MS result was obtained. 
HSA (Sigma®, 0.6 nmol, 40 flL of a 1 mg/mL solution in borate buffer (0.0025 M sodium 
borate, 0.15 M NaCI, pH 7.2)) was analysed by a reversed phase (Agilent, Zorbax 300SB-
C3,5 fl, 2.1 x 150 mm) LC MS system (Waters/Micromass). The standard protein LC MS 
gradient (Section 8.1.2) was employed. A broad peak eluted at a retention time of -47-51 
minutes. The EST-mass spectmm and the MaxEnt deconvoluted, neutral-scale mass 
spectmm, ofHSA (Sigma®), can be seen in Figure 5.5. 
8.5.2 HSA (Sigma®) and F-150 (46) 
HSA (Sigma®, 400 flg, 6 nmol) was dissolved in borate buffer (400 flL, 0.0025 M sodium 
borate, 0.15 M NaCl, pH 7.2). F-150 (46, 12.8 flL of 1 mg/mL in DMF, 30 nmol) was 
added and the reaction was left at RT for 24 hours. The reaction mixture was then 
chromatographed on a G-25 column (Sephadex®, 1 x 40 cm) with distilled water (1 
mUmin) and visualised with a diode array detector set at 206 nm. Two fluorescent yellow 
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bands eluted down the column, one at the void volume (Vo, approximately 20 mL), and 
the other 15 mL later. Both fluorescent bands were collected, and analysed by LC MS 
(Agilent, Z orb ax , C3) using the standard protein LC MS gradient. The first fraction 
showed a single broad peak at a retention time of ~50 minutes with an absorbance at 
A 440 nm. No useful MS result was obtained. The second fluorescent fraction presented a 
peak at a retention time of 34 minutes and was determined to be umeacted F -150 (46). 
8.5.3 LC MS analysis ofHSA (Pharma Dessau, FRG) 
An alternative source ofHSA came from Pharma Dessau, FRG. 
HSA (Pharma Dessau, 0.6 nmol, 40 ~L of a 1 mg/mL solution (60 ~L of commercially 
prepared 20% solution in 16 mM sodium oetanoate diluted with borate buffer (340 ~L, 
0.0025 M sodium borate, 0.15 M NaCl, pH 7.2») was analysed by a reverse phase 
(Agilent, Zorbax 300SB-C3, 5 /-t, 2.1 x 150 mm) LC MS system (WaterslMicromass). 
The standard protein LC MS gradient was utilised and a single broad peak eluted at a 
retention time of 47-52 minutes. The raw ESI data was deconvoluted with MaxEnt to give 
the deconvoluted ESI-mass spectrum presented in Figure 5.6. 
8.5.4 HSA (Pharma Dessau, FRG) and F-150 (46), (62) 
OH 
(62) 
HSA (Pharma Dessau, 400 ~g, 60/-tL of a commercially prepared 20% solution in 16 mM 
sodium octanoate, 6 nmol) was diluted with borate buffer (340 ~L, 0.0025 M sodium 
borate, 0.15 M NaCI, pH 7.2). F-150 (46, 5.1 ~L of 1 mg/mL in DMF, 12 nmol) was 
added and the reaction was left at RT for 12 hours. At this time the sample was analysed 
by LC MS (WaterslMicromass, Zorbax 300SB-C3) using the standard protein LC MS 
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gradient (Figure 5.8). As Figure 5.8 demonstrated, one large broad peak, with a retention 
time of 47 to 52 minutes, was visible in the TIC spectrum. This peak represented protein, 
and was also visible at A 440 nm in the diode array spectrum. A sharp peak at 34.4 
minutes, visible at a wavelength of 440 nm, was unreacted F-150. The protein was 
purified from the excess F-150 by passing the sample through a size-exclusion column 
(Sephadex@ G-25, 1 x 40 cm), eluting with distilled water (1 mLimin) and visualised with 
a diode array detector set at 206 nm. The fluorescent yellow band eluting at the void 
volume (~20 minutes) was collected and taken to dryness by evaporation with N2 • The 
sample was then reconstituted in distilled water (400 jJ,L) and reanalysed by reversed 
phase LC MS (standard protein LC MS gradient) to confirm the purity ofthe sample. This 
analysis showed one broad peak, with a retention time of 47-52 minutes, in both the diode 
array at A 440 nm and the TIC spectra. Analysis of the mass spectral data showed that the 
broad peak encompassed both unreacted albumin and the conjugate product 62 (67,008 
Da, approximately 50% yield) (Figure 5.9). Unreacted protein and the conjugate product 
could not be separated. The sample containing 62 was again taken to dryness by 
evaporation under nitrogen gas flow and stored at 3°C until further analyses took place. 
8.5.5 Tryptic Digest ofHSA-F-150 (62) 
Conjugate 62 (100 jlg, 1.5 nmol) was taken up in ammonium bicarbonate buffer (100 jlL, 
10 roM, pH 8). TPCK treated trypsin (10% by weight to analyte protein, 10 jlL of 1 
mglmL in 1 % acetic acid) was added and the digest left to proceed at 37°C for 24 hours. 
A small amount of dithiothreitol (DTT) was added to the sample. Reverse phase (Zorbax 
300SB-C3) LC MS (WaterslMicromass, standard protein LC MS gradient) was used to 
analyse the digest. See Figure 5.10 for the diode array chromatogram at A 440 nm and the 
TIC ES+ trace. ESI MS data was processed as discussed in Section 5.3. See Table 5.1 for 
the ESI-MS data of this digest, and the assignment of peptide fragments. 
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8.5.6 HSA (Pharma Dessau, FRG) and y-Maleimidobutyric-Gly-Phe-Leu-
Gly-norhomohalichondrin B (32), (63) 
(63) 
HSA (Pharma Dessau, 200 J.tg, 30 J.tL of a commercially prepared 20% solution in 16 mM 
sodium octanoate, 3 nmol) was diluted with borate buffer (170 !-iL, 0.0025 M sodium 
borate, 0.15 M NaCI, pH 7.2). y-maleimidobutyric-Gly-Phe-Leu-Gly-
norhomohalichondrin B (32, 9.8 J.tL of 1 mg/mL in DMF, 6 nmol) was added and the 
reaction was left at RT for three days. The reaction mixture was then chromatographed on 
a G-25 column (Sephadex®, 1 x 40 cm) with distilled water (1 mUmin) and visualised 
with a single beam UV detector set at 206 nm. A peak eluting at Vo (~20 minutes) was 
collected and taken to dryness by evaporation under N2 gas. The sample was reconstituted 
in distilled water (200 !-iL) and analysed by reverse phase (Zorbax 300SB-C3) LC MS 
(Waters/Micromass, standard protein LC MS gradient) to confirm the purity and nature of 
the sample. A single broad peak, with a retention time of 47-52 minutes, was visible in 
the TIC spectrum. MaxEnt deconvolution ofthe'raw ESI-mass spectral data (Figure 5.12) 
demonstrated that the broad peak encompassed both unreacted albumin and the conjugate 
product 63 (68,144 Da, approximately 33% yield) (Figure 5.13). Unreacted protein and 
the conjugate product could not be separated. The remaining sample containing 63 was 
taken to dryness by evaporation with nitrogen and stored at 3°C until further analyses 
took place. 
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8.5.7 HSA (Pharma Dessau, FRG) and y-Maleimidobutyric-Gly-Phe-Leu-
Gly-doxorubicin (35), (64) 
~ ~~JN'\/lN'Y~'(r;.", o H 0 - H 0 yo y 0 OH 0 OCH3 
(64) HOH'C~ 
o OH 0 
HSA (Pharma Dessau, 200 Ilg, 30 ilL of a commercially prepared 20% solution in 16 mM 
sodium octanoate, 3 nmol) was diluted with borate buffer (170 ilL, 0.0025 M sodium 
borate, 0.15 MNaCl, pH 7.2). y-maleimidobutyric-Gly-Phe-Leu-Gly-doxorubicin (35, 6.5 
ilL of 1 mg/mL in DMF, 6 nmol) was added and the reaction was left for 24 hours at RT. 
A G-25 column (Sephadex®, 1 x 40 cm) was used to separate unreacted 35 from the 
protein component. The sample was eluted with distilled water (1 mLimin) and visualised 
with a diode array detector set at 206 nm. The pink fraction that eluted after 20 minutes 
was collected and taken to dryness by evaporation with N2• This fraction was then 
redissolved in distilled water (200 ilL). The sample was analysed by LCMS 
(WaterslMicromass, Zorbax, 300SB-C3, standard protein LC MS gradient). Figure 5.15 
illustrates the single peak visible in the diode array chromatograms at 'A 254 nm and 'A 480 
nm, and the TIC ES+ trace. The ESI-mass spectrum of this peak can be seen in Figure 
5.16, and the MaxEnt deconvoluted, neutral-scale mass spectrum is presented in Figure 
5.17. The broad peak included both umeacted albumin and the conjugate product 64 
(67,531 Da). A further component eluting at the same retention time was identified as 
being a degradation product of the conjugate (67,115 Da). This product represented the 
loss of the anthracycline portion of doxorubicin (see Chapter 4). A small aliquot of the 
sample (50 ilL) was left for 48 hours at RT, then reanalysed by LC MS. Conjugate 64 was 
no longer present and the aforementioned degradation component remained. The 
remaining sample containing 64 was immediately taken to dryness by evaporation with 
nitrogen and stored at 3°C, in the dark, until further analyses took place. 
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8.5.8 Tryptic Digest of HSA-Doxorubicin (64) 
Conjugate 64 (100 Ilg) was taken up in ammonium bicarbonate buffer (100 flL, 10 mM, 
pH 8). TPCK treated trypsin (10 flg in 10 ilL 1 % acetic acid) was added. The digest was 
left at 37°C for 12 hours and monitored by LC MS (Waters/Micromass, Zorbax, 300SB-
C3, standard protein LC MS gradient). See Figure 5.18 for the diode array (Iv 480 nrn) 
and TIC ES+ chromatograms. The ESI-MS data was processed as discussed in Section 
5.5. The relevant ESI-MS data of this digest, and the assignment of peptide fragments can 
be seen in Table 5.2. 
8.5.9 HSA (Pharma Dessau, FRG) and y-Maleimidobutyric-Gly-Phe-Leu-
Gly-tyrosinamide (37), (65) 
OH 
HSA (Pharma Dessau, 200 Ilg, 30flL of a commercially prepared 20% solution in 16 rnM 
sodium octanoate, 3 nrnol) was diluted with borate buffer (170 flL, 0.0025 M sodium 
borate, 0.15 M NaCl, pH 7.2) and combined with y-maleimidobutyric-Gly-Phe-Leu-Gly-
tyrosinamide (37, 4.3 flL of 1 mg/mL in DMF, 6 nrnol). After 24 hours at RT the reaction 
mixture was chromatographed on a G-25 column (Sephadex®, 1 x 40 cm). The sample 
was eluted with distilled water (1 mLimin) and visualised with a diode array detector (Iv 
206 nrn). The peak that eluted after 20 minutes was collected and taken to dryness by 
evaporation with N2. The sample was then reconstituted in distilled water (200 ilL) and 
analysed by reverse phase (Zorbax, 300SB-C3) LC MS (Waters/Micromass, standard 
protein LC MS gradient). A single broad peak, eluting at 47-51 minutes, was represented 
by the mass spectral data presented in Figures 5.20 and 5.21. The peak encompassed 
umeacted HSA and the HSA-tyrosinamide conjugate (65, 67,079 Da). The sample 
containing 65 was again taken to dryness by evaporation under nitrogen gas flow and 
stored at 3°C until further analyses took place. 
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8.5.10 Tryptic Digest of HSA-Tyrosinamide (65) 
Conjugate 65 (1 00 ~g) was taken up in ammonium bicarbonate buffer (100 flL, 10 ruM, 
pH 8). TPCK treated trypsin (10 flg) was added in 1 % acetic acid (1 0 ~L). After 24 hours 
at 37°C the digest was analysed by LC MS (WaterslMicromass, Zorbax, 300SB-C3). The 
ESI-MS data was processed as discussed in Section 5.6. The relevant ESI-MS data of this 
digest, and the assignment of peptide fragments can be seen in Table 5.3. 
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8.6 Work Described in Chapter 6 
8.6.1 Cathepsin B Digest of 54 
Conjugate 54 (1 f-tg, 15 f-tL of stock solution prepared in Section 8.4.5) was diluted with 
phosphate buffer (82 f-tL, 0.05 M KH2P04, 0.001 M EDTA, 0.005 M glutathione, pH 6.0) 
and was incubated with cathepsin B (3 f-tg, 3 f-tL of 1 mg/mL in phosphate buffer from 
above, commercial supply of cathepsin ~30% protein) at 37°C. The degradation of 64 
was monitored by LC MS after 5, 24 and 48 hours of incubation with cathepsin B. An 
analytical reverse phase (Zorbax C18, 2.1 x 150 mm) HPLC system was used at a flow 
rate of 200 f-tLimin. A solvent gradient comprising the following steps was used: a slow 
linear gradient from 0-60% CH3CNIH20 (5% acetic acid) over 60 minutes; a linear 
gradient to 100% CH3CN over two minutes; isocratic at 100% CH3CN for five minutes; a 
return to 100% H20 over five minutes; and finally an isocratic hold on 100% H20 for two 
minutes. The progress of the digestion can be seen in the LC MS traces pictured in Figure 
6.1. Analysis of the LC MS data is discussed in Section 6.2.1. 
8.6.2 ELISA Assay of 52 and 54 
A general outline of the principle and procedure of the gp120-mediated ELISA IS 
discussed in Section 6.2. The exact methodology is outlined below. 
The ELISA assays were performed in a 96-well plate. 100 f-tL Dulbecco's phosphate 
buffered saline (D-PBS) was added to the outermost wells and gp120 (8.3 nM, 100 f-tL of 
a 0.5 f-tg/mL solution) in PBS was added to the central wells. The plates were incubated 
for two hours at room temperature (no rocking). The plates were then washed three times 
(200 f-tL) wash buffer (Tween 20, 0.02% D-PBS (without Ca and Mg)). Incubation with 
D-PBS (200 f-tL, without Ca and Mg), 1 % bovine serum albumin (BSA), and 0.05% NaN3 
overnight at 4°C blocked any unused space in the wells. All wells were then washed 
three times with D-PBS (200 f-tL). The appropriate wells (shown in Figure 6.4) were 
incubated (rocking) with 100 f-tLiwell of variable concentrations of either the CV-N 
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mutant (54) or the CV -N conjugate (52) for one hour at room temperature. The plate was 
again washed three times with D-PBS (200 f.tL) and further incubated (rocking) with 
Rabbit-anti-CV-N antibodies (Rab-2-d-CV-N-Ig, 100 f.tLlwell) for one hour at room 
temperature. After a further three washes the plate was incubated (rocking) with anti-
Rabbit antibodies with a terminal alkaline phosphatase (anti-[rab-IgGJ-Ab-AP, 100 
f.tllwell) for one hour at room temperature. The plates were washed three times with D-
PBS and incubated (rocking) with substrate buffer (PH 9.2, 10% diethanolamine, 1 mM 
MgClz, 4 mg/mL p-nitrophenyl phosphate (pNPP) , 100 f.tL) for 15 minutes. The final 
step was to add EDTA (0.5 M, pH 8.0, 100 f.tL) to each well (without washing off the 
buffer). The plates were read at 405 nm in a plate reader. A graphical representation of 
the results is presented in Figure 6.5. 
8.6.3 Biological Assays 
8.6.3.1 Anti-HIV XTT Assay 
The anti-HN assay is a relatively simple method to determine the ability of a drug to 
protect cells against the cytopathic effects of HIV. T -lymphocyte-derived CEM-SS cells 
are added to 96-well microtitre plates along with cell-free HIV and the test agent at Y2-log 
dilutions over a multi-dose range. Six days after infection, a tetrazolium reagent, XTT, is 
added to the wells. In the presence of viable cells, XTT is metabolized to an orange 
coloured formazan, such that the quantity of viable cells, and thus, the protective ability 
of the test agent, is proportional to the depth of the colour. Uninfected cells are also 
treated with drug in order to determine the cytotoxicity of the drug, if any, to the CEM 
cells. For further detailed information see Wei slow et al. 235 and Gulakowski et al. 236 
These assays were carried out by the MTDP, NCI-Frederick, Frederick, MD, USA. 
The CV-N: K3R, K48R, K74R, K84R-norhomohalichondrin B conjugate (54) and the 
free norhomohalichondrin B amine (31) were submitted for the above HN cytotoxicity 
assay. Graphical and tabular representations of the assay results are presented in Figure 
6.6, and Table 6.1, respectively. 
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8.6.3.2 P388 Biological Assay237 
This is an anti-tumour assay, which involves incubating a dilution series of a sample with 
P388 murine leukaemia cells for 72 hours. The concentration of the sample required to 
reduce the P399 cell growth by 50%, compared to the control cells, is detennined using 
the absorbance values obtained at 540 nm when the yellow MTT tetrazolium is reduced 
by healthy cells to produce purple coloured MTT fonnazan. The result is expressed as an 
ICso in ng/mL. These assays were carried out in the Chemistry Department, University of 
Canterbury, Christchurch, New Zealand. 
y-Maleimidobutyric-Gly-Phe-Leu-Gly-OH (30), norhomohalichondrin B amine (31), 
y-maleimidobutyric-Gly-Phe-Leu-Gly-norhomohalichondrin B (32), the HSA-
norhomohalichondrin B conjugate (63), doxorubicin (34), y-maleimidobutyric-Gly-Phe-
Leu-Gly-doxorubicin (35) and the HSA-doxorubicin conjugate (64) were submitted for 
assay against the P388 murine leukaemia cell line. The doxorubicin samples were 
prepared immediately before analysis. A tabular representation of the results is presented 
Table 6.2. 
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"Life should NOT be a journey to the grave with the intention of 
arriving safely in an attractive and well preserved body, but rather 
to skid in sideways, Champagne in one hand - oysters in the other, 
body thoroughly used up, totally worn out, and screaming WOO 
ROO - What a Ride!" 
